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Summary
Misfolded proteins are prone to engage in aberrant intermolecular interactions that can lead to 
formation of large aggregate structures. Aggregation causes loss-of-function toxicity because 
the aggregating protein fails to reach its native fold and function. In addition, protein 
aggregates may exert gain-of-toxicity, which is due to the shear presence of aggregate 
conformations that sequester important cellular factors and disturb cell morphology. Protein 
aggregation is associated with a large number of human diseases.
The endoplasmic reticulum (ER) is a membrane-bound cellular organelle and the site 
of synthesis of one third of the eukaryotic proteome including secretory proteins and proteins 
destined for the endomembrane system. After co-translational translocation into the ER, 
nascent proteins are assisted to fold by molecular chaperones and are subject to post-
translational modifications. Secretory proteins are retained in the ER lumen until they are 
correctly folded and are then delivered to the Golgi apparatus for further modifications. If a 
protein fails to fold properly after repeated folding cycles, it is instead targeted for 
degradation via the ER-associated degradation pathway (ERAD). 
The aim of the study presented in this thesis was to determine how the human ER
quality control (ERQC) machinery deals with aggregation-prone proteins. This is of great 
interest because protein aggregates are differentially regulated by distinct cellular 
environments and many of the proteins that aggregate in diseases are in fact synthesised in the 
ER. To this end, we utilised de novo designed amyloidogenic β-proteins as generic models for 
protein aggregation. Due to their lack of evolved biological function, these model proteins 
allow the exclusive study of gain-of-function toxicity and enable us to dissect the effect of the 
ER environment on amyloidogenic proteins.
We determined that ER-targeted versions of the model β-sheet proteins are 
significantly less toxic and more soluble than their non-targeted counterparts, which form 
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toxic insoluble aggregates in the cytosol and nucleus. We found that the ER-targeted β-protein 
ER-β23 is recognised by ERQC machinery and efficiently retained in the ER lumen in a 
soluble polymeric state. Strikingly, ER-β23 interacted with factors of the ERAD pathway, 
even though it was not efficiently degraded. Instead, ER-β23 inhibited the degradation of 
other ERAD substrates by sequestering low-abundant ERAD factors. The presented results 
demonstrate a marked capacity of the ER to prevent the secretion of potentially toxic 
aggregation-prone proteins and to limit the formation of insoluble aggregates in the ER
lumen. In addition, the data reveal a mechanism by which amyloidogenic proteins may disturb
ER proteostasis. 
Another aim of this study was to analyse the effects of small molecule proteostasis 
modulators. We found that the anti-dopaminergic drugs fluphenazine and droperidol as well 
as the epidermal growth factor receptor (EGFR) inhibitors gefitinib and erlotinib improved 
proteostasis in the presence of protein aggregates. In case of the former, this effect was most 
likely achieved via induction of the cytosol stress response.
In summary, the work presented in this thesis provides novel insights into how 
aggregation-prone proteins behave in the environment of the ER and also demonstrates the 
potential of using small molecule modulators to improve cellular proteostasis in a disease 
context.
Introduction
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Introduction
Protein folding and molecular chaperones
Virtually all processes within cells depend on the proper functioning of proteins. Proteins are 
synthesised within cells as polypeptide chains that need to be correctly folded into three 
dimensional structures to give rise to fully functional proteins (Dobson et al., 1998; Bartlett 
and Radford, 2009). The conformation at which a protein is functional is referred to as the 
native state of a protein. The native state represents a thermodynamically stable state at the 
minimum of the protein’s accessible free energy (Anfinsen et al., 1961; Anfinsen, 1973). The 
information that specifies a protein’s native conformation is given by its primary structure, 
namely, the amino acid sequence of the polypeptide chain (Anfinsen, 1973). Early studies of 
protein folding showed that some proteins are able to fold spontaneously in vitro and 
suggested mechanisms of protein folding that involved the formation of secondary structures 
in a hierarchical process driven by various interactions between amino acid side chains as 
well as the hydrophobic effect, which favours burial of hydrophobic amino acid residues in 
the inside of the protein and exposure of hydrophilic residues to the aqueous environment 
(Dill et al., 1995; Daggett and Fersht, 2003). However, under physiological conditions the 
process is not as straightforward because in the crowded environment of the cell protein 
folding faces several challenges. One challenge is that long polypeptide chains may not have 
space to move freely to find their native folds due to molecular crowding of highly 
concentrated biomolecules, in particular other proteins (Ellis, 2001). Furthermore, the process 
of translation is relatively slow (about 15-74 seconds per 300 amino acids) and the 
polypeptide chain cannot fold into its native conformation before it is fully synthesised and 
released from the ribosome (Etchells and Hartl, 2004; Lu and Deutsch, 2005). This means that 
during translation the nascent chain can only fold partially and exposes hydrophobic patches 
that would in the folded state be buried in the core of the protein. Unfolded hydrophobic 
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patches are prone to interact aberrantly, potentially leading to toxic misfolding and 
aggregation.
Figure 1. The protein folding funnel. The funnel illustrates the energy landscape of a 
protein during folding and aggregation. Many intermediate conformations 'funnel' to the 
native state via intramolecular interactions (cyan surface). Non-native conformations can lead 
to formation of amorphous aggregates or amyloid fibrils that are based on aberrant 
intermolecular interactions (red surface) but also via folding intermediates or partially folded 
states (moving from cyan to red surfaces). Destabilisation of the native conformation and 
aggregate formation is prevented by chaperones. Figure adapted and modified from (Kim et 
al., 2013) and (Jahn and Radford, 2005).
Taken together, both kinetic and thermodynamic factors determine the folding process 
of a protein. To explain the connection between kinetic and thermodynamic control of protein 
folding the model of the “folding funnel” was introduced. The folding funnel depicts the 
complex energy landscape that a polypeptide chain must navigate during folding (Figure 1) 
(Bryngelson et al., 1995; Dill and Chan, 1997; Clark, 2004; Hartl and Hayer-Hartl, 2009; Kim 
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et al., 2013), and illustrates the different potential energy states of a protein in various 
conformations. The vertical axis represents the internal free energy, which is dependent on the 
properties of a given polypeptide chain and on external conditions such as temperature or 
solvents. A protein’s native conformation represents an energy minimum. The number of 
potential conformations is represented by the lateral area of the funnel. There is not just one 
single folding pathway but multiple paths that may lead from the unfolded chain to the native 
conformation. As folding progresses, the polypeptide chain’s conformational options are more 
and more narrowed towards the native state. However, most cellular proteins form folding 
intermediates that are prone to collapse into more compact and stable non-native 
conformations (Brockwell and Radford, 2007). The intramolecular interactions that such non-
native conformations are based on need to be reversed in order for correct folding to proceed, 
which increases the activation energy required to reach the stable native state. Thus, the path 
from the high energy state of an unfolded polypeptide chain to its native low energy 
conformation via folding intermediates contains kinetic traps of local energy minima that 
make the folding funnel rugged (Jahn and Radford, 2005; Hartl and Hayer-Hartl, 2009)
(Figure 1). The propensity of a protein to get caught in such traps is largely dependent on the 
chemical properties of its amino acid side chains, the length of the polypeptide chain, its 
concentration and the stability of its native state (Netzer and Hartl, 1997; Chiti and Dobson, 
2006; Ciryam et al., 2013). In addition to aberrant intramolecular interactions, non-native 
conformations are also prone to engage in aberrant intermolecular interactions. This is due to 
the fact that unfolded proteins or folding intermediates characteristically expose hydrophobic 
and unstructured regions that would in the native conformation be buried in the core of the 
structure. Such aberrant intermolecular interactions cause two problems: First, they represent 
further kinetic energy traps that slow down the folding process. Second, they can lead to 
aggregate conformations such as amyloid fibrils that may be even more thermodynamically 
stable than the native state (Figure 1). 
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Figure 2. The different functions of molecular chaperones. Chaperones fold newly 
synthesised proteins, remodel misfolded species, dissolve aggregates and target proteins for 
degradation via the ubiquitin proteasome system (UPS) or autophagy. Figure adapted and 
modified from (Kim et al., 2013) and (Eichner and Radford, 2011).
To overcome the challenge of kinetic traps, protein folding in the cell is assisted by 
molecular chaperones (Hartl, 1996) (Figure 1 and 2). Molecular chaperones are proteins that 
bind to a broad range of protein substrates and assist their correct folding without being part 
of the final structure. Chaperones not only facilitate do novo folding, but also refolding, 
prevent protein aggregation, actively dissociate protein aggregates and are also involved in 
protein degradation (Figure 2). Mammalian chaperones can be largely classified into five
families of so called heat shock proteins (HSPs): the ATP-independent small HSPs (sHSPs) 
that are also referred to as holdases and which are almost exclusively stress-induced, and the 
ATP-dependent families HSP60, HSP70, HSP90 and HSP100 that are also referred to as 
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foldases and consist of both cognate and stress-inducible members (Richter et al., 2010; 
Vabulas et al., 2010; Kim et al., 2013).
Proteostasis
Since cells depend on a balance of correctly folded and functioning proteins - a state referred 
to as protein homeostasis or proteostasis - they must tightly regulate the conformations, 
concentrations, interactions and subcellular localisations of all proteins that make up the 
proteome (Balch et al., 2008; Powers et al., 2009; Hipp et al., 2014). For this purpose, cells 
have evolved a network of protein quality control pathways that control transcription, 
translation, protein folding, trafficking, processing, assembly, localisation and degradation 
and are collectively referred to as the proteostasis network (PN) (Douglas and Dillin, 2010)
(Figure 2).
Figure 3. The proteostasis network. Proteostasis is the healthy cellular balance of correctly 
folded and functioning proteins at controlled concentrations and localisations that is 
maintained by the proteostasis network (PN) and can be disturbed by multiple factors.
Proteostasis can be disturbed by destabilising mutations, errors in protein biosynthesis, 
deficiencies of PN components or by environmental stressors (Figure 3). These disturbances 
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can lead to protein misfolding and aggregation which in turn aggravates proteostasis 
imbalance because protein aggregates can interfere with folding, processing, trafficking and 
degradation of other proteins. Impairments in proteostasis induce cellular stress responses, 
which represent a feedback mechanism that up-regulates protein quality control factors of the 
PN (Figure 3). The PN maintains proteostasis under basal conditions and also under 
conditions of intrinsic or environmental stress and is essential to prevent the build-up of 
potentially toxic and aggregation-prone misfolded protein species that can jeopardize cell 
fitness and survival (Douglas and Dillin, 2010).
The endoplasmic reticulum
One third of the eukaryotic proteome is synthesised at a specialised cellular organelle: the 
endoplasmic reticulum (ER) (Ghaemmaghami et al., 2003). The ER forms an interconnected 
network of membrane-bound flat vesicular structures called cisternae that span the cell and 
are continuous with the outer nuclear membrane (Figure 4) (Alberts et al., 2014). The main 
functions of the ER are calcium storage and lipid and protein biosynthesis. Lipid biosynthesis 
takes place in the smooth ER, which in most cells comprises only a small fraction of the 
organelle, whereas the part of the ER where protein synthesis takes place is referred to as the 
rough ER because its surfaces are covered with ribosomes. Proteins that are processed in the 
ER include those destined for the endomembrane system that consists of the ER, the Golgi, 
endosomes, lysosomes and the plasma membrane as well as secretory proteins that are 
transported in membrane-bound vesicles from the ER via the Golgi to the plasma membrane 
for secretion into the extracellular space (Figure 4). 
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Figure 4. The endomembrane system. Secretory proteins are translated at the endoplasmic 
reticulum (ER). After folding in the ER lumen they are transported in vesicles to the Golgi 
apparatus for further modifications and sorting before transport to the plasma membrane and 
secretion.
Protein translocation into the ER
Protein translocation into the mammalian ER usually occurs co-translationally, although there 
are also examples of proteins such as tail-anchored (TA) proteins that are post-translationally 
inserted into the ER after completion of translation in the cytosol (Araki and Nagata, 2011). 
Translation of ER-destined proteins always starts in the cytosol. Once the N-terminal 
signal peptide of an ER-destined nascent chain emerges from the ribosome, it is recognised by 
the signal-recognition particle (SRP) (Figure 5) (Araki and Nagata, 2011). SRP interacts with 
the SRP receptor (SR) at the ER membrane and thus causes relocation of the ribosome-
nascent chain complex (RNC) to the Sec61 translocon complex (Figure 5). Translation then 
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proceeds through the Sec61 translocon (Johnson and Van Waes, 1999; Saraogi and Shan, 
2011). 
Figure 5. The ER quality control machinery. Most ER-destined proteins are co-
translationally translocated into the ER, where they are acted on by molecular chaperones and 
modifying enzymes. Correctly folded secretory proteins are exported from the ER in transport 
vesicles. Terminally misfolded ER proteins are targeted for ER-associated degradation or in 
some cases autophagy.
The special folding environment of the ER
Proteins that enter the ER are exposed to a protein folding environment that is different from 
that of the cytosol in several aspects (Table 1). First, the ER proteostasis network, often 
referred to as the ER protein quality control (ERQC) system, consists of a set of molecular 
chaperones, protein-modifying enzymes and degradation factors that are distinct from those of 
the cytosolic protein quality control machinery. Second, in the ER, proteins are subject to 
distinct post-translational modifications that include N-glycosylation, acetylation, lipidation, 
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membrane insertion and disulphide bond formation. The latter is facilitated by a highly 
oxidising environment (30 times higher than in the cytosol (Hwang et al., 1992)). These 
various post-translational modifications render ER-targeted proteins more vulnerable to errors 
during maturation; however, once a protein is correctly folded these modifications make it in 
fact more thermodynamically stable than cytosolic proteins (Buchberger et al., 2010). 
Parameter ER Cytosol
Redox state Oxidising Reducing
Calcium 0-1 mM <1 µM
Energy generating system No Yes
N-glycosylation machinery Yes No
HSP70 family BiP/GRP78 HSP70/HSP72, HSC70
Large HSP70s NEF family HYOU1/GRP170 HSP110
Sil1-like NEF family Sil1/BAP HspBP1, Bag-1
HSP40 co-chaperone family ERdj1-5 DnaJA1-2,4, DnaJB1,2,4-6
HSP90 family GRP94 HSP90
Major stress response Unfolded protein response Heat shock response
Table 1. Differences in the folding environment of the ER and the cytosol. Modified and 
extended from (Marzec et al., 2012).
Another factor that distinguishes the folding environment of the ER is its unique ion 
composition, which is mainly due to the fact that the ER is the main cellular Ca2+ storage site. 
Fluctuations in calcium levels are buffered by Ca2+-binding ER chaperones (Van et al., 1989). 
Furthermore, ER chaperones and protein-modifying enzymes heavily depend on ATP as a 
source of energy. However, ATP is not synthesised in the ER and must be imported from the 
cytosol by a so far unknown mechanism that may depend on Ca2+ release (Zuehlke and 
Johnson, 2010; Vishnu et al., 2014). Another biomolecule that is not readily available in the 
ER and requires active transport is acetyl-CoA that is important for ER proteostasis, as a 
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donor for protein acetylation. The activity of many ER-resident enzymes and chaperones, as 
well as many secretory and membrane proteins depends on Nε-lysine acetylation (acetylation 
of the ε amino group of lysine residues) by the acetyl-CoA:lysine acetyltransferases 1 and 2 
(ATase 1 and ATase 2) (Ko and Puglielli, 2009). Nε-lysine acetylation is a reversible post-
translational modification that is different from Nα-acetylation (N-terminal acetylation) and 
O-acetylation (Pehar and Puglielli, 2013). Acetyl-CoA, which serves as an acetyl group donor 
for this modification, cannot cross lipid bilayers because it is highly charged and needs to be 
actively imported by the acetyl-CoA transporter 1 (AT-1) (Jonas et al., 2010).
ER protein folding factors
Notably, the Golgi apparatus contains protein modifying enzymes but no molecular 
chaperones (Ellgaard and Helenius, 2003). Thus, protein folding must be completed before 
proteins exit the ER and the ERQC machinery must prevent exit of incompletely folded 
proteins as they may pose a threat to the cell. Thus, proteins are retained by the ERQC 
machinery until either folding is completed or the protein is targeted for degradation in the 
case of terminally misfolded proteins (Figure 5). Due to this mechanism of retention until 
folding is completed, secretory proteins with  increased conformational stability are more 
efficiently secreted (Kowalski et al., 1998). 
The ER contains distinct members of some of the main chaperone families. Namely, 
the HSP90 family member GRP94, the HSP70 family member binding immunoglobulin 
protein (BiP) (also referred to as glucose-regulated protein 78 (GRP78)), and distinct sets of 
HSP40 family co-chaperones and nucleotide exchange factors (NEFs) (Figure 5). In addition, 
the ER contains the lectin chaperones calnexin (CNX) and calreticulin (CRT), peptidyl-prolyl 
isomerases, thiol-disulphide oxidoreductases and protein disulphide isomerases (PDIs) that 
facilitate protein folding. Notably, the ER does not contain members of the HSP100 and 
HSP60 families (Ellgaard and Helenius, 2003; Rodriguez-Lopez et al., 2014). Incompletely 
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folded proteins are recognised by ERQC factors via exposed hydrophobic regions, unpaired 
cysteine residues or specific glycosylation signatures. 
The calnexin/calreticulin system
One of the most important protein folding systems in the ER is the CNX/CRT system, which 
is unique to this organelle (Figure 5). The CNX/CRT cycle integrates protein folding and 
N-glycosylation that affects most secretory proteins and is thus the major quality control 
system for such proteins (Hebert et al., 2005). Both CNX and CRT bind N-linked glycans 
(Hammond et al., 1994; Hebert et al., 1995). The type I membrane protein CNX and the 
soluble ER-luminal protein CRT share about 39% sequence identity and contain Ca2+-binding 
sites (Smith and Koch, 1989; Wada et al., 1991). Both proteins also bind ATP but do not have 
any known ATPase activity (Ou et al., 1995; Saito et al., 1999). 
The glycosylation cycle begins already co-translationally when oligo-
saccharyltransferase (OST) adds the oligosaccharide Glc3Man9GlcNAc2 to asparagine 
residues within the consensus sequence Asn-Xxx-Ser/Thr of emerging polypeptide chains 
(Shibatani et al., 2005; Ruiz-Canada et al., 2009). The outermost glucose of this 
oligosaccharide is then removed by glucosidases I and II to allow for polypeptide chains to be 
recognised by CNX and CRT (Grinna and Robbins, 1979). CNX and CRT assist correct 
protein folding by preventing protein aggregation as well as premature ER exit. Furthermore,
they recruit other chaperones and modifying enzymes including the protein disulphide 
isomerase (PDI) ERp57 (Figure 5) (Williams, 2006; Rutkevich and Williams, 2011). Only 
after removal of the innermost glucose residue by glucosidase II, is a polypeptide released 
from CNX and CRT. Unfolded or incorrectly folded polypeptides are subsequently re-
glycosylated by UDP-glucose/glycoprotein glucosyl transferase (UGGT) and returned into the 
CNX/CRT cycle (Solda et al., 2007; D'alessio et al., 2010). This process is repeated until 
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finally, correctly folded proteins are released from the cycle and transported to their final 
destination (Hebert et al., 2005). 
In addition to binding oligosaccharides, CNX and CRT also recognise proteins via 
their polypeptide-biding sites (Ware et al., 1995; Ihara et al., 1999). Numerous studies have 
demonstrated that both CNX and CRT recognise normally glycosylated clients even in 
glycosylation-deficient cells and also bind unfolded non-glycosylated proteins (Rajagopalan 
et al., 1994; Basu and Srivastava, 1999; Saito et al., 1999; Spee et al., 1999; Danilczyk and 
Williams, 2001; Swanton et al., 2003). These results clearly suggest the possibility of a 
glycan-independent recognition mechanism. However, the existence of this additional client-
binding mechanism is still under debate (Williams, 2006).
The BiP chaperone system
BiP is a member of the highly conserved HSP70 family that can be found in all organisms 
(Gupta and Golding, 1993). There are eight different HSP70 family members in human cells.
HSP70s can be found in the cytosol, the ER, mitochondria and in the nucleus (Kampinga et 
al., 2009). BiP is one of the most abundant chaperones in the ER (Araki and Nagata, 2011), 
where it is co-translationally targeted via an N-terminal signal sequence and retained via a 
C-terminal KDEL retention signal (Behnke et al., 2015). Proper morphology and functioning
of the ER depends on BiP activity (Hendershot et al., 1995; Paton et al., 2006). The BiP 
folding cycle is thought to be the most important quality control system for non-glycosylated 
proteins as well as for proteins that are glycosylated relatively late in their folding cycle
(Molinari and Helenius, 2000). BiP’s activities include facilitating client protein folding, 
prevention of aggregation as well as delivering proteins for ER-associated degradation 
(ERAD) (Figure 5) (Brodsky et al., 1999; Hendershot, 2004; Christianson et al., 2008; 
Hosokawa et al., 2008; Olzmann et al., 2013). BiP is present in cells in an active state, which 
is thought to be unmodified and monomeric, and in an inactive state that is AMP-ribosylated,
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phosphorylated and oligomeric (Carlsson and Lazarides, 1983; Welch et al., 1983; Freiden et 
al., 1992; Behnke et al., 2015). It is thought that BiP is present mostly in its inactive state 
forming an oligomeric pool, which can be readily activated when required, for example 
during conditions of stress. Unfolded protein substrates as well as elevated ATP levels cause 
dissociation of BiP oligomers into the active monomeric form (Carlino et al., 1992; Freiden et 
al., 1992; Blond-Elguindi et al., 1993; Behnke et al., 2015).
All HSP70 family members contain an N-terminal ATPase domain, also called the 
nucleotide binding domain (NBD), and a peptide-binding domain (PBD). The PBD contains 
an extended hydrophobic stretch that interacts with hydrophobic regions of client proteins 
(Bertelsen et al., 2009). In the ATP-dependent client binding and release cycle that is the 
common activity cycle of all HSP70s, the NBD regulates the conformation of the PBD (Gaut 
and Hendershot, 1993; Hendershot et al., 1996; Kampinga and Craig, 2010). In the ATP-
bound state, HSP70s rapidly bind and release client proteins. ATP hydrolysis then locks client 
binding tightly. However, due to the very weak intrinsic Mg2+-dependent ATPase activity of 
HSP70s (Kassenbrock and Kelly, 1989; Mayer et al., 2003), their activity cycle requires the 
HSP40 J-domain-containing co-chaperone family (HSP40/DNAJ) that stimulate the ATPase 
activity to stabilise the client interactions after delivery of client proteins to HSP70 (Laufen et 
al., 1999). HSP40s are structurally very diverse and the large number of different HSP40s is 
thought to determine both substrate specificity and differential functions of HSP70s. 
ER-localised Hsp40 family members control the various functions of BiP by regulating client
binding and release rates (Kampinga and Craig, 2010; Behnke et al., 2015). Seven members 
of the HSP40 family, ERdj1-7, have been identified as BiP co-chaperones (Araki and Nagata, 
2011). The transmembrane proteins ERdj1 and ERdj2 are homologues of the yeast 
translocation protein Sec63 and are thus thought to recruit BiP to the translocon, where it
assists folding of newly synthesised polypeptides (Lyman and Schekman, 1997; Muller et al., 
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2010; Araki and Nagata, 2011). The HSP40 member ERdj3 assists in de novo protein folding
and also acts in a complex with BiP, GRP94, GRP170 and other folding factors to assist 
folding of immunoglobulin G (Meunier et al., 2002; Otero et al., 2010). During conditions of 
ER stress, ERdj3 is secreted and binds misfolded proteins to prevent their toxic aggregation in 
the extracellular space (Genereux et al., 2015). ERdj4 and ERdj5 interact with the ERAD
components p97 and EDEM, respectively, and target misfolded proteins for degradation 
(Dong et al., 2008; Ushioda et al., 2008). ERdj6 (also referred to as p58IPK) is involved in de 
novo protein folding (Gale et al., 1998; Yan et al., 2002).
Once a substrate is correctly folded, BiP needs to return from its ADP- to its ATP-
bound state to release its client and complete the chaperone cycle. For this release step, the 
activity of nucleotide exchange factors (NEFs) is required. NEFs swap ADP for ATP, which 
loosens the HSP70-client interaction and thus NEFs control substrate release (Dragovic et al., 
2006). BiP especially relies on NEFs because nucleotide exchange is thought to be the rate-
limiting step of the chaperone cycle in the folding environment of the ER. This is due to the 
fact that the high Ca2+ concentration increases the affinity of BiP for ADP by almost 
1000-fold (Lamb et al., 2006; Behnke et al., 2015). The ER-localised NEFs that are 
responsible for BiP regulation are the hypoxia up-regulated protein 1 (HYOU1/ GRP170/
ORP-150) and BiP-associated protein (BAP/ Sil1) (Lin et al., 1993; Chung et al., 2002; 
Meunier et al., 2002; Kampinga and Craig, 2010; Behnke et al., 2015). HYOU1 is conserved 
in eukaryotes and is, like the cytosolic NEF HSP110, a member of the family of the so-called 
large HSP70s that have a similar domain organisation as the HSP70 family (Chen et al., 1996; 
Craven et al., 1997; Easton et al., 2000). HYOU1 bears a similar NBD as BiP but with higher 
ATP affinity (Dierks et al., 1996). However, unlike BiP, HYOU1 is highly glycosylated and 
the two proteins vary greatly in their SBDs. HYOU1 also facilitates protein folding directly 
via interactions with unfolded proteins through a mechanism that is distinct from the 
Introduction
22
chaperone activity of HSP70s (Behnke and Hendershot, 2014). HYOU1 lacks a highly 
conserved arginine residue that is present not only in all HSP70s but also in the cytosolic 
large HSP70s and is required for interactions with HSP40s. Thus, HYOU1 must be regulated 
by a distinct mechanism (Behnke et al., 2015). HYOU1 is retained in the ER via a C-terminal 
KNDEL retention signal (Ikeda et al., 1997). Notably, the cytosolic NEF HSP110 has been 
suggested to act as a disaggregase (Rampelt et al., 2012; Mattoo et al., 2013) but it is hitherto
unknown whether HYOU1 has a similar activity. The second ER-localised NEF, Sil1, shares
some identity with the cytosolic NEF HSPBP1, consisting of four armadillo motifs that fold 
around the ATPase domain of BiP (Behnke et al., 2015). The interaction with BiP is thought 
to be responsible for ER retention since Sil1 does not contain a retention signal (Howes et al., 
2012). HYOU1 and Sil1 do not interact with one another and regulate BiP in a mutually 
exclusive manner (Behnke et al., 2015). Taken together, the chaperone cycle of BiP is 
controlled by the relative concentrations of both HSP40s and NEFs.
The GRP94 chaperone
The ER chaperone 94 kDa glucose regulated protein (GRP94/endoplasmin/HSP90B1) is part 
of the highly conserved HSP90 chaperone family that also includes the cytosolic HSP90A and 
mitochondrial TNFR-associated protein (TRAP) (Taipale et al., 2010). GRP94, which is 
retained in the ER by a C-terminal retention signal, is found in all multicellular animals and 
plants but not in yeast or other unicellular organisms (Marzec et al., 2012). Unlike other major
ER chaperones, GRP94 is very selective. To date, less than twenty substrates that rely on
GRP94 for folding and/or assembly have been identified. These mainly include secretory and 
membrane proteins. GRP94 is essential for animal and plant development. However, it is not 
required for global protein trafficking and secretion and is also not essential for mammalian 
cells grown in cell culture, most likely because of its selectivity for a small number of 
substrates (Marzec et al., 2012). GRP94 is active mostly as a dimer in a conformational cycle
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that is common to HSP90 family members and requires its ATPase activity (Stefanovic and 
Hegde, 2007; Taipale et al., 2010; Marzec et al., 2012). ATP binding via the N-terminal 
domain (NTD) results in a closed conformation of HSP90s. Subsequent hydrolysis of ATP to 
ADP and ADP dissociation restores the open conformation. Due to the similar affinity of 
GRP94 for ATP and ADP (Soldano et al., 2003; Immormino et al., 2004), which is 
uncommon amongst HSP90 chaperones, GRP94 has a unique mechanism of regulation. 
GRP94 is subject to N-glycosylation, acetylation and phosphorylation and is a potent
Ca2+ carrier. Ca2+ binding induces a conformational change and thus regulates GRP94 activity
(Van et al., 1989; Marzec et al., 2012). The cytosolic HSP90 is regulated by different co-
chaperones (Zuehlke and Johnson, 2010). In comparison, GRP94 also interacts with other ER 
proteins that may act as co-chaperones, including protein canopy homolog 3 (CNPY3), which 
is required for proper folding of toll-like receptor (TLR) (Liu et al., 2010), ATPase ASNA1, 
which is required for delivery of TA proteins, and the protein OS-9, which targets misfolded 
proteins for ERAD (Kao et al., 2007; Stefanovic and Hegde, 2007; Christianson et al., 2008; 
Liu et al., 2010). Thus, in addition to its role in protein folding, GRP94 is also involved in
directing misfolded proteins to the ERAD machinery (Figure 5).
Degradation of ER proteins
ER proteins that are terminally misfolded and thus cannot reach their native state, are 
prevented from exiting the ER by retention in chaperone cycles and are targeted for ER-
associated degradation (ERAD) (Figure 5) (reviewed in (Olzmann et al., 2013)). Terminal 
misfolding can occur due to destabilising mutations, erroneous protein synthesis or 
deficiencies in the ER proteostasis network. ER-localised proteins must be relocated into the 
cytosol before they can be degraded by the proteasome. Thus, after recognition of an ERAD
substrate, the substrate is retro-translocated (dislocated) through the dislocon in the ER 
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membrane. In the cytosol, the substrate is then subject to ubiquitination followed by 
proteasomal degradation. 
Most ERAD substrates are recognised via their specific glycosylation signature, which 
is generated by mannosidases that trim mannose residues from misfolded glycans. This glycan 
is then further processed by the activity of EDEM1, EDEM3, ERMan1, and Man1C1, 
stimulating progressive removal of terminal mannose residues. The resulting demannosylated 
and deglucosylated substrates cannot re-enter the CNX/CRT cycle and are thus irreversibly 
targeted for degradation (Gonzalez et al., 1999; Tremblay and Herscovics, 1999; Olivari et al., 
2006; Hosokawa et al., 2007; Hosokawa et al., 2009; Lederkremer, 2009; Aebi et al., 2010; 
Hosokawa et al., 2010). The substrate recognition factors OS-9 and XTP3-B then bind 
substrates via their mannose-6-phosphate receptor homology (MRH) domains (Bernasconi et 
al., 2008; Christianson et al., 2008; Hosokawa et al., 2008). Even though OS-9 and XTP3-B 
share little sequence homology except for the MRH domain, they have some redundant 
activity and only simultaneous knock-down of both genes affects the stability of model 
substrates (Bernasconi et al., 2010). OS-9 and XTP3-B are also involved in ERAD of non-
glycosylated substrates (Sekijima et al., 2005; Okuda-Shimizu and Hendershot, 2007; 
Bernasconi et al., 2008; Christianson et al., 2008; Hosokawa et al., 2008). However, while the 
mechanisms of glycosylated substrate recognition have been studied extensively, the 
underlying molecular mechanisms of non-glycosylated substrate recognition are not as well 
understood. Both OS-9 and XTP3-B may recognise misfolded regions within a substrate in 
addition to the glycosylation signature (Hosokawa et al., 2009). Alternatively, OS-9 and 
XTP3-B may bind non-glycosylated substrates indirectly via an interaction with GRP94 and 
with BiP (Christianson et al., 2008; Hosokawa et al., 2008). BiP is also thought to be involved 
in ERAD via its co-chaperone ERdj5, which interacts with EDEM1 (Ushioda et al., 2008). 
Introduction
25
Another suggested mechanism for degradation of non-glycosylated substrates involves 
targeting via post-translational glycosylation (Sato et al., 2012). 
Following substrate recognition, EDEM1, EDEM3, OS-9 and XTP3-B bind the 
adaptor protein SEL1L that links substrate recognition complexes to the dislocon factor Hrd1 
(Bernasconi et al., 2008; Christianson et al., 2008; Hosokawa et al., 2008; Cormier et al., 
2009; Carvalho et al., 2010; Saeed et al., 2011; Hosokawa and Wada, 2016). SEL1L is a 
transmembrane protein and interacts with the integral membrane proteins AUP1, Derlin-1, 
Derlin-2, Herp, UBXD8 and VIMP. The cytosolic VCP/p97 complex is recruited to this 
complex to facilitate substrate dislocation into the cytosol (Mueller et al., 2006; Christianson 
et al., 2008; Hosokawa et al., 2008; Mueller et al., 2008; Iida et al., 2011; Klemm et al., 2011; 
Christianson et al., 2012). In addition to SEL1L, the intramembrane proteins Erlin-1 and 
Erlin-2 are also substrate adaptors that connect substrates to the E3 ubiquitin ligases gp78, 
Hrd1 and Trc8 (Christianson et al., 2012; Olzmann et al., 2013). E3 ubiquitin ligases bind 
substrates and catalyse transfer of ubiquitin from E2 ligases to target substrates for 
proteasomal degradation (Berndsen and Wolberger, 2014).
It remains to be fully elucidated which factors make up the dislocon through which 
ERAD substrates are retro-translocated into the cytosol but Derlins 1-3, Hrd1, Sec61 and the 
signal peptidase (SP) have been proposed to be involved (Plemper et al., 1997; Lilley and 
Ploegh, 2004; Ye et al., 2004; Loureiro et al., 2006; Scott and Schekman, 2008; Carvalho et 
al., 2010). Notably, retro-translocation does not require substrates to be completely unfolded, 
unlike translocation of proteins into the ER through the Sec61 translocon, as it has been 
reported that substrates with tightly folded and ligand-stabilised domains, proteins with 
glycosylated residues and even whole virus particles can be retro-translocated (Fiebiger et al., 
2002; Tirosh et al., 2003; Blom et al., 2004; Lilley et al., 2006; Geiger et al., 2011). The 
mechanism of retro-translocation must be fundamentally different from that of classic protein 
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channels such as the Sec61 complex because substrates that are even larger than the Sec61 
pore complex itself can be retro-translocated through the dislocon. Despite the finding that 
partially folded proteins can be retro-translocated, it is thought that a reduction of disulphide
bonds is required (Olzmann et al., 2013).
Once a substrate emerges from the dislocon complex, it is recognised by the 
cytoplasmic homohexameric ATPase p97/VCP that drives further retro-translocation. In the 
cytosol, substrates are processed by deglycosylating enzymes, ubiquitin-binding proteins and 
deubiquitinating enzymes. The polytopic RING domain ligases gp78 and Hrd1 are among the 
major E3 ubiquitin ligases that are thought to be involved in ERAD (Bays et al., 2001; Fang et 
al., 2001; Nadav et al., 2003; Kikkert et al., 2004). In addition, the more specialised ligases 
Kf-1/RNF103, Nixin, RFP2/TRIM13, RNF5/Rma-1, RNF170 and TEB4/MARCH6 have also 
been implicated as playing a role in ERAD (Hassink et al., 2005; Younger et al., 2006; Lerner 
et al., 2007; Maruyama et al., 2008; Stagg et al., 2009; Altier et al., 2011; Lu et al., 2011; 
Neutzner et al., 2011). These ligases may work in parallel depending on substrate specificity, 
simultaneously on different residues of the same substrates, cooperatively or sequentially 
(Olzmann et al., 2013). ERAD substrates are then subject to degradation by the 26S 
proteasome, whose substrates also include cytosolic proteins that are also targeted for 
degradation cooperatively by molecular chaperones and E3 ubiquitin ligases (Kim et al., 
2013).
The second major cellular degradation pathway is lysosomal degradation via the 
autophagy pathway. This involves double-membrane-bounded structures, so-called 
autophagosomes, which enclose substrates to deliver them to the lysosome. Autophagosomes 
are thought to also pinch off elements of the ER for degradation (Perlmutter, 2011). Some 
aggregated proteins that accumulate in the ER have been reported to be degraded via this 
pathway (Teckman and Perlmutter, 2000; Kamimoto et al., 2006; Hidvegi et al., 2010).
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Cellular stress responses
Destabilising mutations or PN impairment can lead to the accumulation of misfolded or 
unfolded proteins. This in turn often causes a vicious cycle of further misfolding and 
aggregation due to progressive overburdening of the PN that eventually leads to proteostasis 
collapse (Figure 3). Cells have evolved specialised response pathways that sense disturbances 
in proteostasis and increase the cellular capacity to deal with the stress by inducing the 
expression of PN factors (Figure 3).
The cytosolic stress response
The accumulation of misfolded proteins in the cytosol induces the heat shock response (HSR) 
that stimulates the upregulation of proteostasis factors, most prominently molecular 
chaperones that assist protein folding and counteract aggregation. Other factors induced by 
the HSR include degradation factors, nucleic acid-modifying enzymes, metabolic enzymes, 
transcription factors, and kinases as well as proteins involved in transport, membrane 
modulation and in maintaining intracellular structures (Richter et al., 2010). The cellular HSR 
is characterised by activation of heat shock factor 1 (HSF1) that induces the expression of 
HSPs (Parker and Topol, 1984; Kingston et al., 1987). As its name suggests, the heat shock 
response was originally discovered as a cellular response to elevated temperatures (Ritossa, 
1962); however, the HSR is not exclusive induced by heat stress but can also be activated by 
oxidative stress, heavy metals or chemicals that cause similar cellular damage (Bauman et al., 
1993; Mcduffee et al., 1997). Cellular recovery from such stress is accompanied by an 
acquired tolerance to more severe stress (Richter et al., 2010). However, prolonged, severe 
stress may lead to cell death.
The unfolded protein response
Protein folding stress in the ER induces a distinct stress response, namely the unfolded protein 
response (UPR) (Figure 6) (Walter and Ron, 2011). Protein folding in the ER can be disturbed 
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by a range of endogenous and external conditions including destabilising mutations, protein 
overload, alterations in Ca2+ levels, hypoxia, and glucose deprivation that causes a drop in 
ATP levels. Conditions that disrupt protein folding and maturation lead to accumulation of 
misfolded proteins in the ER and are referred to as ER stress. UPR factors sense ER stress and
transmit a signal to the cytosol and nucleus to activate specific transcription factors that 
induce a coordinated stress response (Walter and Ron, 2011). The UPR relieves stress by 
inhibiting general translation, while simultaneously up-regulating proteins involved in protein 
degradation, folding, processing and trafficking as well as lipid biosynthesis in order to re-
establish ER homeostasis. The UPR is thus an important physiological adaptation mechanism. 
However, during conditions of severe or prolonged ER stress that cannot be resolved, the 
UPR induces cell death via apoptosis (Puthalakath et al., 2007). 
ER stress is first sensed by activating transcription factor 6 (ATF6), inositol requiring 
enzyme 1 α (IRE1α, Endoplasmic reticulum-to-nucleus signalling 1, ERN1) and the PKR-like 
ER kinase (PERK) that are located in the ER membrane and transmit the stress signal to the 
cytosol (Walter and Ron, 2011). In the absence of stress, the three sensors are present in an 
inactive BiP-bound state. Upon accumulation of misfolded proteins in the ER, BiP is 
sequestered by misfolded substrates and dissociates from the UPR sensors allowing for their
activation. 
The ATF6 branch
The transcription factor ATF6 is retained as an ER transmembrane protein by association with 
BiP. Upon ER stress, BiP dissociates allowing for ATF6 translocation to the Golgi apparatus, 
where the transmembrane domain is cleaved releasing a transcription factor, which 
subsequently translocates to the nucleus to activate target genes (Figure 6) (Chen et al., 2002).
ATF6 targets include genes involved in ER protein processing and ERAD (Adachi et al., 
2008; Shoulders et al., 2013). ATF6 activity is thus cytoprotective as it improves ER 
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proteostasis. ATF6 also transcriptionally induces X-box binding protein 1 (XBP1) that is 
activated by cleavage of its mRNA by IRE1α (Yoshida et al., 2001). Furthermore, ATF6 
collaborates with XBP1 in transcriptional activation (Yamamoto et al., 2004).
Figure 6. The unfolded protein response. The accumulation of misfolded proteins in the ER 
causes the activation of the ER stress sensors ATF6, PERK and IRE1α that transmit a signal 
into the cytosol and nucleus to induce a coordinated stress response.
The IRE1α branch
IRE1 is a type I ER transmembrane protein that has serine-threonine kinase as well as 
endoribonuclease activity owing to a cytosolic kinase-extension nuclease (KEN) domain (Lee 
et al., 2008b; Ali et al., 2011). IRE1 is present in two different isoforms: the extensively 
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studied and ubiquitously expressed IRE1α, and IRE1β, which has so far only been found in 
epithelial cells of the gastrointestinal tract and in the bronchi (Wang et al., 1998; Bertolotti et 
al., 2001; Martino et al., 2013). BiP dissociation during stress leads to oligomerisation and 
subsequent trans-autophosphorylation of IRE1α. Phosphorylation activates the 
endoribonuclease domain, which then splices the pre-mRNA of XBP1 (Figure 6) (Cox and 
Walter, 1996; Kawahara et al., 1997; Calfon et al., 2002). The XBP1 pre-mRNA is recruited 
to the ER membrane co-translationally together with the stalled translation complex and the 
emerging nascent chain of the unspliced XBP1 (Yoshida et al., 2001; Yanagitani et al., 2009; 
Plumb et al., 2015).  At the ER membrane, IRE1α cuts a 26 nucleotide intron out of XBP1 
mRNA (Yoshida et al., 2001). The spliced XBP1 (XBP1s) mRNA is then ligated by RtcB (Lu 
et al., 2014). The resulting frame shift allows for translation of the active transcription factor 
XBP1s and down-stream induction of its target genes that are involved in protein folding, 
trafficking, degradation and glycosylation, and in lipid synthesis and thus increase the ER’s
capacity to deal with misfolded proteins (Lee et al., 2003; Yoshida et al., 2003; Oda et al., 
2006; Acosta-Alvear et al., 2007; Lee et al., 2008a; Shoulders et al., 2013). During recovery,
XBP1s activity is regulated by a negative feedback loop that involves the translational product 
of the unspliced mRNA (XBP1u) (Yoshida et al., 2006; Guo et al., 2010). Activated IRE1α 
also splices certain mRNAs in order to degrade them, a mechanism referred to as IRE1-
dependent decay (RIDD) (Figure 6) (Han et al., 2009; Hollien et al., 2009; Gaddam et al., 
2013). The purpose of this mechanism is to reduce translation of secretory proteins and in this 
way lower the burden on the ER (Hollien et al., 2009). On the other hand, RIDD may also 
contribute to ER stress-induced cell death as it was reported to activate pro-apoptotic 
signalling (Han et al., 2009)
IRE1α also recruits the adaptor protein E3 ubiquitin ligase TNF-receptor-associated 
factor 2 (TRAF2), which links the apoptosis signalling kinase-1 (ASK1) to IRE1α kinase 
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activity (Nishitoh et al., 1998; Nishitoh et al., 2002). ASK1 in turn induces the mitogen-
activated protein (MAP) kinase member c-Jun N-terminal kinase (JNK) (Figure 6), which is 
associated with pro-apoptotic signalling (Urano et al., 2000; Nishitoh et al., 2002). IRE1α-
induced TRAF2 also activates the transcription factor nuclear factor kappa-light-chain-
enhancer of activated B-cells (NF-κB), which is in this context associated with pro-survival 
signalling (Kaneko et al., 2003). IRE1α has also been suggested to induce the extracellular 
signal-regulated kinases (ERK) and the MAP kinases p38 (Zhao et al., 2011). Thus, ER 
stress-induced IRE1α signalling can induce both pro-survival and pro-apoptotic responses and 
it is not yet fully understood how these opposing effects are coordinated. Several cytosolic 
factors have been proposed to regulate the various functions of IRE1α (Marcu et al., 2002; 
Lisbona et al., 2009; Gupta et al., 2010).
The PERK branch
In a similar manner as IRE1α, the serine/threonine protein kinase PERK is also activated by 
dimerisation and trans-autophosphorylation after dissociation of BiP. Activated PERK 
phosphorylates the α-subunit of eukaryotic initiation factor 2 (eIF2α) (Figure 6). The
eukaryotic initiation factors play important roles in translation as they recognise either the 
m7G cap at the 5’ end or the poly(A) tail at the 3’ end of mRNA, which allows binding of the 
pre-initiation complex (PIC) that consists of the small ribosomal subunit carrying Met-tRNAi. 
The PIC then searches for the start codon by scanning the mRNA sequence (Sonenberg and 
Hinnebusch, 2009). Phosphorylated eIF2 acts as an inhibitor of its own nucleotide exchange 
factor, eIF2B, because it has increased affinity for eIF2B but nucleotide exchange cannot 
occur in the phosphorylated state of eIF2. In this way, phosphorylation of eIF2α prevents it to 
return into its active state and thus blocks the translation initiation process leading to 
translational arrest of most mRNAs and a reduction in ER protein load (Kao et al., 2007). 
However, a few mRNAs, including many UPR targets and transcription factors, contain so-
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called internal ribosome entry sites (IRESs) near the start codon that allow for PIC binding 
and translation initiation independent of this scanning mechanism (Sonenberg and 
Hinnebusch, 2009). Another mechanism of translation that occurs after eIF2α phosphorylation 
is that of the transcription factor ATF4. In fact, ATF4 translation occurs preferentially once 
eIF2α is phosphorylated because its mRNA contains short upstream open reading frames 
(uORFs) in the 5’ untranslated region that are predominantly targeted by the PIC under 
normal conditions. Ribosome initiation at these uORFs hinders translation of the further 
downstream coding sequence. Only after phosphorylation of eIF2α this mechanism is blocked 
allowing for a stochastic bypass of the uORFs and ribosome access to the start codon of the 
downstream coding sequence of ATF4 (Hinnebusch, 2014; Starck et al., 2016). Thus, eIF2α 
phosphorylation blocks general translation but induces the transcription factor ATF4 and 
allows translation of UPR target genes. Notably, PERK is not the only kinase that 
phosphorylates eIF2α. Three related kinases, called general control nonderepressible 2 
(GCN2), heme-regulated inhibitor kinase (HRI), and interferon-induced dsRNA–dependent 
kinase (PKR) phosphorylate eIF2α in response to various conditions of stress that include heat 
shock, amino acid deprivation, osmotic shock, oxidative stress and viral infection (Donnelly 
et al., 2013). Induction of the eIF2α kinases leading to ATF4 activation is collectively referred 
to as the integrated stress response (ISR). ATF4 target genes include factors involved in 
restoring ER homeostasis and also other cytoprotective genes that are not ERQC-related as 
well as pro-apoptotic factors including the transcription factor C/EBP-homologous protein 
(CHOP, also referred to as GADD153) (Harding et al., 2000; Bi et al., 2005; Blais et al., 
2006). PERK was also reported to induce NF-κB in an eIF2α phosphorylation-dependent 
manner (Deng et al., 2004).
PERK also activates the transcription factor nuclear factor-erythroid 2-related factor 2 
(NRF2) (Figure 6). After phosphorylation by PERK, NRF2 dissociates from its negative 
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regulator Kelch-like ECH-associated protein 1 (KEAP1). NRF2 target genes play a role in
cytoprotective redox signalling (Cullinan et al., 2003). 
The ordered protein response
Notably, ER luminal accumulation of some aggregation-prone mutant proteins does not 
induce the UPR. These proteins include disease mutants of the serpin proteins α1-antitrypsin 
(A1AT) and neuroserpin (NRS) that form polymers within the ER (Graham et al., 1990; 
Hidvegi et al., 2005; Davies et al., 2009). One explanation for why these mutant serpin 
proteins do not induce the UPR, even though they are prone to aggregate, is that they may not 
be recognised as misfolded protein species because they closely resemble the native state of 
the monomer (Yamasaki et al., 2008; Perlmutter, 2011). However, ER-retained polymers of 
both mutant A1AT (Lawless et al., 2004; Hidvegi et al., 2005) and mutant NRS (Davies et al., 
2009) induce the transcription factor NFκB in a UPR-independent manner. At least in the case 
of NRS polymers, this UPR-independent NFκB activation was caused by an increased flux of 
Ca2+ from the ER into the cytosol (Davies et al., 2009). NFκB activation by serpin polymers 
was first described as the ER overload response (EOR) but later renamed the ordered protein 
response (OPR) to underline that it is distinct from the UPR (Davies et al., 2009).
Protein aggregation toxicity
Protein aggregation is associated with a large number of different human diseases, the so-
called protein misfolding or protein conformational diseases (Chiti and Dobson, 2006;
Knowles et al., 2014). Protein aggregation can be caused by the synthesis of folding-
incompetent protein species or by defects in the protein quality control machinery. If such 
species are not efficiently degraded, they are prone to form insoluble aggregate 
conformations. 
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Human diseases that are characterised by protein aggregates exhibit a wide variety of
clinical symptoms (Table 2). Despite the diverse identities and properties of the aggregating 
proteins the aggregate conformations they form are very similar and elicit common toxic 
effects and cellular responses. Among the most prominent aggregate conformations are
amyloid-like fibrils that consist of cross-β structures. Amyloid-like aggregates are associated 
with a range of human diseases including neurodegenerative disorders, non-neuropathic 
localised amyloidoses and non-neuropathic systemic amyloidosis, including sporadic and 
hereditary forms (Chiti and Dobson, 2006). 
Disease Clinical Features Aggregating protein
Cellular location
of aggregates
Alpha 1-antitrypsin 
deficiency
Lung and liver disease α1-antitrypsin (A1AT) Endoplasmic Reticulum
Alzheimer‘s disease 
(AD)
Progressive dementia Amyloid-β (Aβ) and tau
Extracellular, 
cytoplasmic
Amyotrophic lateral 
sclerosis
Movement disorder Superoxide dismutase Cytoplasmic
Familial 
encephalopathy with 
neuroserpin inclusion 
bodies (FENIB)
Dementia Neuroserpin (NRS) Endoplasmic Reticulum
Huntington‘s disease 
(HD)
Dementia, motor and 
psychiatric symptoms
Huntingtin (Htt) Nuclear
Parkinson‘s disease 
(PD)
Movement disorder α-synuclein Cytoplasmic
Transmissable 
spongiform 
encephalopathies
Dementia, ataxia, 
psychiatric problems
Prion protein (PrP) Extracellular
Transthyretin 
amyloidosis
Progressive sensory 
and motor 
polyneuropathy
Transthyretin (TTR) Extracellular
Table 2. Diseases associated with protein aggregation. Modified from (Soto, 2003).
Conformational diseases caused by mutant ER proteins
Aggregation toxicity can be caused by loss-of-function as well as gain-of-function effects and 
in many cases both effects contribute to the disease. Misfolded secretory proteins are 
recognised by the ERQC machinery and are retained in the ER until they reach their native 
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state or are targeted for degradation to protect cells from the accumulation of toxic 
aggregation-prone proteins. However, retention and degradation can cause disease due to loss-
of-function toxicity (Figure 7). Loss-of-function toxicity is caused by the loss of important 
protein activities and can be mimicked by knockout of a specific gene. It should however be 
noted that this effect is distinct from specific loss-of-function mutations because even though 
destabilising mutations affect the folding efficiency of a protein, the protein may be functional 
if correct folding is assisted. Thus, in the case of conformational diseases, loss-of-function 
toxicity is not the result of non-functionality of a specific protein activity. Instead, it is caused 
by aggregation and/or degradation of a protein before it can reach its native state (Hebert and 
Molinari, 2007; Molinari, 2007). The important difference is that loss-of-function disorders 
that are caused by folding-deficient mutants could potentially be treated by therapies that 
increase protein folding efficiency or protein trafficking. For example in the autosomal 
recessive disorder cystic fibrosis, folding deficient mutants of  the membrane protein cystic 
fibrosis transmembrane conductance regulator (CFTR) do not reach their native state and 
target location and are degraded by ERAD (Cheng et al., 1990; Jensen et al., 1995; Ward et 
al., 1995). Other examples of diseases caused by loss-of-function toxicity are diabetes 
mellitus, familial hypercholesterolemia and retinitis pigmentosa (Hebert and Molinari, 2007). 
If the ERQC fails to target folding-deficient secretory proteins for degradation they 
can cause gain-of-function toxicity (gain-of-toxicity) (Figure 7). Gain-of-function toxicity is 
caused by the shear presence of aggregate conformations independent of the native identity of 
the aggregating proteins. Secretion of toxic misfolded protein species can lead to disorders 
such as the light chain and the transthyretin amyloidoses (Sorgjerd et al., 2006; Blancas-Mejia 
and Ramirez-Alvarado, 2013). However, ER retention of such aggregation-prone proteins 
causes intracellular gain-of-toxicity such as in the case of the serpinopathies, in which 
destabilised mutant serpin proteins accumulate in the ER as ordered polymers that interact 
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with each other via mobile loops and β-sheets. Serpinopathies are caused by point mutations 
in neuroserpins (NRS), α1-antitrypsin (A1AT), antithrombin or 1-antichymotrypsin, all of 
which are members of the serine proteinase inhibitor (serpin) superfamily (Fitton et al., 1997; 
Gooptu et al., 2000; Sivasothy et al., 2000; Davis et al., 2002; Irving et al., 2011). Single point 
mutations in the NRS gene (S49P, S52R, H338R, or G392E) cause the dementia familial 
encephalopathy with neuroserpin inclusion bodies (FENIB). NRS proteins with any one of 
these mutations polymerise and are retained in the ER of neurons, where they cause toxicity 
leading to progressive dementia (Davis et al., 2002; Miranda et al., 2004). Mutations in the 
serpin A1AT cause A1AT deficiency that manifests itself in lung and liver disease 
(Perlmutter, 2011). 
Notably, FENIB and A1AT deficiency are associated with both loss-of-function and
gain-of-function toxicity. A1AT normally inhibits neutrophil proteases and loss of A1AT 
function leads to uncontrolled activation of these proteases resulting in damage to lung tissue 
(Perlmutter, 2011). Conversely, in this case A1AT replacement therapy has not proven 
effective and it is thus suspected that in addition to loss-of-function effects, gain-of-toxicity of 
A1AT mutants affects respiratory epithelial cells (Perlmutter, 2011). A1AT mutants have 
been shown to block the mobility of ER proteins, causing gain-of-toxicity that is thought to be 
responsible for liver disease at later stages of A1AT deficiency (Ordonez et al., 2013). 
In Alzheimer’s disease, amyloid β protein (Aβ) forms amyloid fibrils predominantly in 
the extracellular space as well as within cells leading to gain-of-toxicity. The aggregation-
prone Aβ is generated by cleavage of the amyloid precursor protein (APP) at the plasma 
membrane and the late Golgi (O'brien and Wong, 2011). In addition, intracellularly
accumulated Aβ is thought to be generated in the ER (LaFerla et al., 2007; Skovronsky et al., 
1998; Wild-Bode et al., 1997).
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Figure 7. The different fates and potential modes of toxicity of terminally misfolded 
proteins in the ER. Some destabilised disease proteins aggregate in the ER or are secreted 
and form toxic aggregates in the extracellular space. Protein aggregation can cause gain-of-
function and loss-of-function toxicity. If misfolded proteins are retained in the ER and 
efficiently targeted for degradation via ERAD, this can also cause loss-of-toxicity. 
Even though protein aggregation is associated with cytotoxicity in many diseases it 
should be noted that it is unclear whether toxicity is caused by large aggregates or rather by 
smaller oligomeric conformations en route to formation of larger inclusions. It has been 
suggested that the formation of large aggregates may serve as a protective mechanism, 
whereby toxic protein species are deposited in large inert inclusions, even though large 
aggregates have also been demonstrated to cause toxicity in various contexts (Haass and 
Selkoe, 2007).
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Mutations in ERQC factors can cause diseases
The importance of the ERQC for human health is exemplified by the detrimental symptoms of 
the multisystem disorder Marinesco-Sjögren syndrome (MSS) that include cataracts,
cerebellar ataxia, growth-restriction, mental retardation and myopathy. MSS is caused by 
mutations in Sil1 (Senderek et al., 2005). Other examples include bleeding disorders that are 
caused by mutations in ERGIC53, a protein trafficking factor, leading to reduced secretion of 
blood coagulation factors (Nichols et al., 1998).
ER stress responses in disease
In cancer, the proteostasis network is often co-opted to promote cancer cell growth and 
survival. Increased rates of protein synthesis during tumorigenesis can overburden the ERQC 
leading to ER stress. Cancer cells adapt to such conditions by up-regulating components of
the ERQC machinery or the ER stress response. In particular,  factors of the UPR are often
up-regulated in cancer cells (Healy et al., 2009). For example, in multiple myeloma (MM), a 
cancer of B lymphocytes, which are highly specialised in antibody production and secretion, 
the ERQC is burdened by massive production of paraprotein, an abnormal immunoglobulin 
fragment. Due to the increased requirement for protein folding in the ER, MM cells depend on 
the ERQC system as well as on the activity of the UPR (reviewed in (Vincenz et al., 2013)).
In addition to relieving the stress caused by high rates of protein synthesis, the UPR also
promotes adaptation of cancer cells to conditions of hypoxia that are usually present in solid 
tumours.
In neurodegenerative diseases, ER stress can contribute to neuroprotection but also to 
neuronal loss. For example, XBP1s is induced by Aβ and has neuroprotective activity in 
models of AD (Casas-Tinto et al., 2011). However, Aβ as well as the Prion disease protein 
PrPSc have been demonstrated to induce apoptosis via ER stress in cortical neurons (Ferreiro 
et al., 2006; Hetz et al., 2003; Nakagawa et al., 2000). 
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ER quality control in aging
Aging is accompanied by the progressive accumulation of irreparable damage to cellular 
components and concurrently an impairment of the ability to induce cellular stress responses. 
This leads to compromised cellular homeostasis, particularly under conditions of stress, and to 
vulnerability to certain diseases. Proteostasis is especially affected by aging, which is 
exemplified by the progressive accumulation of protein aggregates in diseases such as 
Alzheimer’s (AD), Parkinson’s (PD) and Huntingtin’s disease (HD). Studies of aging 
nematodes have revealed the global effects of aging on cellular proteostasis, which include
protein misfolding, aggregation, proteome imbalances, and severe impairment of the HSR and
UPR (Ben-Zvi et al., 2009; Walther et al., 2015).
ER proteostasis is impaired during aging due to several factors. First, total levels of 
ER chaperones and folding factors are decreased during aging. For example BiP, CNX and 
PDI have been reported to be down-regulated in aging rats (Paz Gavilan et al., 2006; Hussain 
and Ramaiah, 2007; Naidoo et al., 2008). Second, these factors accumulate irreparable
damage leading to impairments in protein folding. For example, BiP, PDI and also CRT have 
been found to acquire oxidative damage in aging mice (Rabek et al., 2003). This age-related 
oxidative damage was shown to impair the ATPase activity of BiP as well as the enzymatic 
activity of PDI (Nuss et al., 2008). Third, the ability of cells to adapt to ER stress declines 
with age. In rodents the UPR-mediated activation of ER chaperones is impaired during aging 
leading to an increased induction of the apoptotic cell death pathway upon exposure to 
stressors (Paz Gavilan et al., 2006; Hussain and Ramaiah, 2007; Naidoo et al., 2008). It has 
also been demonstrated in nematodes that the activity of the IRE1 axis of the UPR declines 
with aging (Taylor and Dillin, 2013).
Increased UPR activity is thought to promote life span extension and thus the ERQC may 
represent a therapeutic target in age-related diseases (Taylor, 2016). In particular, XBP1s 
Introduction
40
activity has been demonstrated to promote longevity. In C. elegans, activation of XBP1s in 
nerve cells was shown to be sufficient to extend nematode life spans (Taylor and Dillin, 
2013). XBP1s acts in collaboration with the transcription factor DAF-16 to promote longevity 
by increasing the resistance to ER stress in long-lived C. elegan mutants (Henis-Korenblit et 
al., 2010). It has also been shown that downstream induction of the ERAD pathway as well as
autophagy by the XBP1s-induced hexosamine biosynthetic pathway (HBP) extends the life 
span of C. elegans, diminishes the toxicity of aggregation-prone proteins, and protects mice 
from oxidative stress and Ca2+ overload (Denzel et al., 2014; Vincenz and Hartl, 2014; Wang 
et al., 2014). This protective pathway may represent a promising therapeutic strategy because
it can be induced simply by supplementation of cells with HBP metabolites.
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Aims of the study
Aim of part 1
The aim of the work described in part 1 of this thesis was to better understand gain-of-toxicity 
and how cells deal with the accumulation of aggregation-prone proteins. Aggregating proteins 
in different diseases vary in their native function and do not share common amino acid 
sequences or structural homology (Chiti and Dobson, 2006). However, the aggregates that are 
formed are strikingly similar in their conformation and biochemical properties; they often 
form amyloid-like fibrils based on cross-β structures (Chiti and Dobson, 2006). Since gain-of-
toxicity is independent of the specific native structure and function of a disease protein but 
rather depends on the aggregate conformation, studying gain-of-toxicity of aggregating 
proteins will enable us to better understand cellular mechanisms that may be relevant for a 
range of different disorders.
In order to study protein aggregation independently of a specific disease protein’s 
identity, we use artificial model proteins that were de novo designed to form β-sheet 
structures that spontaneously aggregate into amyloid-like fibrils (Figure 8) (West et al., 1999; 
Olzscha et al., 2011). The β-strand secondary structure of these proteins is driven by an 
alternating pattern of polar and nonpolar amino acid residues (Figure 8) (Xiong et al., 1995; 
West et al., 1999). 
Since these proteins were de novo designed, they lack physiological function and thus 
enable us to study gain-of-function effects of amyloidogenic proteins and at the same time 
exclude loss-of-function effects and other indirect effects caused by the overexpression of 
natural disease mutants. In previous studies these de novo β-proteins have been demonstrated 
to form amyloid-like aggregates also when expressed in mammalian cells (Olzscha et al., 
2011; Woerner et al., 2016). The formation of these amyloid-like fibrils was toxic and
experiments using β-protein constructs of similar size but with varying hydrophobicities 
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revealed that aggregation propensity correlated with the cytotoxicity of these proteins due to 
an increased ability to promote aberrant protein interactions with metastable cellular proteins 
leading to their sequestration (Olzscha et al., 2011).
Figure 8. Designed β-sheet proteins form amyloid-like fibrils. An alternating pattern of 
polar (blue) and nonpolar (yellow) amino acid residues determine the β-sheet secondary 
structure of the de novo designed β-proteins that consist of six β-strands and spontaneously 
form amyloid-like aggregates.
The aggregation propensity of a protein as well as the biochemical properties and 
toxicity of aggregates vary depending on the subcellular location. For example, it was shown 
that in the cytosol toxic amyloid-like aggregates block nucleo-cytoplasmic transport of 
proteins and RNA but nuclear aggregates of the same proteins are much less toxic and do not 
block nucleo-cytosplasmic transport (Liu et al., 2015; Zhang et al., 2015; Woerner et al., 
2016). As mentioned above, the ER is the site of synthesis of one third of the proteome 
including many disease-related proteins with protein aggregation occurring in the ER lumen 
or extracellularly (Table 2). Since the ER is characterised by a unique folding environment 
and a proteostasis network distinct from that of the cytosol, aggregation-prone proteins may 
be handled differently than in other cellular compartments. Indeed, it was reported that 
targeting amyloidogenic polyQ proteins to the ER or to mitochondria renders them more 
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soluble (Rousseau et al., 2004). However, the fate of amyloidogenic proteins in the ER and 
how exactly aggregation is modified by the ERQC system are poorly understood. In order to
gain a more in-depth understanding of the underlying cellular mechanisms of protein 
aggregation, the aim of this work was to better understand the fate of amyloidogenic proteins 
in the ER. Such an understanding may provide new insights that will be beneficial for the 
development of novel therapeutic strategies.
Figure 9. Potential fates of ER-targeted β-sheet proteins. ER-directed β-proteins are 
targeted for co-translational translocation into the ER via an N-terminal signal sequence (1). 
Without an ER retention signal, proteins that pass the ERQC may potentially be secreted (2). 
Proteins that are recognised as terminally misfolded and aggregation-prone may instead be 
targeted for degradation via ERAD (3). In the ER lumen, β-proteins may show different 
aggregation behaviour than in the cytosol (4). Aggregation-prone β-proteins may interact with 
molecular chaperones and other factors of the ERQC system (5). 
Specifically, the aim of this project was to investigate the fate of the de novo designed
β-proteins when targeted to the mammalian secretory pathway and to determine how they are 
handled by the ER proteostasis network. To this end, β-sheet constructs with an N-terminal 
signal sequence, but importantly no ER retention sequence, were utilised to address the 
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questions (1) whether amyloidogenic β-proteins can be efficiently targeted to the ER, (2) 
whether they can be secreted, (3) whether they are targeted for degradation, (4) whether they
form toxic amyloid-like aggregates in the ER similarly to those found in the cytosol,
(5) which factors of the ERQC system recognise amyloidogenic β-proteins (Figure 9). 
Furthermore, we addressed the question of how amyloidogenic β-proteins affect ER 
proteostasis and whether they induce the UPR.
Aim of part 2
The aim of the work presented in part 2 of this thesis was to analyse the effects of small 
molecule proteostasis modulators. The proteostasis network has emerged as a therapeutic 
target for a variety of diseases ranging from neurodegenerative conditions, to metabolic 
diseases and cancers. Therapeutic strategies include both proteostasis enhancement and 
inhibition. Proteostasis enhancement may be a promising therapeutic strategy in diseases that 
are caused by misfolded proteins. In some diseases, mutant proteins are folding-deficient 
leading to their rapid degradation or aggregation before the proteins can reach their native 
conformations. In such cases, the proteins could potentially still carry out their native function 
if proper folding and trafficking was assisted. Mutant misfolded proteins whose functionality 
could potentially be rescued by assisted folding include the class II mutations of CFTR that 
cause cystic fibrosis (Kerem, 2005), mutations of alpha-galactosidase in Fabry disease, a rare 
genetic lysosomal storage disease (Okumiya et al., 1995), and mutants of A1AT that cause 
A1AT deficiency (Burrows et al., 2000). A number of compounds including so-called 
chemical chaperones have been reported to increase protein folding and trafficking efficiency 
and to have therapeutic potential in disease models and also in clinical trials (Bernier et al., 
2004; Hebert and Molinari, 2007; Molinari, 2007). However, the clinical feasibility of using 
such compounds is not yet clear because many of them seem to act by a rather non-specific 
mechanism of action and are effective only at high dosages (Hebert and Molinari, 2007). 
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Enhancement of proteostasis does not only include improved protein folding efficiency but 
also improved clearance of toxic protein aggregates. For example, induction of autophagy has 
been demonstrated to relieve liver damage in a mouse model of A1AT (Hidvegi et al., 2010). 
Thus, proteostasis enhancement has the potential to target both loss-of-function and gain-of-
function toxicity and there is great interest in identifying and developing more potent 
proteostasis modifiers. 
A screen for small molecule proteostasis enhancers that was carried out previously in 
our group led to the identification of a set of drugs that were already approved by the US 
Food and Drug Administration (FDA) for medical purposes, owing to properties other than 
proteostasis modulation. We tested the effects of the antipsychotic drug fluphenazine and the 
epidermal growth factor receptor (EGFR) inhibitor gefitinib on the proteostasis network in the 
presence of a Huntigton’s-disease-causing mutant of the protein huntingtin (Htt) (Table 2). 
Huntington’s disease (HD) is caused by genetic mutations in the Htt gene that lead to an 
extension of a trinucleotide repeat sequence (CAG) encoding a polyglutamine (polyQ) stretch. 
This polyQ stretch is present in the Htt protein of healthy individuals and can vary in length. 
However, polyQ extensions over around 40 repeats cause neurodegeneration. Extended polyQ 
proteins aggregate into large inclusions that disturb the proteostasis network leading to
exhaustion of the ubiquitin proteasome system (UPS) and accumulation of ubiquitinated 
proteins (Hipp et al., 2012). The first aim of the work presented in part 2 was to test whether 
the compounds could alleviate UPS impairment induced by polyQ aggregates. To this end, we 
utilized a UPS reporter cell line. Furthermore, we tested the effect of the compounds on polyQ 
protein aggregation and whether the compounds may act on the proteostasis network via 
induction of the HSR.
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Materials
Chemicals
Acetic acid Merck, Darmstadt, Germany
Acetone Sigma-Aldrich, St. Louis, MO, USA
Acetonitrile (ACN) VWR International, Radnor, PA, USA
Acrylamide:Bisacrylamide; 37.5:1; 30% Serva, Heidelberg, Germany
Agar Sigma-Aldrich, St. Louis, MO, USA
Agarose LE Biozym Scientific, Oldendorf, Germany
Ammonium Persulfate (APS) Sigma-Aldrich, St. Louis, MO, USA
Ampicillin Carl Roth, Karlsruhe, Germany
Arg0HCl Sigma-Aldrich, St. Louis, MO, USA
Arg6HCl Cambridge Isotope Laboratories, MA, 
USA
Arg10HCl Cambridge Isotope Laboratories, MA, 
USA
Bacto-Tryptone BD Biosciences, CA, USA
Bacto-Yeast Extract BD Biosciences, CA, USA
BCA Protein Assay Kit Pierce, Thermo Fisher Scientific, MA, 
USA
Bis-Tris Fluka, Buchs, Switzerland
Boric acid VWR International, Radnor, PA, USA
Bovine albumin Fraction V (BSA) Serva, Heidelberg, Germany
Brefeldin A (BFA) Sigma-Aldrich, St. Louis, MO, USA
Bromophenol Blue Sodium Salt Sigma-Aldrich, St. Louis, MO, USA
BSA Standard Pierce, Thermo Fisher Scientific, MA, 
USA
Calcium chloride-dihydrate VWR International, Radnor, PA, USA
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Complete Protease Inhibitor Cocktail Roche, Basel, Switzerland
CutSmart buffer New England Biolabs, Ipswich, MA, 
USA
Cycloheximide Sigma-Aldrich, St. Louis, MO, USA
4',6-Diamidino-2-Phenylindole (DAPI) Life Technologies, Carlsbad, CA, USA
dihydrochloride
DharmafectDuo Transfection Reagent GE Healthcare Dharmacon, Lafayette, 
CO, USA
DharmaFECT Transfection Reagent GE Healthcare Dharmacon, Lafayette, 
CO, USA 
N,N-Dimethylformamide (DMF) Sigma-Aldrich, St. Louis, MO, USA
Dimethylsulphoxide (DMSO) Sigma-Aldrich, St. Louis, MO, USA
3-(4,5-Dimethylthiazol-2-yl)- Sigma-Aldrich, St. Louis, MO, USA
2,5-diphenyltetrazoliumbromide (MTT)
Dithiothreitol (DTT) Sigma-Aldrich, St. Louis, MO, USA
DNA Loading Buffer Fermentas, St. Leon-Rot, Germany
dNTP Set Metabion, Martinsried, Germany
Droperidol Sigma-Aldrich, St. Louis, MO, USA
Dulbecco’s Modified Eagle’s medium (MEM) Biochrom AG, Merck Millipore, 
Darmstadt, Germany
Dulbecco’s Modified Eagle’s medium (MEM) Biochrom AG, Merck Millipore, 
without phenol red Darmstadt,Germany
Dulbecco’s Modified Eagle’s medium (MEM), PAA Laboratories, Dartmouth, MA, USA
High glucose, without Arg, Lys, l-glutamine
Erlotinib HCl Selleck Chemicals, TX, USA
Ethanol Absolute Merck, Darmstadt, Germany
Fetal Bovine Serum (FBS) Gibco, Thermo Fisher Scientific, MA, 
USA
Fluorescent Mounting Medium DAKO, Hamburg, Germany
Fluphenazine HCl Sigma-Aldrich, St. Louis, MO, USA
Formic acid Merck, Darmstadt, Germany
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FuGENE 6 Transfection Reagent Promega, WI, USA
Gefitinib Biotang, Thermo Fisher Scientific, MA, 
USA
GeneRuler 100bp DNA ladder Fermentas, Thermo Fisher Scientific, 
MA, USA
GeneRuler 1kb DNA ladder Fermentas, Thermo Fisher Scientific, 
MA, USA
Geneticin (G418) Calbiochem, Merck Millipore, 
Darmstadt, Germany
Glycerol Carl Roth, Karlsruhe, Germany
Immersion oil VWR International, Darmstadt, Germany
Iodoacetamide Sigma-Aldrich, St. Louis, MO, USA
Kanamycin Sigma-Aldrich, St. Louis, MO, USA
L-Glutamine Gibco, Thermo Fisher Scientific, MA, 
USA
Low fat milk powder Saliter, Obergünzburg, Germany
Lumigen ECL Ultra Lumigen Inc., MI, USA
Luminata Classico Western HRP substrate Merck Millipore, Darmstadt, Germany
Lys0HCl Sigma-Aldrich, St. Louis, MO, USA
Lys42HCl Cambridge Isotope Laboratories, MA, 
USA
Lys8HCl Cambridge Isotope Laboratories, MA, 
USA
Manganese chloride Merck Millipore, Darmstadt, Germany
2-(N-Morpholino)ethanesulfonic acid (MES) Sigma-Aldrich, St. Louis, MO, USA
Methanol p.a. Merck, Darmstadt, Germany
β-Mercaptoethanol Merck, Darmstadt, Germany
MG132 Cayman Chemical, MI, USA
3-(N-Morpholino) propanesulfonic acid (MOPS) Sigma-Aldrich, St. Louis, MO, USA
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N,N’,,N’-Tetramethyl-ethane-1,2-diamine Sigma-Aldrich, St. Louis, MO, USA
(TEMED)
NuPAGE Antioxidant Thermo Fisher Scientific, MA, USA
Opti-MEM I Gibco, Thermo Fisher Scientific, MA, USA
PageRuler Prestained Protein Ladder Thermo Fisher Scientific, MA, USA
Paraformaldehyde, 16% Thermo Fisher Scientific, MA, USA
Penicillin-streptomycin (Pen Strep) Gibco, Thermo Fisher Scientific, MA, 
USA
Phenylmethanesulfonylfluoride (PMSF) Serva, Heidelberg, Germany
Phosphate Buffered Saline (PBS) pH 7.2 Gibco, Thermo Fisher Scientific, MA, 
USA
Phosphoric acid Sigma-Aldrich, St. Louis, MO, USA
Ponceau S solution Sigma-Aldrich, St. Louis, MO, USA
Potassium acetate (KAc) Sigma-Aldrich, St. Louis, MO, USA
1-Propanol p.a. Merck, Darmstadt, Germany 
Rubidium chloride (RbCl) Sigma-Aldrich, St. Louis, MO, USA
Sodium bisulphite Sigma-Aldrich, St. Louis, MO, USA
Sodium chloride Merck, Darmstadt, Germany
Sodium deoxycholate Sigma-Aldrich, St. Louis, MO, USA 
Sodium hydroxide Merck, Darmstadt, Germany
Sodiumdodecylsulfate (SDS) Serva, Heidelberg, Germany
Sodium-Ethylenediaminetetraacetic acid (EDTA) Merck, Darmstadt, Germany
Stable glutamine (dipeptide Gln-Ala) PAA Laboratories, Dartmouth, MA, USA
Steady-Glo Luciferase Assay System Promega, Madison, WI, USA
Sybr Safe DNA gel stain Life Technologies, Carlsbad, CA, USA
T4 DNA ligase buffer New England Biolabs, Ipswich, MA, 
USA
Trichloric acid (TCA) Sigma-Aldrich, St. Louis, MO, USA
Trifluoroacetic acid (TFA) VWR International, Radnor, PA, USA
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Tris (Trizma base) Sigma-Aldrich, St. Louis, MO, USA
Triton X-100 Sigma-Aldrich, St. Louis, MO, USA
TrypLE Express Gibco, Thermo Fisher Scientific, MA, 
USA
Tween 20 Sigma-Aldrich, St. Louis, MO, USA
Antibodies
For immunoblotting
Primary antibodies
Anti-BiP/GRP78 (rabbit pAB, ab21685) Abcam, Cambridge, United Kingdom
Anti-Calnexin (rabbit pAB, SPA860) Enzo Life Sciences Inc., Farmingdale, 
New York, USA
Anti-Erlin-2/SPFH2 (rabbit mAB, ab128924) Abcam, Cambridge, United Kingdom
Anti-GAPDH (mouse mAB, MAB374) Merck Millipore, Billerica, MA, USA
Anti-GFP (mouse, mAB, 11814460001) Roche, Basel, Switzerland
Anti-GRP94 (rat mAB, MA3-016) Thermo Fisher Scientific, Waltham, MA, 
USA
Anti-HYOU1 (rabbit, mAB, ab134944) Abcam, Cambridge, United Kingdom
Anti-mCherry (rat, mAB, M11217) Life Technologies, Carlsbad, CA, USA
Anti-Myc (mouse mAB produced Max Planck Institute of Biochemistry,
in hybridoma cell line Myc-9E10) Martinsried, Germany
Anti-Neuroserpin (mouse mAB, ab55587) Abcam, Cambridge, United Kingdom
Anti-OS-9 (rabbit mAB, ab109510) Abcam, Cambridge, United Kingdom
Anti-PDIA6 (rabbit mAB, ab154820) Abcam, Cambridge, United Kingdom
Anti-SEL1L (rabbit pAB, S3699) Sigma Aldrich, St. Louis, MO, USA
Anti-α-Tubulin (mouse mAB, T5168) Sigma Aldrich, St. Louis, MO, USA
Secondary antibodies
Anti-mouse IgG-Peroxidase (goat pAB, A4416) Sigma Aldrich, St. Louis, MO, USA
Anti-rat (goat pAB, A9037) Sigma Aldrich, St. Louis, MO, USA
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Anti-rabbit (goat pAB, A9169) Sigma Aldrich, St. Louis, MO, USA
For immunofluorescence
Primary antibodies
Anti-Calreticulin (chicken pAB, ab14234) Abcam, Cambridge, United Kingdom
Anti-ERp57 (rabbit pAB, ab10287) Abcam, Cambridge, United Kingdom
Anti-Giantin (rabbit pAB, ab24586) Abcam, Cambridge, United Kingdom
Anti-Myc (mouse mAB, sc-40) Santa Cruz Biotechnology, Dallas, TX, 
USA
Secondary antibodies
Anti-mouse Cy3 (goat pAB, 115-165-062) Jackson ImmunoResearch Laboratories, 
West Grove, PA, USA
Anti-rabbit FITC (goat pAB, F2765) Invitrogen by Thermo Fisher Scientific, 
Waltham, MA, USA
Anti-rabbit Alexa Fluor 405 (goat pAB, A-31556) Life Technologies, Carlsbad, CA, USA
Anti-chicken Alexa Fluor 488 (goat pAB, A-11039) Life Technologies, Carlsbad, CA, USA
Enzymes
AgeI New England Biolabs, Ipswich, MA, 
USA
Benzonase Max Planck Institute of Biochemistry,
Martinsried, Germany
DpnI New England Biolabs, Ipswich, MA, 
USA
Endo H New England Biolabs, Ipswich, MA, 
USA
KpnI New England Biolabs, Ipswich, MA, 
USA
PNGase F New England Biolabs, Ipswich, MA, 
USA
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Q5 High Fidelity polymerase New England Biolabs, Ipswich, MA, 
USA
T4 DNA Ligase New England Biolabs, Ipswich, MA, 
USA
Trypsin, proteomics grade Roche, Basel, Switzerland
Bacterial strains
DH5αF‟ F’/endA1 hsdR17 (rk-, mk+) glnV44 thi-
1 recA1 gyrA (NA1r) relA1Δ (lacIZYA-
argF) U169 deoR [φ80dlacΔ (lacZ)M15]
Mammalian cell lines
Human embryonic kidney cells 293T (HEK293T) American Type Culture Collection 
(ATCC), Manassas, VA, USA 
Human epithelial cervix adeno carcinoma (HeLa) American Type Culture Collection 
(ATCC), Manassas, VA, USA 
Buffers 
All buffers are water-based.
Britton & Robinson Buffer (BRUB): 20 mM acetic acid, 20 mM phosphoric acid, 20 mM 
boric acid, at pH 3, 4, 5, 6, 8, and 11 (pH adjusted with 1 M NaOH).
CAPS/methanol transfer buffer: 10 mM CAPS, 20% (v/v) methanol, final pH 11.
Laemmli sample buffer: 300 mM Tris-HCl, pH 6.8, 10% (w/v) SDS, 20% (v/v) Glycerol, 
25% (v/v) β-Mercaptoethanol, 5 mM PMSF, 0.1 % (w/v) Bromophenolblue.
MES buffer: 50 mM MES, 50 mM Tris, 1 mM EDTA (pH 8), 0.1% SDS.
MOPS buffer: 50 mM MOPS, 50 mM Tris, 1 mM EDTA (pH 8), 0.1% SDS.
MTT stop buffer: 40% DMF and 20% SDS.
PBS: 137 mM NaCl, 27 mM KCl, 10 mM Na2HPO4, 1.76 mM KH2PO4, pH 7.2.
RIPA buffer: 25 mM Tris pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 
0.1% SDS.
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TAE buffer: 40 mM Tris, 20 mM acetic acid, 1 mM EDTA.
TBS: 50 mM Tris-Cl, pH 7.6, 150 mM NaCl.
TBS-T: 50 mM Tris-Cl, pH 7.6, 150 mM NaCl, 0.1% (v/v) Tween 20.
Transformation buffer (TfB) I: 100 mM RbCl, 50 mM MnCl2X2H2O, 
10 mM CaCl2X2H2O, 30 mM KAc, 15% glycerol, pH 5.8 (by addition of acetate), filter 
sterilised.
TfB II: 10 mM MOPS, 10 mM RbCl, 75 mM CaCl2X2H2O, 15% glycerol, pH 7 (by addition 
of NaOH), filter sterilised.
UA buffer: 8 M urea, 0.1 M Tris, pH 8.5.
Urea sample buffer: 8 M urea, 5% SDS, 200 mM Tris at pH 6.8, 0.1 mM EDTA, 
0.1% Bromophenolblue, 5% β-mercaptoethanol, 10% glycerol
Polyacrylamide Bis-Tris gels
Resolving gel: 360 mM Bis-Tris pH 6.8, 0.07% APS, 0.2% TEMED, 8-16% polyacrylamide 
(Acrylamide:Bisacrylamide; 37.5:1)
Stacking gel: 360 mM Bis-Tris pH 6.8, 0.07% APS, 0.35% TEMED, 4-8% polyacrylamide 
(Acrylamide:Bisacrylamide; 37.5:1)
Media
Full growth medium: DMEM supplemented with 10% FBS, 1% penicillin-streptomycin and 
1% L-glutamine.
LB agar: 15 mg ml-1 agar, 10 mg ml-1 NaCl, 10 mg ml-1 bacto-tryptone, 5 mg ml-1 bacto-yeast 
extract, in H2O, autoclaved and supplemented with either 100 µg ml-1 ampicillin or 35 µg ml-1
kanamycin.
LB medium: 1% bacto-tryptone, 1% NaCl, 0.5% bacto-yeast extract in H2O, autoclaved.
SILAC media: DMEM with 4.5 g l-1 glucose without arginine, lysine and glutamine, 
supplemented with 10% dialysed FBS (dialysed against 0.15 M NaCl), Pen/Strep and stable 
glutamine (dipeptide Gln-Ala), the following combinations of different isotopes of arginine 
(0.28 mM) and lysine (0.56 mM) were added: Light: Arg0HCl and Lys0HCl
Medium: Arg6HCl and Lys42HCl
Heavy: Arg10HCl and Lys8HCl
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Kits
BCA Protein Assay Kit Thermo Fisher Scientific, MA, USA
EndoFree Plasmid Maxi Kit Qiagen, Hilden, Germany
HiSpeed Plasmid Maxi Kit Qiagen, Hilden, Germany
MemCodeReversible Protein Stain Kit Thermo Fisher Scientific, MA, USA
NativePAGE Sample Prep Kit Thermo Fisher Scientific, MA, USA
Steady Glo Luciferase Assay System Promega, Madison, WI, USA
Wizard SV gel and PCR Clean Up System Promega, Madison, WI, USA
Other materials and Instruments
AG285 and PB602 Balances Mettler Toledo, Gießen, Germany
Avanti J-25 Centrifuge with Beckman, Munich, Germany
Rotors JLA 10.500 and JA 25.50
Plate reader Synergy HT BioTek Instruments, Winooski, VT, USA
C18 Empore disks IVA, Analysentechnik, Meerbusch, 
Germany
Centrifuge 5415 R Eppendorf, Hamburg, Germany
Confocal laser scanning microscope LSM780 ZEISS, Jena, Germany
Cryo-tubes Nunc, Roskilde, Denmark
DU 640 UV/VIS Spectrophotometer Beckman, Munich, Germany
Empore High Performance Extraction Disks IVA Analysentechnik, Meerbusch, 
Germany
End-over-end rotor, stuart rotator SB3 Bibby Scientific, Staffordshire, UK
Exactive orbitrap mass spectrometer Thermo Fisher Scientific, MA, USA
FACSAriaIII BD Biosciences, San Jose, CA, USA
FACSCalibur BD Biosciences, San Jose, CA, USA
Gel Documentation System BioCapt MWG BiotechAG, Göttingen, Germany
Gene Pulser cuvette, 0.4 cm Biorad, CA, USA
Gene Pulser Xcell electroporations system Biorad, CA, USA
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ImageReader LAS-3000 FUJI, Tokyo, Japan
Innova 4430 Incubator New Brunswick Scientific, Nürtingen, 
Germany
LAS 3000 image reader FujiFilm, Tokio, Japan
Light Microscope Diavert Leitz, Wetzlar, Germany
Luminometer Lumat LB 9507 Berthold, Bad-Wildbad, Germany
Magnetic rack Miltenyi Biotec, Bergisch Gladbach, 
Germany
µMacs anti-Myc beads Miltenyi Biotec, Bergisch Gladbach, 
Germany
µMACS 20µ columns Miltenyi Biotec, Bergisch Gladbach, 
Germany
Millex SV Filter Units, pore size 0.22 μM Merck Millipore, Darmstadt, Germany
MilliQ Plus Deionization System Merck Millipore, Darmstadt, Germany
MiniProtean2 Electrophoresis Chamber Bio-Rad, Munich, Germany
Mini Sub Cell Bio-Rad, Munich, Germany
Nanodrop 1000 Spectrophotometer Thermo Fisher Scientific, MA, USA
Nano-HPLC autosampler Thermo Fisher Scientific, MA, USA
NativePAGE Novex 4-16% Bis-Tris Thermo Fisher Scientific, MA, USA
Protein Gels, 1.0 mm, 10-well
Nitrocellulose Amersham PROTRAN GE Healthcare, Chicago, IL, USA 
Blotting Membrane, 0.45 µm pore size
NuPAGE™ Novex™ 4-12% Bis-Tris Thermo Fisher Scientific, MA, USA
Protein Gels, 1.0 mm, 10-well
OMIX96 C18 tips Agilent Technologies, Oberhaching, 
Germany
PCR Tubes AB-0266 Thermo Fisher Scientific, MA, USA
pH-Meter pH538 WTW, Weilheim, Germany
PicoTip Emitter Silica Tip, New Objective, Woburn, MA, USA
ID 75 µm, 30 cm long, 8 µm tip opening,
Pipettes Eppendorf Research Eppendorf, Hamburg, Germany
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Poly-L-Lysine (PLL) Round Coverslips, 12mm BD Biosciences, CA, USA
Polyvinylidene difluoride (PVDF) Western Roche, Basel, Switzerland
Blotting Membrane, 0.2 µm pore size
Proxeon EASY-nLC 1000 nano-HPLC system Thermo Fisher Scientific, MA, USA
QIAprep Spin Miniprep Kit Qiagen, Hilden, Germany
Reprosil-Pur C18-AQ Dr. Maisch HPLC, Ammerbuch, 
Germany
Safe Imager 2.0 Blue-Light Life Technologies, Carlsbad, CA, USA
Transilluminator
ScepterTM Automated Cell Counter Millipore, MA, USA
ScepterTM Sensors - 60μM Millipore, MA, USA
µ-Slide 8 Well Plates Ibidi, Martinsried, Germany
Sonicator Sonorex RK100 Bandelin electronic GmbH, Berlin, 
Germany
Tank Blot System Bio-Rad, Munich, Germany
Thermocycler PCR T3 Biometra, Göttingen, Germany
Thermomixer Comfort Eppendorf, Hamburg, Germany
Tissue Culture Dish 100 X 20 mm Becton and Dickinson, New Jersey, USA
Falcon Tissue Culture Plates, flat bottom, 6 well, Thermo Fisher Scientific, MA, USA
12 well, 24 well, 48 well and 96 well
Transformer for Electrophoresis PAC300 Bio-Rad, Munich, Germany
Vacuum concentrator Speedvac SPD121P Thermo Fisher Scientific, MA, USA 
Vivacon 10 kDa, ultrafiltration devices Sartorius, Göttingen, Germany
Vortex-Genie 2 Scientific Industries, NY, USA
Weighing Balance CP3202P Sartorius, Göttingen, Germany
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Plasmids
Name Description Backbone
Antibiotic 
resistance
Source
CMV-Luc
Firefly luciferase under 
the CMV promoter
pcDNA3.1(+) myc/His Amp Gupta et al., 2011
CPY*-mCh
ER-targeted CPY*-
mCherry
pShooter 
pCMV/myc/ER
Amp
Rajat Gupta, see 
methods
ER-α
α-S824 with N-terminal 
SP-B signal peptide
pcDNA3.1(+) myc/His Amp Dolfe et al., 2015
ER-β4
β4 with N-terminal SP-
B signal peptide
pcDNA3.1(+) myc/His Amp Dolfe et al., 2015
ER-β17
β17 with N-terminal 
SP-B signal peptide
pcDNA3.1(+) myc/His Amp Dolfe et al., 2015
ER-β23
β23 with N-terminal 
SP-B signal peptide
pcDNA3.1(+) myc/His Amp Dolfe et al., 2015
ER-mCh
ER-targeted mCherry, 
see methods section
pcDNA3.1(+) myc/His Amp
This study, see 
methods
ER-α-mCh
ER-α cloned into 
mCherry N1 upstream 
of mCherry
mCherry N1 Kan
This study, see 
methods
ER-β23-
mCh
ER-β23-mCh cloned 
into mCherry N1 
upstream of mCherry
mCherry N1 Kan
This study, see 
methods
ER-β23-
mChA
ER-β23-mCh cloned 
into pcDNA3.1(+) with 
point mutation C24A
pcDNA3.1(+) myc/His Amp
This study, see 
methods
ER-GFP
pShooter vector 
pCMV/Myc/ER/ GFP
pShooter Amp
Life Technologies, 
Carlsbad, CA, USA
ERSE I-Luc
Firefly luciferase under 
the ERSE I promoter
pGL3 luciferase 
reporter
Amp Bouman et al., 2011
ERSE II-Luc
Firefly luciferase under 
the ERSE II promoter
pGL3 luciferase 
reporter
Amp Bouman et al., 2011
Hsp70-Luc
Firefly luciferase under 
the HSPA1A promoter
pUB/Bsd Amp
Prof. H. Wagner, 
Technical University 
of Munich, Germany
mCherry pmCherry N1 mCherry N1 Kan Clontech, CA, USA
NRS
Neuroserpin 
(SERPIN1)
pcDNA3.1(+) Amp
Schipanski et al., 
2014
NRSG392E
Neuroserpin mutant 
G392E
pcDNA3.1(+) Amp
Schipanski et al., 
2014
NRSG392E-
GFP
Neuroserpin G392E 
mutant with C-terminal 
EGFP tag
pcDNA3.1(+) Amp
Schipanski et al., 
2014
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NRSG392EΔNN
Neuroserpin-G392E-
N157/321I
pcDNA3.1(+) Amp
Schipanski et al., 
2014
NRS-GFP
Neuroserpin with C-
terminal EGFP tag
pcDNA3.1(+) Amp
Schipanski et al., 
2014
NRSΔNN NeuroserpinN157/321I pcDNA3.1(+) Amp
Schipanski et al., 
2014
nt-α α-S824 pcDNA3.1(+) myc/His Amp Olzscha et al., 2011
nt-β17 β17 pcDNA3.1(+) myc/His Amp Olzscha et al., 2011
nt-β23 β23 pcDNA3.1(+) myc/His Amp Olzscha et al., 2011
nt-β4 β4 pcDNA3.1(+) myc/His Amp Olzscha et al., 2011
pcDNA3.1 Empty vector pcDNA3.1(+) myc/His Amp
Thermo Fisher 
Scientific, MA, USA
Q25
Exon 1 fragment of 
huntingtin Q25 fused 
N-terminally to 
mCherry
pcDNA3.1(+) myc/His Amp Gupta et al., 2011
Q97
Exon 1 fragment of 
huntingtin Q97 fused 
N-terminally to 
mCherry
pcDNA3.1(+) myc/His Amp Gupta et al., 2011
SEL1L
Human full length 
SEL1L
pcDNA3.1(+) myc/His Amp
This study, see 
methods section
UPRE-Luc
Firefly luciferase under 
the UPRE promoter
pGL3 luciferase 
reporter
Amp Bouman et al., 2011
siRNAs
Non-targeting control siRNA 3 GE Healthcare Dharmacon, Lafayette, 
CO, USA
OS-9 siRNA smart pool GE Healthcare Dharmacon, Lafayette, 
CO, USA
SEL1L siRNA smart pool GE Healthcare Dharmacon, Lafayette, 
CO, USA
Softwares 
Adobe Illustrator CS6 Adobe Systems, San Jose, USA
Chromas (Version 1.45) Griffith University, Queensland, 
Australia
FlowJo (Version 9.9) FlowJo, LLC, Ashland, OR, USA
ImageJ (Version 1.49v) National Institutes of Health, MD, USA
MaxQuant (Version 1.3.0.5) Max Planck Institute of Biochemistry, 
Martinsried, Germany
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Perseus (Version 1.5.2.12) Max Planck Institute of Biochemistry, 
Martinsried, Germany
Methods
Production of chemically competent E. coli
DH5α cells were pre-cultured in LB medium at 37 °C, overnight, shaking. The OD was then 
measured at 600 nm, cells were diluted to an OD of 0.05 in a total of 100 ml LB medium and 
cultured further until an OD of 0.5 was reached. Cells were then incubated shortly on ice 
before centrifugation at 2,500 xg for 10 min at 4 °C. The cell pellet was re-suspended in 30 ml 
ice-cold TfBI buffer and incubated on ice for 1 h. Cells were then again pelleted by 
centrifugation before resuspension in 9 ml ice-cold TfBII buffer. Cell suspensions were then 
aliquoted, frozen in liquid N2 and stored at -80 °C.
Plasmid preparation
To 100 µl chemically competent DH5α cells, 100-200 ng plasmid DNA were added. Cells 
were incubated on ice for 20 min, heat shocked at 42 °C for 90 s and again incubated on ice. 
After 5-10 min on ice, 900 µl LB medium were added and cells were cultured at 37 °C, 
shaking, for 45-60 min before plating 0.1-100% of the culture on LB agar plates 
supplemented with either ampicillin (Amp) or kanamycin (Kan) and overnight incubation at 
37 °C. Single colonies were picked, added to 5 ml LB medium supplemented with appropriate 
antibiotics (50 µg ml-1 Amp or 10 µg ml-1 Kan) and incubated at 37 °C, overnight, shaking. 
For cloning purposes, plasmids were purified from 5 ml cultures using the QIAprep Miniprep 
Kit following the manufacturer’s instructions. To prepare plasmids for transfection of 
mammalian cells, 200-500 µl of the 5 ml overnight cultures were added to 100-200 ml LB 
medium and cultured for an additional night before plasmid preparation using the EndoFree 
Plasmid Maxi Kit or the HiSpeed Plasmid Maxi Kit following the manufacturer’s
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instructions. Plasmids were sequenced by the Max Planck Institute sequencing core facility 
(Martinsried, Germany).
PCR amplification and purification of PCR products
All PCR amplifications were carried out using the Q5 polymerase following the 
manufacturer’s instructions. PCR products were resolved on 1% agarose gels containing SyBr 
Safe DNA gel stain in TAE buffer. For purification, gel pieces containing resolved PCR 
products were cut from gels and the DNA was extracted using the Wizard SV gel and PCR 
Clean Up System following the manufacturer’s instructions.
DNA Restriction Digestion and Ligation
Restriction digestions were carried out using 1 µg DNA and 1 µl each of the required
restriction enzymes in 5 µl CutSmart buffer in nuclease-free water at 37 °C for 2 h. DNA
ligations were carried out at a molar ratio of 1:4 of backbone to insert using T4 DNA ligase in 
1X T4 DNA ligase buffer at 16 °C for 18 h.
Cloning of expression plasmids
The signal peptide of human pulmonary surfactant-associated protein (SP-B) 
(MAESHLLQWLLLLLPTLCGPGTA) was inserted upstream of the Myc-tag of 
pcDNA3.1(+) plasmids containing αS-824, β4, β17 and β23 (Olzscha et al., 2011) (here 
named nt-α, nt-β4, nt-β17 and nt-β23) by (Dolfe et al., 2015) to generate ER-α, ER-β4, 
ER-β17 and ER-β23, respectively. To generate mCherry-tagged constructs for live cell 
imaging, ER-β23 and ER-α were excised from the pcDNA3.1(+) plasmids using KpnI and 
AgeI after generation of a downstream AgeI site via the QuikChange PCR method (Agilent 
Technologies) and inserted into mCherry N1 vectors. To generate the ER-β23C24A-mCherry 
construct (ER-β23-mChA) for FLIP experiments, a point mutation (C24A) was introduced 
into the ER-β23-mCh construct using Quik change. The insert was then amplified by PCR, 
simultaneously adding a 5’ BamH1 and a 3’ Not1 digestion site. Amplified inserts were then 
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inserted it into the pcDNA3.1(+) vector using BamH1 and Not1. To generate the control
ER-mCh construct for FLIP, the signal peptide of SP-B followed by one alanine residue and a 
Myc-tag was fused upstream to mCherry by PCR amplification. A C-terminal KDEL 
sequence, as well as a 5’ BamH1 and a 3’ Not1 digestion site were also added by PCR 
amplification. The purified PCR product was then inserted into the pcDNA3.1(+) plasmid 
using BamH1 and Not1. The ER-targeted CPY*-mCherry construct (CPY*-mCh) was 
generated by Rajat Gupta by insertion of the insert of non-targeted CPY*-mCherry (CmCh*)
(Park et al., 2013) into the pShooter vector pCMV/Myc/ER via XhoI/NotI. The insert 
encoding human SEL1L flanked by BamH1 and Not1 digestion sites was purchased from 
Thermo Fisher Scientific and inserted into the pcDNA3.1(+) plasmid via BamH1/Not1. DNA 
was sequenced by the Max Planck Institute sequencing core facility (Martinsried, Germany).
Cell culture and transfections
Human HEK293T and HeLa cell lines were cultured in full growth medium at 37 °C in an 
atmosphere of 5% CO2. Cell lines were regularly tested for mycoplasma contamination. Cells 
were transfected with a total of 1 µg plasmid DNA in 6-well plates using 3 µl FuGene 6 
transfection reagent prepared in Opti-MEM I buffer following the manufacturer’s instructions.
After preparation of the transfection reagent mix, this was added dropwise to cells in full 
growth medium. For transfection of cells in other culturing containers, amounts of 
transfection reagents were up- or down-scaled accordingly.
Immunofluorescence imaging
Cells were seeded in µ-Slide chambered coverslips (for live cell imaging) or on poly-L-
lysine-coated glass coverslips (for immunofluorescence experiments) 24 h prior to 
transfection. Transfected cells were either directly analysed in chambered coverslips or fixed 
with 4% paraformaldehyde, washed with PBS, permeabilised with 0.1% Triton X-100 in PBS 
for 5 min followed by additional washes in PBS, blocked with 1% BSA and labelled with 
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primary antibodies diluted 1:500 in 1% BSA in PBS. After three washes in PBS, the cells 
were stained with fluorescently-labelled secondary antibodies at dilutions of 1:200 in 
1% BSA in PBS. For live cell imaging, cells were grown in µ-Slide 8 Well plates in DMEM
without phenol red supplemented with 10% FBS, 1% penicillin-streptomycin and 
1% L-glutamine. Throughout analysis cells were kept in a chamber at 37 °C, 5% CO2.
Images were recorded at the Imaging Facility of the Max Planck Institute of 
Biochemistry, Martinsried, on a ZEISS LSM780 confocal laser scanning microscope 
equipped with a ZEISS Plan-APO 63x/NA1.46 oil immersion objective and analysed using 
ImageJ software (ImageJ 1.49v, http://imagej.nih.gov/ij/). Representative images or videos of 
at least three independent experiments are shown.
Immunoblotting
Denaturing electrophoresis
Cells were harvested after one wash in PBS and lysed in RIPA buffer supplemented with 
cOmplete Protease Inhibitor Cocktail and benzonase. After lysis for at least 20 min on ice 
with occasional vortexing, cell debris was removed by centrifugation at 5,000 xg for 5 min at 
4 °C and transfer of lysates to fresh tubes. Protein concentrations were measured using the
BCA assay kit. Lysates were denatured in Laemmli sample buffer at 70 °C for 10 min and 
then 20 μg of protein were resolved on 8%, 10% or 12% Bis-Tris gels (homemade) or on 
commercial NuPAGE 4-12% Bis-Tris gels in MES or MOPS buffer supplemented either with 
5 mM sodium bisulphite or with NuPAGE Antioxidant following the manufacturer’s 
instructions.
Native electrophoresis
Cells were lysed using the NativePAGE Sample Prep Kit supplemented with cOmplete 
Protease Inhibitor Cocktail and benzonase. After lysis for 30 min on ice, cell debris was 
removed by centrifugation at 5,000 xg for 5 min at 4 °C and lysates were transferred to fresh 
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tubes. Protein concentrations were measured using the BCA assay kit. Per sample, 45 µg 
protein were resolved on 4-16% NativePAGE Novex Bis-Tris gels.
Transfer and staining
Proteins were transferred to nitrocellulose or PVDF (preferred for β-sheet proteins) 
membranes in 3-(Cyclohexylamino)-1-propanesulfonic acid (CAPS)/methanol buffer at 
110 V for 60-90 min at 4 °C. Membranes were blocked for 1 h in 5% low fat dry milk in 
TBS-T and then incubated with primary antibodies diluted in 5% low fat dry milk at 4 °C 
overnight at the indicated dilutions: BiP (1:1,000, Abcam #ab21685), calnexin (1:500, Enzo 
Life Sciences, #SPA860), Erlin-2 (1:1,000, Abcam, #ab128924), GAPDH (1:1,000, Millipore 
#MAB374), GFP (1:1,000, Roche, #11814460001), GRP94 (1:1,000, Pierce, #MA3-016), 
HYOU1 (1:1,000, Abcam #ab134944), mCherry (1:1,000, Life Technologies, #M11217), 
Myc (1:200, mouse monoclonal produced in hybridoma cell line Myc-9E10), OS-9 (1:1,000, 
Abcam, #ab109510), PDIA6 (1:500, Abcam #ab154820), SEL1L (1:1,000, Sigma #S3699), 
α-tubulin (1:1,000, Sigma #T5168). Membranes were washed three times with TBS-T and 
then incubated with HRP-conjugated secondary antibodies diluted in TBS-T (anti-mouse, 
1:5,000, Sigma #A4416; anti-rat, 1:2,000, Sigma #A9037) or 5% milk (anti-rabbit, 1:20,000, 
Sigma #A9169) for 1.5 h at RT. After additional washing in TBS-T, HRP substrate was added 
and chemiluminescence was quantified using a Fuji LAS 3000 image reader. Protein bands 
from at least three independent experiments were quantified using ImageJ software. 
Representative blots from at least three independent experiments are shown.
Solubility analysis
Cells were lysed in 1% Triton X-100 in PBS supplemented with cOmplete Protease Inhibitor 
Cocktail and benzonase for 1 h at 4 °C with end-over-end rotation. Protein concentrations 
were measured using the BCA assay. A fraction of each lysate was put aside for analysis of 
total protein content; the remainder was centrifuged at 14,000 xg for 10 min at 4 °C to 
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separate soluble from insoluble proteins. The supernatant containing soluble protein was 
transferred to a fresh tube. Both soluble and total fractions were denatured by addition of 
concentrated Urea sample buffer to give a concentration corresponding to 1x sample buffer. 
The pellet was re-suspended directly in 1x sample buffer. All samples were heated to 70 °C 
for 10 min and subsequently analysed by denaturing immunoblotting as described above.
Cell viability assay
HEK293T cells were trypsinised at exponential growth rate and 4 x 106 cells were re-
suspended in 400 µl DMEM supplemented with 25% FBS and electroporated with 30 µg 
plasmid DNA in a 0.4 cm Gene Pulser cuvette in the Gene Pulser Xcell electroporations 
system at 225 V, 950 µF. After electroporation, cells were allowed to recover for 10 min in 
full growth medium before seeding at 2 x 105 cells ml-1 into 24 well plates (1 ml cells in full 
growth medium per well). After 72 h, 500 µl of 0.5 mg ml-1 MTT was added (0.17 mg ml-1
final) and cells were incubated at 37 °C for 1 h before the reaction was stopped by the 
addition of MTT stop buffer. Concentrations of formazan, the product of the reduction of 
MTT by cellular reductases, were analysed by measuring absorbance at 570 nm in a plate 
reader.
Analysis of secreted proteins
HEK293T cells were seeded and transfected in a 6 well plate and media was exchanged 24 h 
after transfection to 600 µl full growth medium in the presence or absence of 1 µg ml-1
brefeldin A (BFA). After overnight incubation, media and cells were harvested separately. 
Cell pellets were washed, lysed, quantified and denatured as described above. Media samples 
were centrifuged at 5,000 xg for 5 min at 4 °C and transferred to fresh tubes to ensure 
elimination of any floating cells. Then, 6 µl 2% sodium deoxycholate were added to media 
samples followed by vortexing and incubation at 4 °C for 30 min before addition of 60 µl 
trichloric acid (TCA) and incubation at 4 °C overnight. Precipitated proteins from media 
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samples were then collected by centrifugation at 16,000 xg for 14 min at 4 °C. Pellets were 
dried and then resuspended in 1x Urea sample buffer. TrisCl at pH 8.8 was added dropwise 
until the pH was neutralised. Proteins were denatured at 70 °C for 10 min. Samples from 
conditioned media and cell lysates were brought to the same volumes. For immunoblotting,
equal volumes of concentrated protein from media samples were loaded per well (equivalent 
to 20 µg of cell lysates). After transfer, PVDF membranes were stained using the 
MemCodeReversible Protein Stain Kit and nitrocellulose membranes using Ponceau to 
provide loading controls.
Cycloheximide chase
Cells were transfected in one dish and after 24 h trypsinised and reseeded into 12 well plates. 
After a recovery period of 24-48 h, cells were treated with 0.5 mM cycloheximide (CHX). 
Cells were harvested at indicated time points for analysis by immunoblotting. Images were 
analysed using the ImageJ software.
SILAC labelling
SILAC media for light (L), medium (M) or heavy (H) labelling were prepared as follows: 
DMEM with 4.5 g L-1 glucose and without arginine, lysine, and glutamine (PAA Laboratories 
#E15-086) was supplemented with 10% dialyzed FBS, Pen/Strep and stable glutamine 
(dipeptide Gln-Ala) (PAA Laboratories). Combinations of different isotopes of arginine 
(0.28 mM) and lysine (0.56 mM) were added. HEK293T cells were cultured in either L, M or 
H media for at least 5 passages and efficient incorporation of amino acid isotopes was 
confirmed by mass spectrometry (MS). 
Sample preparation for SILAC-MS analysis
SILAC-labelled HEK293T cells were transfected by lipofection with Fugene 6 
(L: pcDNA3.1, M: ER-α and H: ER-β23), harvested 48 h later and lysed in 1% Triton X-100 
in PBS supplemented with cOmplete Protease Inhibitor Cocktail and benzonase. After 1 h of 
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end-over-end rotation at 4 °C, cell debris was removed by centrifugation at 2,000 xg for 5 min 
at 4 °C and lysates were transferred to fresh tubes. 1.5 mg protein (in a total of 1 ml) were 
incubated with 50 µl µMacs anti-Myc beads at 4 °C on an end-over-end rotor overnight. 
Samples were then applied to µMACS columns that were equilibrated with 200 µl lysis buffer 
on a magnetic rack. Columns were washed once with 200 µl lysis buffer and then three times 
with 200 µl 0.1% Triton X-100/PBS and once with PBS. Proteins were eluted by addition of 
70 µl hot Urea sample buffer. Eluates from H, M and L samples were mixed 1:1:1 before 
separation on a NuPAGE Bis-Tris gradient gel in MES buffer according to the manufacturer’s 
instructions. For analysis of total protein, input lysates were directly mixed (1:1:1) and 
separated on a gradient gel. Gels were sliced into 12 equal slices per lane and proteins were 
reduced, alkylated, and digested within the gel as described in (Ong and Mann, 2006). After 
extraction, peptides were desalted using homemade columns of 200 µl tips containing C18 
Empore disks. Peptides were eluted with 1% formic acid in 70% acetonitrile (ACN) and dried 
in a vacuum concentrator.
Sample preparation for label-free MS analysis
For analysis of total amounts of ER-β23-mCh in cell lysates, cells were transfected as above. 
Cells were lysed in RIPA buffer and after quantification using the BCA assay, proteins were 
reduced with 1 mM DTT and denatured in 2% SDS at 96 °C for 5 min. Proteins were digested 
using the filter-aided sample preparation (FASP) method (Wisniewski et al., 2011). Vivacon 
filtration columns were equilibrated with UA buffer before applying 100 µg of protein lysates. 
After three washes with UA buffer, proteins were reduced with 10 mM DTT (45 min, RT), 
acetylated with 50 mM Iodoacetamide (30 min, RT) and again washed twice with UA buffer 
before elution with 40 mM NH4HCO3 and digestion with trypsin at 37 °C overnight. Trypsin 
was then inactivated by acidification with TFA and peptides dried in a speedvac. Peptides 
were then fractionated using homemade SAX microcolumns (6 layers of Empore High 
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Performance Extraction Disks in 200 µl pipette tip) using BRUB at decreasing pH (11-3). 
After extraction of the last peptide fraction with MeOH/H2O (1:1)/1% formic acid, all 
fractions were acidified with TFA. Peptides were then desalted using homemade columns 
containing C18 Empore disks or commercial OMIX96 C18 tips. Peptides were eluted with 
1% formic acid in 70% ACN and dried in a vacuum concentrator.
LC-MS/MS
Peptides eluted from desalting tips were dissolved in 5% (v/v) formic acid and sonicated for 
5 min. Samples were analysed on a Proxeon EASY-nLC 1000 nano-HPLC system coupled to 
a Q-Exactive orbitrap mass spectrometer. Peptides were separated on home-made spray-
columns (PicoTips packed with 1.9 µm Reprosil-Pur C18-AQ) using a 2 h linear gradient 
between 5 % solvent A (0.2 % formic acid in water) and 30 % solvent B (0.2 % formic acid in 
ACN). Samples were loaded on the column by the nano-HPLC autosampler at a flow rate of 
0.5 µL per minute. No trap column was used. The HPLC flow rate was set to 0.25 µL per 
minute during analysis. MS/MS analysis was performed with standard settings using cycles of 
1 high resolution (70,000 FWHM) MS scan followed by 10 MS/MS scans of the most intense 
ions with charge states of 2 or higher at a resolution setting of 17,500 (FWHM). 
Analysis of MS data
Protein identification and SILAC-based quantitation was performed with MaxQuant (version 
1.3.0.5) (Tyanova et al., 2014) using default settings. The human sequences of UNIPROT 
(version 2012-06-14) were selected as the database for protein identification. MaxQuant used 
a decoy version of the specified UNIPROT database to adjust the false discovery rates for 
proteins and peptides below 1%. The protein OS-9 was identified in one replicate with SILAC 
ratios of 6.57 but could not be quantified by the MaxQuant algorithm in two other 
experimental replicates. However, this protein was also enriched in these replicates as judged 
based on the extracted ion intensities of light and heavy labelled peptides, which was 
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confirmed by visual inspection of the mass spectra. OS-9 was thus included in the interactor 
set. Normalized ratios (H/L) and combined ratios (H/L) from three independent experiments 
as calculated by MaxQuant were used for analysis. Identified interactors were further 
analysed using Perseus (1.5.2.12). For the label-free analysis of the proteome from 
ER-β23-mCh-expressing cells, three independently prepared and measured samples were 
analysed by MaxQuant.
Fluorescence-activated cell sorting (FACS)
Transfected cells were detached using TrypLE Express 48 h after transfection followed by 
suspension in PBS. Cells were kept on ice until analysis. Cells were analysed using the BD 
FACSCalibur or the BD FACSAriaIII instruments. FACS data were analysed using the 
FlowJo software (Version 9.9). 
siRNA knockdowns
HEK293T cells were transfected with 100 nM non-targeting control siRNA 3 (Ctrl), OS-9 
siRNA smart pool or SEL1L siRNA smart pool and CPY*-mCh using DharmafectDuo 
transfection reagent following the manufacturer’s instructions. Protein levels were analysed 
48 h after transfection.
Luciferase assays
HEK293T cells were co-transfected with the luciferase constructs and either empty 
pcDNA3.1, ER-β23 or ER-α in a ratio of 1:1. 24 h after transfection cells were trypsinised and 
seeded in 96-well plates in 100 μl DMEM. After indicated treatments 30 μl of Steady-Glo 
Luciferase Assay system buffer were added directly to the wells followed by incubation for 
15 min in the dark at room temperature. Luminescence was recorded in a luminometer (2 s 
acquisition time). Untransfected cells incubated with Steady-Glo served as blanks.
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Deglycosylation
Transfected HEK293T cells were lysed in RIPA buffer supplemented with protease inhibitors 
and benzonase. After removal of cell debris by centrifugation and quantification using the 
BCA assay, 40 μg protein were denatured and incubated with 2 μl Endo H or PNGase F 
following the manufacturer’s instructions.
Analysis of Q97 inclusions by fluorescence microscopy
HEK293T cells were transfected with Q97 or Q25 using FuGene6 as described above and 
24 h later trypsinised and reseeded on PLL-coated coverslips in 12 well plates. Cells were 
allowed to settle for 24 h before treatment with 20 µM gefitinib, 20 µM fluphenazine, 20 µM 
erlotinib or 50 µM droperidol for 20 h. After the treatment, cells were washed twice with PBS 
and fixed with 4% paraformaldehyde for 1 h at RT. Cells were again washed twice with PBS
followed by DAPI staining (300 nM DAPI in PBS) for 5 min at RT. Cells were washed a 
further 3 times in PBS and mounted on glass slides with DAKO fluorescent mounting 
medium. Cells were analysed by confocal microscopy using a Zeiss LSM confocal 
microscope. 15 random images were taken per sample each using the 516 nm laser (mCherry) 
at two different laser strengths (0.7 and 7%) and the 405 nm laser (DAPI) at only one laser 
strength (1.0). The images with the lower 516 nm laser strength were used to analyse 
inclusion size and number and the images with the high laser strength were used only to count 
the total number of transfected cells. 5 random images per sample were analysed (about 300 
transfected cells in total) using ImageJ. The total number of transfected cells was manually 
counted using the cell counter plugin. Inclusions were analysed using a macro following the 
same automated steps for each sample to ensure unbiased analysis: a Gaussian Blur (sigma=2) 
and the Renyi Entropy dark threshold were applied. Automatic watershedding was applied to 
separate overlapping particles. Particles of pixel sizes 7.00 to 44117.4 with a circularity of 
0.00 to 1.00 were analysed by size (in pixels) and total number per image. 
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Results 
Part 1 - How the ER handles aggregation-prone β-sheet proteins
Targeting an aggregation-prone β-protein to the ER
The model proteins β4, β17 and β23 have been de novo designed to fold into six β-strands and 
form amyloid-like fibrils with cross-β structure in vitro and when expressed in the 
mammalian cytosol (West et al., 1999; Olzscha et al., 2011). To determine how the ERQC 
machinery handles aggregation-prone β-sheet proteins, we targeted these β-sheet proteins to 
the ER. The most aggregation-prone of these, β23, was chosen as the primary model protein 
for this study. In addition, initial experiments addressing the fate of these proteins in the ER 
were performed also with β4 and β17 to test whether the observed behaviour was sequence-
specific or common to all β-sheet proteins. As a control protein we used α-S824, a de novo
designed α-helical protein, similar in amino acid composition to the designed β proteins, that 
folds into a 4-helical bundle (Wei et al., 2003; Olzscha et al., 2011) (ER-α, Figure 10A). The 
model proteins were targeted to the ER by addition of an N-terminal signal peptide derived 
from the secretory pulmonary surfactant-associated protein B (SP-B) (Dolfe et al., 2015)
(Figure 10A). This signal peptide targets SP-B for co-translational translocation into the ER 
followed by processing and transport through the secretory pathway (Ueno et al., 2004). 
The ER-targeted proteins had the same apparent molecular weight on SDS-PAGE as 
their cytosolic counterparts after expression in human embryonic kidney cells (HEK293T) 
(Figure 10B), suggesting that the signal peptide was efficiently cleaved by the signal peptide 
peptidase in the ER membrane and thus pointing towards efficient ER-targeting. Furthermore, 
this result suggests that the ER-targeted model proteins were not subjected to any specific 
post-translational modifications that would affect their mobility in SDS-PAGE and would
allow them to be discriminated from their cytosolic counterparts.
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Figure 10. Targeting β-proteins to the ER. (A) Model β-proteins were designed to form a
β-sheet consisting of six β-strands (indicated by red arrows), and α-proteins were designed to 
form 4-helical bundles (indicated by blue rods). ER-targeted constructs were designed by 
addition of an N-terminal signal peptide upstream of the Myc-tag of the non-targeted 
constructs (nt-β and nt-α, respectively). The signal peptidase cleavage sites are indicated by 
arrows. (B) Immunoblot analysis of ER-targeted (ER) model proteins after 48 h of expression 
in HEK293T cells revealed no shifts in mobility compared to the non-targeted (nt) proteins. 
Analysis by confocal microscopy confirmed localisation of the ER-targeted model proteins to 
the ER. Human epithelial adenocarcinoma cells (HeLa) were used here as an additional model 
cell line for microscopy because their flat morphology facilitates clearer distinction of cellular 
organelles.
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Figure 11. Model α- and β-proteins are efficiently targeted to the ER. HeLa or HEK293T 
cells were fixed after 48 h expression of the indicated model proteins and stained with 
anti-Myc (magenta) and either anti-ERp57 or anti-calreticulin (CRT) (green) antibodies, 
followed by fluorescently labelled secondary antibodies and analysis by confocal microscopy. 
Representative images from at least 3 independent experiments are shown. Scale bars 
represent 10 µm.
All four proteins, ER-β4, ER-β17, ER-β23 and ER-α, co-localised with the ER marker 
proteins ERp57 and CRT in HeLa and in HEK293T cells (Figure 11). In contrast, the non-
targeted proteins, nt-β4, nt-β17, nt-β23 and nt-α, did not co-localise with ER markers 
(Figure 11). 
Taken together, the SP-B signal peptide efficiently targets the model proteins for co-
translational translocation into the ER.
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ER-β proteins are retained in the ER
After removal of the signal peptide, correct folding and modification, secretory proteins are 
transported in vesicles to the Golgi and subsequently to the plasma membrane for secretion, 
whereas proteins that fail to fold properly are usually retained in the ER until correct folding 
is completed or, should they fail to fold correctly, they are targeted for degradation (Araki and 
Nagata, 2011). The model α- and β-proteins did not contain an ER-retention signal and we 
thus wondered whether they could pass the ERQC for secretion. As expected, the majority of 
the control protein ER-α was detected in the conditioned medium of HEK293T cells two days 
after transfection (2-fold higher levels than intracellular, p<0.01) (Figure 12A-B). The 
possibility of non-specific protein leakage into the media could be excluded because media 
samples did not contain any GAPDH or α-tubulin (Figure 12A-B). Furthermore, secretion of 
ER-α was strongly reduced by treatment of cells with brefeldin A (BFA), which inhibits 
protein transport from the ER to the Golgi (Klausner et al., 1992), indicating that ER-α exits
the cell via the classic secretory pathway (Figure 12B). In contrast, ER-β4, ER-β17 and 
ER-β23 were not detectable in the media, indicating that the β-proteins are retained in the 
secretory pathway, despite their high intracellular concentration (Figure 12A-B).
The observed defect in the secretion of ER-β proteins prompted the question at what 
stage of the secretory pathway trafficking may be impaired. To test whether ER-β4, ER-β17 
or ER-β23 were transported from the ER to the Golgi, the Golgi was stained with an antibody 
against the Golgi membrane protein giantin. 
As expected, ER-α clearly co-localised with giantin in both HeLa and HEK293T cells 
(Figure 12C). In contrast, no co-localisation between giantin and ER-β4, ER-β17 or ER-β23 
could be detected (Figure 12C), indicating that all three ER-β proteins were retained within 
the ER.
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Figure 12. β-proteins are retained in the ER. (A) Conditioned media were collected after 
overnight incubation with HEK293T cells expressing the indicated model proteins for 48 h. 
Proteins from media were TCA-precipitated and equal fractions of protein from media and 
cell lysates were analysed by immunoblotting against the Myc-tag. GAPDH levels 
demonstrated the absence of cell leakage. Membrane staining was performed to provide a 
loading control. (B) HEK293T cells expressing the indicated model proteins were treated with 
1 µg ml-1 brefeldin A (BFA) for 18 h. Proteins from conditioned media and cell lysates were 
analysed as in (A). Tubulin levels demonstrated absence of cell leakage. Membrane staining is 
used as a loading control. (C) HeLa or HEK293T cells were fixed after 48 h expression of the 
indicated model proteins and stained with anti-Myc (magenta) and anti-giantin (green) 
antibodies, followed by fluorescently labelled secondary antibodies and analysis by confocal 
microscopy. Representative images from at least three independent experiments are shown. 
Scale bars represent 10 µm.
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Misfolded proteins that are retained in the ER are usually recognised by ER 
chaperones and targeted for degradation (Olzmann et al., 2013). Since ER-targeted β-proteins 
do not seem to pass the ERQC for secretion, they may instead be targeted for degradation. 
Thus, the stability of ER-β23 was tested by inhibiting protein synthesis using cycloheximide 
(CHX). Strikingly, ER-β23 was found to be a remarkably stable protein with a half-life of 
more than 24 h (Figure 13), considerably exceeding the half-life of classic ERAD substrates 
(Finger et al., 1993). For example, mutant carboxypeptidase Y (CPY*) fused to mCherry 
(CPY*-mCh) was rapidly degraded, with a half-life of less than 3 h, (Figure 13). Thus, 
ER-β23 is retained in the ER, but is not successfully targeted for degradation by ERAD.
Figure 13. ER-β23 is more stable than ERAD substrate CPY*-mCh. HEK293T cells 
expressing either ER-β23 or CPY*-mCh for 72 h were treated with 0.5 mM cycloheximide 
(CHX) and harvested after indicated times of treatment. Protein levels were analysed by 
immunoblotting against the Myc-tags. Mean protein levels of ER-β23 and CPY*-mCh from 
three independent experiments were quantified and shown as percentage of levels in untreated 
cells (0 h). The p value shown was determined using the Student's t-test (unpaired t-test).
Retention of ER-β23 was also determined by live cell imaging. To enable detection, a
fluorescent C-terminal mCherry-tag was added to ER-β23 (ER-β23-mCh) and ER-α
(ER-α-mCh). The mCherry-tag did not alter the localisation of ER-α and ER-β23. As 
observed for the myc-tagged constructs, ER-β23-mCh was retained in the ER, whereas 
ER-α-mCh was detected in conditioned media and in the Golgi of HEK293T cells 
(Figure 14A-B). 
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Imaging of cells over a 192 s time span revealed that ER-β23-mCh mostly localised to 
large network-like structures (Figure 14C), whereas ER-α-mCh was mainly present in vesicle-
like structures that rapidly moved laterally through the cell (Figure 14C).
Figure 14. ER-β23-mCh is retained in the ER. (A) Proteins from conditioned media of 
HEK293T cells after 48 h expression of the indicated proteins were concentrated by TCA 
precipitation and equal fractions of media and cell lysate samples were analysed by 
immunoblotting with anti-mCherry antibody. (B) HeLa cells expressing ER-β23-mCh or 
ER-α-mCh were fixed and stained with anti-calreticulin (CRT) (green) and anti-giantin (blue) 
antibodies, followed by fluorescently labelled secondary antibodies and analysis by confocal 
microscopy. Scale bars represent 30 µm. Enlarged regions (zoom) are indicated by white 
boxes. (C) Live HEK293T cells expressing ER-β23-mCh or ER-α-mCh for 48 h were 
analysed by confocal microscopy. The movement of mCherry-tagged proteins was recorded 
over 192 s. The movement of a vesicle containing ER-α-mCh is indicated by white arrow
heads. Scale bars represent 10 µm.
Targeting β-protein to the ER reduces toxicity and aggregation propensity
The non-targeted β-proteins nt-β4, nt-β17, and nt-β23 formed inclusion bodies (IBs) in the 
cytosol and nucleus, whereas nt-α distributed diffusely throughout the cytosol (Figure 11), as 
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described previously (Olzscha et al., 2011). The β-protein inclusions were markedly larger in 
HEK293T cells than in HeLa most likely due to higher expression levels. However, no clear 
inclusions could be observed after expression of the ER-targeted β-proteins (Figure 11).
Furthermore, the ER-targeted β-proteins were almost completely soluble in buffer containing 
1% Triton, in contrast to the largely insoluble non-targeted β-proteins that fractionated mostly 
to the pellet fraction after centrifugation (Figure 15A-B). 
Non-targeted β-proteins were previously shown to reduce cell viability and this
toxicity correlated with their aggregation propensity, nt-β23 being the most toxic (Olzscha et 
al., 2011). However, expression of ER-β23 did not result in significant toxicity (Figure 15C). 
This observation is in line with its increased solubility. Notably, the reduced toxicity and 
aggregation propensity was not due to lower expression levels of ER-β23. In fact, intracellular 
ER-β23 levels were more than 4-fold higher than the levels of nt-β23 (Figure 15D). Thus, 
despite high concentrations the ER has a much higher capacity to maintain aggregation-prone 
β-sheet proteins in a more soluble and less toxic state.
The observations that ER-targeting renders β-proteins more soluble and less toxic 
regardless of their specific amino acid sequence indicates the existence of a potent ER quality 
control pathway independent of specific amino acid composition that retains proteins rich in 
β-structure in the ER and prevents them from forming amyloid-like, insoluble aggregates.
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Figure 15. ER-targeting prevents β-protein aggregation and toxicity. (A) Solubility of 
ER-targeted model proteins (ER) and their non-targeted counterparts (nt) was analysed after 
48 h of expression in HEK293T cells. Lysates were fractionated by centrifugation and 
fractions analysed by immunoblotting with anti-Myc antibody. T: total lysate, S: soluble 
fraction, P: pellet fraction. (B) Protein levels in P versus S from four independent experiments 
were quantified and mean values plotted. (C) Viability of HEK293T cells was measured by 
the MTT assay after 72 h of expression of the indicated constructs. Mean cell viability from 
three independent experiments was calculated as percentage of the max (ER-α). (D) The 
relative expression levels of ER-β23 and n-β23 in HEK293T cells was quantified based on 
immunoblotting described in Figure 10B. Total levels of ER-β23 were quantified and shown 
as fold increase over nt-β23. Mean values from four independent experiments are shown. 
Error bars represent SD and p values are based on the Student's t-test (unpaired t-test). 
*p<0.05; **p≤0.01; ***p≤0.001.  
To test whether ER-β23 forms higher-order macromolecular assemblies, cell extracts 
were analysed by blue native PAGE (Figure 16A).  A small fraction of ER-β23 migrated as a 
monomeric band, but a larger fraction migrated as higher molecular weight species above 200 
kDa (Figure 16A), indicating the presence of a range of oligomers.
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Figure 16. ER-β23 forms oligomers. (A) Lysates from HEK293T cells expressing either 
pcDNA (Ctrl), ER-β23, ER-α, nt-β23 or nt-α for 48 h were separated on blue native PAGE 
and analysed by immunoblotting with anti-Myc antibody. (B) Lysates from HEK293T cells 
expressing ER-β23 for 48 h were either treated with reducing agents (1 mM DTT and 5% 
β-mercoptoethanol) or left unreduced, separated on denaturing PAGE and analysed by 
immunoblotting against the Myc-epitope.
In contrast, the majority of nt-β23 formed large complexes that did not move into the 
gel and no monomeric protein was detectable. As expected, a monomeric band was detected 
for nt-α but no high molecular weight signal over background could be observed for the 
secreted protein ER-α. Taken together, these findings indicate that nt-β23 and ER-β23 have 
markedly different aggregation properties: nt-β23 forms predominantly large, insoluble 
aggregates, whereas ER-β23 accumulates mainly as soluble oligomers that are significantly
less toxic. Notably, ER-β23 only contains one cysteine residue at the very N-terminus 
excluding the possibility of disulphide-linked polymers. Furthermore, no higher molecular 
bands could be observed by SDS-PAGE under non-reducing conditions confirming the 
absence of intramolecular disulphide bridges (Figure 16B).
Since ER-β23 is not permitted to exit the ER, the polymer formation might reduce the 
diffusion mobility of ER-β23. To test the mobility of ER-β23, fluorescence loss in
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photobleaching (FLIP) experiments were performed and the behaviour of mCherry-tagged 
ER-β23 (ER-β23-mCh) was compared to ER-mCh-KDEL (ER-mCh), which contains the 
same signal sequence but also a C-terminal ER retention signal to prevent secretion. A small 
area within the ER of transfected cells was continuously bleached and images recorded after 
each bleaching cycle. ER-mCh fluorescence rapidly decreased within the whole cell as 
expected for a soluble monomeric protein. Strikingly, ER-β23-mCh fluorescence only 
decreased within the area where the bleaching laser was pointed (Figure 17A) but remained 
relatively constant in a more distant ER area within the same cell (FLIP area, Figure 17A-B) 
demonstrating that ER-β23-mCh was immobilised. Over time, the bleached area increased,
which may indicate slow local movement. 
The reduced mobility of ER-β23-mCh indicates either that the protein is immobilised 
due to formation of immobile oligomers, or alternatively, that ER-β23-mCh accumulation 
leads to fragmentation of the ER restricting the exchange of luminal components through the 
ER network. To distinguish between these two possibilities, the mobility of ER-targeted GFP 
(ER-GFP) was analysed in the presence of ER-β23-mCh. After continuous photobleaching of 
a small area of the ER, ER-GFP fluorescence rapidly decreased within the whole ER both in 
the presence of ER-β23-mCh (Figure 17A-B) and in the control ER-mCh (Figure 17A and C) 
indicating that ER-GFP freely moved through a connected ER network. Thus, even though 
ER-β23-mCh is immobilised compared to monomeric ER-mCh, it allows for free movement 
of other ER-localised proteins. Taken together, this indicates that ER-β23-mCh forms a 
network of soluble oligomers that fills the ER like a gel.
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Figure 17. ER-β23-mCh forms oligomers with restricted mobility. (A) Fluorescence loss 
in photobleaching (FLIP) was performed in HEK293T cells after 48 h of expression of
ER-GFP-KDEL (ER-GFP) in combination with either ER-β23-mCherry (ER-β23-mCh) or 
ER-mCherry-KDEL (ER-mCh). Before bleaching, three images were recorded by confocal 
microscopy to control for variations and possible bleaching during image recording. Then, 
small areas within the ER of cells (bleaching region) were repeatedly bleached using the 
561 nm (for mCherry), 488 nm and 458 nm (for GFP) lasers and images recorded after each 
bleaching cycle (every 77.4 s). Relative changes in mean fluorescence of areas within the ER 
of the same cells (ER FLIP region) were plotted for (B) mCherry and (C) GFP, each
normalised to the fluorescence measured at the first data point. Representative data from four
independent experiments are shown. Scale bars represent 10 µm.
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However, it should be noted that ER-β23 may be more dynamic than the mCherry-
tagged version because the cellular concentrations of ER-β23-mCh were higher than those of 
non-tagged ER-β23, and consequently, ER-β23-mCh showed increased insolubility 
(Figure 18). 
Figure 18. ER-β23-mCh is expressed at higher levels than ER-β23. Solubility of ER-β23 
and ER-β23-mCh in HEK293T cells was analysed 48 h after transfection by centrifugation of 
lysates and immunoblotting against the Myc-tag. T: total lysate, S: soluble fraction, P: pellet 
fraction. Right panel: Protein amounts in the pellet fraction were quantified and presented as 
% of total (S+P). Error bars represent SD from four independent experiments and p values are 
based on the student's t-test (unpaired t-test). **p≤0.01.
Nevertheless, non-tagged ER-β23 was efficiently retained in the ER where it 
accumulated at high concentrations and formed oligomers. The reduced mobility of the 
mCherry-tagged construct indicates that this type of oligomer may have restricted mobility.
ER-β17 is also retained in a detergent-soluble state in stably expressing cell lines
It has recently been reported that a small fraction of ER-β17 expressed in stable HEK293 cell 
lines may be insoluble and that a small amount could be detected extracellularly after 
immunoprecipitation (Dolfe et al., 2015). 
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Figure 19. ER-β17 is detergent-soluble and retained in the ER in stably expressing cell 
lines. (A) Lysates and conditioned media samples from HEK293T cells stably expressing the 
indicated model proteins were analysed as described in Figure 12A. (B) HEK293T cells 
stably expressing ER-β17 or transiently transfected with ER-β17 were fixed and stained with
anti-Myc (magenta), anti-CRT (gray) and anti-giantin (green) antibodies, followed by 
fluorescently labelled secondary antibodies and analysis by confocal microscopy. Scale bars 
represent 10 µm. Enlarged regions (Zoom) are indicated by white boxes. (C) Solubility of 
nt-β17 and ER-β17 from transiently transfected cells or from the stably expressing HEK293T 
cells was analysed 48 h after transfection as described in Figure 15A. T: total lysate, 
S: soluble fraction, P: pellet fraction.
We thus set out to determine whether ER-β17 may be handled differently after 
prolonged and increased expression in stable cell lines compared to transiently transfected 
cells. However, no differences between stably or transiently expressed ER-β17 were 
detectable in conditioned medium or in co-localisation studies with the Golgi marker giantin 
(Figure 19A-B). Similar to the transiently expressed ER-β17, ER-β17 from stable cell lines 
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was mostly soluble in 1% Triton (Figure 19C). We conclude that insoluble ER-β17 represents 
only a minor fraction (less than 10%) of total ER-β17 and that ER-β proteins seem to be 
handled in a similar manner in a stably expressing HEK293 cell line as in transiently 
transfected cells.
Analysis of the ER-β23 interactome
To identify the components of the ERQC machinery that interact with ER-β23, we performed 
a quantitative proteomic analysis using stable isotope labelling with amino acids in cell 
culture (SILAC) (Ong and Mann, 2006). After labelling HEK293T cells with amino acid 
isotopes in cell culture and verification of full incorporation of amino acids by mass 
spectrometry, labelled cells were transfected with ER-β23, ER-α or the empty pcDNA vector 
(Figure 20A). Myc-tagged proteins were immuno-precipitated and equal amounts of eluates 
were mixed before preparation for mass spectrometry. Immuno-precipitation (IP) of ER-β23 
resulted in an enrichment of about 6-fold with minimal loss of protein in the flow-through 
(Figure 20B). However, ER-α could not be isolated as efficiently with almost 60% of protein 
lost in the flow-though and minimal (less than 0.1 fold) enrichment (Figure 20B). Not 
surprisingly, therefore, no specific ER-α interactors over the control (pcDNA) could be 
detected. Comparison of protein levels on a coomassie-stained gel confirmed equal amounts 
of total protein contents and specific band patterns for input versus eluate samples 
(Figure 20C). 
A total of 3,317 proteins were identified in the mixed eluate sample by mass
spectrometry in three independent experiments (Figure 20D and Appendix Suppl. Table 2). 
Of these, 83 proteins were more than 2-fold (up to 8.9-fold) enriched in ER-β23 compared to
the control (pcDNA) in at least two of three independent experiments and were thus defined 
as specific ER-β23 interactors (Figure 20D and Appendix Suppl. Table 2).
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Figure 20. Analysis of the ER-β23 interactome. (A) Design of SILAC-based MS analysis to 
identify proteins that preferentially interact with ER-β23. (B) ER-β23 and ER-α were 
immuno-precipitated from HEK293T cell lysates after 48 h of expression using anti-Myc 
antibody coupled magnetic beads. The IP input lysates, flow-through, wash fractions and 
eluates were analysed by immunoblotting using a different anti-Myc antibody. (C) Input 
lysates and IP eluates were separated by SDS-PAGE and analysed by Coomassie staining. (D)
The H/L ratios (ER-β23 over control) of all proteins identified in IP eluates were analysed 
using Perseus (1.5.2.12) to generate a volcano plot showing the mean H/L ratio in log2 (Log2 
t-test difference) versus the negative log of the p value for all identified proteins. Proteins that 
were enriched more than 2-fold in ER-β23 eluates over the control in at least two out of three 
experiments were defined as ER-β23 interactors (indicated as purple dots, all other proteins 
shown as grey dots). 
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Figure 21. Cellular localisation of ER-β23 interactors. Gene Ontology Cellular Component 
(GOCC) annotations were assigned to ER-β23 interactors using Perseus (1.5.2.12). All 
interactors are listed grouped by their main localisations and sorted by their SILAC 
enrichment. The enrichment of the GOCC category annotations among the set of interactors 
was calculated over the background of GOCC category annotations of all proteins identified 
using the Fisher exact test. Enrichment factors of the significantly enriched organelle parts 
(ER lumen and mitochondrial membrane) are shown in red and orange.
Analysis of total protein levels in the input lysates revealed that the 83 interactors of ER-β23
were not significantly up-regulated (Appendix Suppl. Table 2), indicating that the observed 
interactions are not due to altered total protein levels.
ER-β23 interacts with a distinct set of ER chaperones and ERAD factors
The set of ER-β23 interactors is significantly enriched for ER luminal proteins and with lower 
significance for mitochondrial and ER membrane proteins when comparing gene ontology 
annotations of ER-β23 interactors to the background of all identified proteins (Figure 21 and 
Results
87
Appendix Suppl. Table 3). Interactions of ER-β23 with mitochondrial membrane proteins 
could be due to localisation to ER-mitochondria contact sites. Other components of the 
secretory pathway were not significantly enriched, consistent with the finding that ER-β23 is 
retained in the ER. ER-β23 also interacted with a large set of cytosolic and nuclear proteins, 
including proteins of the nuclear envelope, but neither the cytosol nor the nucleus were 
significantly enriched as cellular components.
Figure 22. Overlap of the ER-β23 and the nt-β23 interactomes. Comparison of the 
identified interactors of ER-β23 (83 proteins, represented by red circle) and the interactors of 
nt-β23 (Olzscha et al., 2011) (105 proteins, represented by grey circle) revealed six common 
interactors (gene names listed).
Less than 10% (6 proteins) of the ER-β23 interactors were previously found to interact 
with nt-β23 (Olzscha et al., 2011) (Figure 22). This confirms that the proteins have distinct 
cellular localisations and that the majority of identified interactions are not due to post-lysis 
artefacts. Interestingly, 4 of the 6 interactors common to ER-β23 and nt-β23 are mitochondrial 
proteins. 
Amongst the interactors of ER-β23 we identified several ER-resident chaperones 
(Figure 23A-B). These include the HSP90 family member GRP94, the HSP70 BiP, the lectin 
chaperone calnexin (CNX), the nucleotide exchange factor of the HSP110 family HYOU1 
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and the protein disulphide-isomerase A6 (PDIA6). The latter has recently been demonstrated
to play a role in protein folding as well as regulation of the UPR (Eletto et al., 2014). 
Surprisingly, we also identified several interactors of ER-β23 that are part of the ERAD 
machinery: the substrate binding protein OS-9, the adapter protein SEL1L and the 
intramembrane adapter protein Erlin-2 (Figure 23A-B and Appendix Suppl. Table 2). These 
interactions were striking because ER-β23 does not seem to be efficiently degraded via the 
ERAD pathway (Figure 13). Notably, no cytosolic members of the ERAD pathway interacted 
with ER-β23 suggesting that ER-β23 may be targeted for ERAD and recognised by substrate 
recognition factors but not be efficiently dislocated into the cytosol for degradation by the 
UPS.  
Of the 83 ER-β23 interactors, 90% contributed less than 2% each to the total amount 
(in ppm) of proteins found in the IP eluate (relative abundance calculated using IBAQ values) 
(Appendix Suppl. Table 4). However, BiP strikingly stood out as one of the most abundant 
interactors making up more than 20% of total interacting proteins in the eluate (Appendix 
Suppl. Table 4).
The specific interactions of ER-β23 with SEL1L, OS-9, HYOU1, PDIA6, GRP94, 
Erlin-2, CNX and BiP were confirmed by immunoblotting. It is worth noting that for many 
chaperones only a small fraction (~0.2-3%) of the total amount of the protein present in cells 
could be immuno-precipitated (Figure 23B). Thus, even though the IP eluate contained a large 
amount of BiP, this reflected only a small fraction of total cellular BiP levels suggesting that a 
depletion of the free chaperone pool by ER-β23 is unlikely. In contrast, high amounts of the 
ERAD components SEL1L and OS-9 compared to their total cellular levels interacted with 
ER-β23 (about 10% of total SEL1L and about 50% of total OS-9). Notably SEL1L and OS-9 
are very low-abundance proteins in HEK293T cells. Label-free MS quantification revealed 
that cellular levels of SEL1L and OS-9 were over 200-fold lower than the levels of GRP94 
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and BiP (Appendix Suppl. Table 5). Thus, sequestration of these factors by ER-β23 may have 
functional consequences. 
Figure 23. ER-β23 is recognised by a set of ER chaperones and ERAD factors. 
(A) Enrichment ratios of ER-β23-interacting ERQC factors (combined H/L ratios from three
independent experiments calculated by MaxQuant (version 1.3.0.5)) are shown. (B) Detail of 
volcano blot described in Figure 20D. The ER-β23-interacting chaperones and ERAD factors 
are indicated in red, all other ER-β23 interactors as purple dots and non-enriched proteins that 
were identified as grey dots. (C) The interactions of SEL1L, OS-9, HYOU1, PDIA6, GRP94, 
Erlin-2, CNX and BiP with ER-β23 were confirmed by immunoblotting after IP of ER-β23 as 
described in Figure 20B.
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ER-β23 accumulates at levels exceeding those of interacting chaperones
Binding of ER-β23 to ER-resident chaperones might contribute to its retention in the ER. To 
test whether HEK293T cells contained sufficient amounts of the ER chaperones BiP, CNX, 
GRP94, HYOU1 and PDIA6 to bind all ER-β23 molecules, the abundance of ER chaperones 
relative to ER-β23 was analysed by MS. Tryptic digestion of ER-β23 did not produce any
peptides that could be detected by MS, making it impossible to quantify ER-β23 by 
proteomics. However, tryptic digestion of the mCherry-tagged version of ER-β23 
(ER-β23-mCh) generated sufficient peptides to allow intensity-based absolute quantification 
(IBAQ) (Schwanhausser et al., 2011). Thus, relative chaperone levels were quantified in 
HEK293T cells expressing ER-β23-mCh. The abundances of proteins were calculated as ppm 
of all identified proteins after normalisation for transfection efficiency (Figure 24A) to 
exclude proteins from untransfected cells from the analysis. Strikingly, ER-β23-mCh levels 
were significantly higher than the levels of each individual interacting ER chaperone and even 
exceeded the combined amount of all interacting chaperones (Figure 24B). 
BiP has previously been reported to reach low millimolar concentrations in the ER (up 
to 5 mM) (Weitzmann et al., 2007). This provides an estimate for the cellular concentration of 
ER-β23, which must be in the millimolar range even after taking into account that the 
mCherry-tagged version is expressed at higher levels (Figure 18). Based on these high levels 
of ER-β23, a 1:1 molar interaction between a major fraction of ER-β23 and any interacting 
chaperone is very unlikely, especially because only a few percent of the total of each 
chaperone was co-immunoprecipitated (Figure 23B). Thus, chaperones may bind to only a 
small fraction of ER-β23 at any given time, for example the monomeric form. A single 
chaperone molecule may also be able to bind and retain ER-β23 oligomers. Alternatively, 
ER-β23 may be retained due to the formation of oligomers and higher order polymers 
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(Figure 16A) that are immobilised (Figure 17A-B) preventing their packaging into secretory 
vesicles. 
Figure 24. Total abundances of ER-β23 interactors. (A) Transfection efficiency was 
analysed 48 h after transfection of HEK293T cells with ER-β23-mCh by measuring mCherry 
fluorescence using fluorescence-activated cell sorting (FACS). The fraction of mCherry-
positive cells (right panel) was calculated using the FlowJo software after generating a gate 
including all mCherry-positive cells and excluding the untransfected control cells 
(representative plot shown in left panel). (B) Cellular abundance values of ER chaperones and 
ERAD factors relative to the abundance of ER-β23-mCh. IBAQ values of proteins measured 
in ER-β23-mCh-expressing cells are plotted as fractions of the IBAQ value of ER-β23-mCh 
after normalisation for transfection efficiencies shown in (A). Error bars represent SD of three
independent experiments. Proteins are sorted from left to right in order of their enrichment in 
the ER-β23 interactome (see Figure 23A).
ER-β23 inhibits UPR induction
Since ER-β23 is recognised by ER chaperones and retained within the ER lumen at high 
concentrations, it may induce the UPR. However, MS analysis revealed that ER-β23 
expression for 48 h did not lead to increased levels of UPR targets (Appendix Suppl. Table 6). 
To test further how ER-β23 expression affected UPR signalling, cells were co-transfected 
with ER-β23 and UPR sensor constructs that express firefly luciferase under the control of the
UPR-induced UPRE, ERSE I and ERSE II promoters (Bouman et al., 2011), which are 
induced by the UPR transcription factors XBP1 (UPRE) and ATF6 (ERSE I and II)
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(Yamamoto et al., 2004). We found that ER-β23 expression did not lead to increased UPRE-
induced luciferase activity but, on the contrary, resulted in a significantly reduced basal 
UPRE-regulated expression (Figure 25A). Tunicamycin (Tm) treatment, which causes ER 
stress by inhibition of protein glycosylation (Takatsuki and Tamura, 1971), resulted in 
induction of UPRE-luciferase in control cells but failed to cause a detectable induction in 
ER-β23-expressing cells (Figure 25A). In contrast, the control protein ER-α did induce 
UPRE-luciferase. Indeed, it would be expected that high overexpression of a secretory protein 
requires the cell to increase its ERQC capacity via UPR induction (Calfon et al., 2002). 
Figure 25. ER-β23 inhibits UPR induction. HEK293T cells were co-transfected with a 
combination of pcDNA (Ctrl), ER-β23 or ER-α and either (A) UPRE-, (B) ERSE I-, (C)
ERSE II- or (D) CMV-promoter-driven-luciferase and 48 h later treated with 1 µg ml-1
tunicamycin (Tm) for 24 h were indicated. Luciferase expression was then analysed by 
measuring luminescence. Mean luminescence values of three independent experiments are 
plotted as fold change from untreated control cells (Ctrl). Error bars represent SD and p 
values are based on the student's t-test (unpaired t-test). *p<0.05; **p≤0.01; ***p≤0.001.
The ERSE I- and ERSE II-promoters were, in contrast to UPRE, induced by ER-β23
as well as ER-α (Figure 25B-C). Tm treatment led to a mild additional induction of the 
promoters in the presence of ER-α. Yet, in the presence of ER-β23 no further induction by Tm 
treatment could be detected (Figure 25B-C), indicating a mild inhibitory effect of ER-β23 also 
on the ERSE-promoters. Co-expression of ER-β23 and CMV-driven luciferase verified that 
the observed effects were promoter-specific and not due to a general inhibition of translation
or luciferase folding (Figure 25D). It was previously shown that nt-β23 does not induce the 
cytosolic stress response and in fact inhibited its activation (Olzscha et al., 2011). ER-β23
Results
93
appears to have a similar inhibitory effect on the IRE1α/XBP1 axis of the UPR and to some 
extent on the ATF6 axis. 
ER-β23 is not glycosylated
Many of the ER-β23 interactors are known to bind glycosylated substrates. ER-β23 contains 
several asparagines (Appendix Suppl. Table 1) but the NetNGlyc 1.0 Server algorithm (Blom 
et al., 2004) predicted no N-glycosylation sites. Furthermore, the fact that ER-β23 migrates at 
the same size as nt-β23 in electrophoresis strongly suggested that ER-β23 was not subject to 
glycosylation (Figure 10B). In addition, ER-β23 did not show any shift in electrophoretic 
mobility after treatment of lysates with the deglycosylating enzymes endoglycosydase H 
(Endo H) or peptide-N-glycosidase F (PNGase F). In contrast, the endogenous ER protein 
SEL1L was clearly deglycosylated under these conditions in the same lysates (Figure 26A). 
Thus, ER-β23 is not glycosylated and is recognised by these lectins either via an additional 
client recognition mechanism such as a peptide binding domain or the lectins bind ER-β23 
indirectly as parts of larger protein complexes. 
ER-β23 inhibits ERAD
Surprisingly, even though ER-β23 was degraded with very slow kinetics, it interacted strongly 
with ERAD factors OS-9, SEL1L and Erlin-2 that serve as substrate recognition and adaptor 
proteins, respectively. However, no downstream factors of the ERAD pathway involved in 
substrate translocation or ubiquitination were identified as interactors of ER-β23. Together 
with the findings that ER-β23 was very stable and was exclusively detected in the ER, these 
selective interactions with early ERAD factors suggest that ER-β23 does not pass the dislocon 
for retro-translocation into the cytosol. Thus, ER-β23 may interact with components of the 
early ERAD pathway in a non-productive manner and in this way block degradation of other 
ERAD substrates. To test this hypothesis, the effect of ER-β23 on the degradation of the 
ERAD model substrate CPY*-mCh was analysed. 
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Figure 26. ER-β23 inhibits ERAD. (A) Lysates from ER-β23-expressing HEK293T cells 
were treated with deglycosylating enzymes Endo H or PNGase F before analysis by 
immunoblotting with anti-SEL1L and anti-Myc antibodies, using 8% and 12% Bis-Tris gels 
for SEL1L and ER-β23, respectively, to ensure maximum resolution. (B) HEK293T cells co-
transfected with CPY*-mCh and either pcDNA (Ctrl), ER-β23 or ER-α were treated with 
0.5 mM cycloheximide (CHX) for 3 h where indicated. Levels of CPY*-mCh, ER-β23 and 
ER-α were analysed by immunoblotting with anti-Myc antibody. CPY*-mCh levels were 
quantified, normalised with the loading control tubulin and presented as % of untreated cells 
(0 h). Error bars represent SD from three independent experiments and p values are based on 
the Student's t-test (unpaired t-test). (C) Cells were co-transfected with a combination of 
CPY*-mCh and non-targeting siRNA (mock) or siRNA pools targeting OS-9 or SEL1L. 
Stability of CPY*-mCh was analysed as in (B). (D) Cells were co-transfected with 
CPY*-mCh, pcDNA (Ctrl), ER-β23 plus pcDNA or ER-β23 plus SEL1L. Stability of 
CPY*-mCh was analysed as in (B). *p<0.05, **p≤0.01.
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As expected from previous findings, only ~30% of CPY*-mCh remained after 3 h in pcDNA-
transfected control cells and in cells expressing ER-α but strikingly, in the presence of 
ER-β23, CPY*-mCh was stabilised to levels higher than 70% (Figure 26B). Thus, ER-β23 
inhibits degradation of ERAD substrate CPY*-mCh. The observed interactions of OS-9 
and/or SEL1L with ER-β23 might lead to depletion of these ERAD factors and in this way 
stabilise ERAD substrates such as CPY*, whose degradation, at least in yeast, is dependent on 
Yos9p and Hrd3p, the yeast homologues of OS-9 and SEL1L, respectively (Buschhorn et al., 
2004; Bhamidipati et al., 2005; Gauss et al., 2006). However, it had so far not been 
demonstrated that CPY* degradation in mammalian cells is also dependent on these factors. 
To test whether degradation of CPY*-mCh by the mammalian ERAD system is dependent on 
OS-9 and SEL1L, knockdowns of these factors was performed using siRNAs. 
Surprisingly, simultaneous knockdown of both OS-9 isoforms, OS-9.1 and OS-9.2, 
had no significant effect on CPY*-mCh stability (Figure 26C). This may be due to redundant 
activities of OS-9 and the ERAD substrate recognition lectin XTP3-B, at least for the 
degradation of soluble ERAD substrates (Bernasconi et al., 2010). In contrast, knockdown of 
SEL1L, which is thought to be required for mammalian ERAD (Sun et al., 2014), caused a 
significant stabilisation of CPY*-mCh with almost 90% of CPY*-mCh remaining after 3 h of 
CHX treatment (Figure 26C). Taken together, this strong dependence on SEL1L 
(Figure 26C), the large fraction of total SEL1L interacting with ER-β23 non-productively 
(Figure 23B) and the low basal cellular abundance of SEL1L (Figure 24B), all indicate that 
the sequestration of SEL1L by ER-β23 may be sufficient to block ERAD. Indeed, mild 
overexpression of SEL1L in combination with ER-β23 and CPY*-mCh rescued ERAD of 
CPY*-mCh (Figure 26D). Thus, ER luminal accumulation of ER-β23 inhibits ERAD by 
titration of SEL1L.
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NRSG392E interacts productively with SEL1L
Mutants of the neuroserpin (NRS) protein that form polymers within the ER cause the 
dementia familial encephalopathy with neuroserpin inclusion bodies (FENIB) (Davis et al., 
2002; Miranda et al., 2004). The wild type NRS is a secretory protein but the disease mutant 
NRSG392E, as well as the GFP-tagged version NRSG392E-GFP, were reported to form polymers 
that are retained in the ER (Schipanski et al., 2014). We confirmed this specific retention of 
NRSG392E-GFP and the formation of higher order oligomers in HEK293T cells
(Figure 27A-B). Similar to ER-β23, NRSG392E was almost completely soluble in 1% Triton 
(Figure 27C).
Importantly, SEL1L interacted selectively with the NRSG392E mutant but not with wild 
type NRS (Figure 27D). It has previously been reported that NRSG392E is degraded via ERAD 
(Schipanski et al., 2014). Thus, in contrast to ER-β23, NRSG392E may interact with SEL1L in a 
productive manner without blocking ERAD of other substrates. Indeed, co-expression with 
NRSG392E did not lead to stabilisation of CPY*-mCh (Figure 27E). The secretory wt NRS 
could not be detected by immunoblotting in this experiment, most likely due to its low 
intracellular levels, particularly under conditions of co-expression with another ER-targeted 
protein (Figure 27E). To test whether the productive interaction with SEL1L was dependent 
on glycosylation of NRSG392E, a mutant that lacks two major N-glycosylation sites, 
NRSG392EΔNN was utilised. NRSG392EΔNN was also shown to form polymers in the ER and was 
previously reported to be more stable than the glycosylated protein and may thus block ERAD 
(Schipanski et al., 2014). Lack of glycosylation could be confirmed by an electrophoretic 
shift; however, NRSG392EΔNN did not affect stability of CPY*-mCh (Figure 27E). Taken 
together, mutant NRS proteins that accumulate in the ER in a similar manner as ER-β23 do 
not cause a block of ERAD but interact with SEL1L in a productive manner leading to their 
clearance.
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Figure 27. NRSG392E interacts with SEL1L but does not inhibit ERAD of CPY*-mCh.
(A) HEK293T cells expressing NRS-GFP or NRSG392E-GFP were treated with 1 µg ml-1 BFA 
for 18 h before collection of conditioned media and cells. Proteins from media were TCA-
precipitated and equal fractions of protein from media and cell lysates were analysed by 
immunoblotting with anti-GFP antibody. GAPDH levels demonstrated the absence of cell 
leakage. Membrane staining was performed to provide a loading control. (B) Cell lysates from 
HEK293T cells transfected with NRS or NRSG392E were separated on blue native PAGE and 
analysed by immunoblotting with an anti-NRS antibody. (C) Solubility of NRS-GFP and 
NRSG392E-GFP expressed in HEK293T cells was analysed by fractionation of lysates and 
immunoblotting with anti-GFP antibody. T: total lysate, S: soluble fraction, P: pellet fraction. 
(D) NRSG392E-GFP and NRS-GFP were immuno-precipitated from HEK293T cell lysates 
using anti-GFP antibody-coupled magnetic beads. The IP input lysates and eluates were 
analysed by immunoblotting using a different anti-GFP antibody. (E) HEK293T cells co-
transfected with a combination of CPY*-mCh and either empty pcDNA (Ctrl), wt NRS
(NRS), NRSG392E, or NRSG392EΔNN were treated with 0.5 mM CHX for 3 h where indicated. 
Levels of CPY*-mCh and NRS were analysed by immunoblotting with anti-Myc and anti-
NRS antibodies, respectively. CPY*-mCh levels were quantified, normalised with the loading 
control tubulin and presented as % of untreated cells (0 h). Error bars represent SD from three
independent experiments.
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Part 2: Small molecule enhancers of proteostasis
Fluphenazine and gefitinib reduce HttQ97-induced UPS impairment
The FDA-approved drugs fluphenazine and gefitinib (Figure 28) were identified in a screen 
for small molecule modulators of the proteostasis network. Fluphenazine is an antipsychotic 
drug that is used to treat schizophrenia and other psychoses and gefitinib is an epidermal 
growth factor receptor (EGFR) inhibitor that is used in cancer treatment. We set out to better 
understand how these compounds modulate the PN.
Figure 28. Chemical structures of the proteostasis modulators. (A) Structure of the
antipsychotic drug fluphenazine. (B) Structure of the EGFR inhibitor gefitinib.
To better understand how these compounds may affect the PN, their potential to
alleviate toxic effects of protein aggregates of the HD model protein HttQ97 (Q97) were 
tested. The HD model protein Q97 consists of the Htt exon 1 and includes a 97 residue polyQ
stretch as well as a mCherry tag. As a control, a similar construct that contains only a 
25 residue long glutamine stretch and is less aggregation-prone (Q25) was utilised. 
Accumulation of aggregation-prone polyQ repeat fragments leads to proteostasis imbalance 
and, as a result, to exhaustion of the UPS and an accumulation of UPS substrates (Hipp et al., 
2012). 
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Figure 29. Proteasomal activity can be measured with the UbG76V-GFP reporter. 
HEK293 cells stably expressing UbG76V-GFP were treated with 10 µm MG132 for 20 h or left 
untreated. Changes in GFP fluorescence intensity compared to wt cells (Ctrl) were then 
measured by FACS.
This toxic effect of Q97 can be measured using a reporter HEK293 cell line that stably 
expresses UbG76V-GFP. In healthy cells, the highly unstable UbG76V-GFP is rapidly degraded
by the proteasome. Upon proteasomal inhibition, such as with the proteasomal inhibitor 
MG132, UbG76V-GFP accumulation can easily be measured by FACS (Figure 29). 
Figure 30. Fluphenazine and gefitinib reduce Q97-induced UPS impairment.
UbG76V-GFP reporter or wt HEK293 (Ctrl) cells were transfected with HttQ25-mCherry (Q25) 
or HttQ97-mCherry (Q97) and 48 h later treated with 20 µM fluphenazine (Flu), 20 µM 
gefitinib (Gef) or DMSO (Ctrl) for 20 h. Accumulation of UbG76V-GFP in Htt-mCherry-
expressing cells was analysed by FACS and (A) plotted against mCherry fluorescence. (B)
After gating for transfected cells (mCherry expression), mean GFP fluorescence of 50,000 
cells was quantified. Representative results of five independent experiments are shown.
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After transfection with Q97, UbG76V-GFP accumulated in cells that highly expressed 
Q97 as measured by mCherry fluorescence and to a lesser extent in cells that expressed Q25
(Figure 30A), indicating strong inhibition of the UPS by Q97. This UPS inhibition by Q97 
was alleviated by treatment with either fluphenazine (Flu) or gefitinib (Gef) (Figure 30A-B). 
Thus, these compounds clearly improve cellular proteostasis in the presence of protein 
aggregates.
Fluphenazine induces the heat shock response
One mechanism for how these compounds might improve proteostasis capacity could be via 
induction of cellular stress responses. To test whether either Flu or Gef may induce the HSR,
a luciferase sensor consisting of firefly luciferase driven by the HSP70-promoter that is 
induced by HSF1 upon activation of the HSR was utilised. Strikingly, Flu significantly 
induced the HSR in a dose-dependent manner, whereas Gef did not (Figure 31A). This 
indicates that Flu may alleviate Q97-induced UPS impairment by inducing the HSR-driven 
upregulation of molecular chaperones, whereas Gef seems to alleviate the effect of Q97 by a 
different mechanism.
Droperidol also induced the HSR and improved proteostasis
Fluphenazine is a known dopamine antagonist and we thus asked whether other anti-
dopaminergic compounds may have a similar effect on HSR induction and proteostasis 
improvement. To address this question, the effects of the anti-dopaminergic drug droperidol 
(Dro) (Figure 32A) were tested. Interestingly, Dro also mildly induced the HSR (Figure 31B) 
and alleviated UPS impairment in the presence of Q97 (Figure 31C) in a similar manner to 
Flu. This suggests that anti-dopaminergic drugs share common features that may induce the 
HSR leading to improved proteostasis under conditions of stress. Alternatively, the HSR may 
be induced via inhibition of dopamine receptor signalling. However, even though dopamine 
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receptors play important roles in the renal system (Hussain and Lokhandwala, 2003), it is 
unclear whether they are present in HEK293 cells.
Figure 31. Fluphenazine and droperidol induce the heat shock response. HEK293 cells 
were transfected with a HSP70-promoter-luciferase construct and treated with (A) DMSO 
(Ctrl), or 5 or 20 µM of either fluphenazine (Flu) or gefitinib (Gef) or (B) with 10, 20 or 
50 µM droperidol (Dro) for 20 h before measuring luciferase activity. (C) UbG76V-GFP 
reporter or wt HEK293 (Ctrl) cells were transfected with Q25 or Q97 and 48 h later treated 
with 50 µM droperidol (Dro) or DMSO (Ctrl) 20 h. Accumulation of UbG76V-GFP in Htt-
mCherry expressing cells was analysed by FACS and plotted against mCherry fluorescence. 
Representative results of three independent experiments are shown.
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Figure 32. Chemical structures of droperidol and erlotinib. (A) Structure of the
antipsychotic drug droperidol. (B) Structure of the EGFR inhibitor erlotinib.
Erlotinib also reduces HttQ97-induced UPS impairment
Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)
(Maemondo et al., 2010). We were thus wondering whether other EGFR inhibitors may also 
improve proteostasis capacity in the presence of Q97. Interestingly, the EGFR inhibitor 
erlotinib (Erl) (Figure 32B) alleviated Q97-induced UPS impairment to the same extent as 
Gef (Figure 33). This may suggest that inhibition of EGFR, which we measured to be
expressed in HEK293T cells at about 5 ppm as determined by quantitative proteomics,
improves proteostasis by an unknown mechanism.
Figure 33. Erlotinib reduces Q97-induced UPS impairment. UbG76V-GFP reporter or wt 
HEK293 (Ctrl) cells were transfected with HttQ25-mCherry (Q25) or HttQ97-mCherry (Q97) 
and 48 h later treated with DMSO (Ctrl), 20 µM Erl or Gef for 20 h. Accumulation of 
UbG76V-GFP in transfected cells was analysed by FACS and plotted against mCherry 
fluorescence.
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Importantly, neither Flu, Dro, Gef nor Erl had an effect on the UPS in the absence of 
Q97 (Figure 34), thus confirming that the compounds alleviated an impairment that was 
caused by Q97 and did not directly affecting basal UPS activity.
Gefitinib reduces the size of Q97 aggregates
To understand in more detail how these compounds may alleviate the stress on the UPS 
caused by Q97, the effects on Q97 aggregate formation were tested. Neither of the 
compounds reduced the total number of cells with inclusions (Figure 35A-B). However, Gef
treatment led to a mild but significant reduction in inclusion size (Figure 35C). This indicates 
that Gef may alleviate proteotoxic stress by increasing the capacity of cells to prevent Q97 
aggregation.
Figure 34. Treatments with Dro, Flu, Erl or Gef do not affect fluorescence properties of 
UbG76V-GFP in absence of Htt-mCh. UbG76V-GFP reporter HEK293 cells were treated with 
DMSO (Ctrl), 50 µM Dro, 20 µM Flu, 20 µM Erl or 20 µM Gef for 20 h. GFP fluorescence 
intensity was analysed by FACS.
In summary, the anti-dopaminergic drugs fluphenazine and droperidol and the EGFR 
inhibitors gefitinib and erlotinib had a remarkable effect on the PN, in particular in the 
presence of aggregating Q97 disease protein. The anti-dopaminergic drugs may improve 
cellular proteostasis by induction of the HSR. 
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Figure 35. Gefitinib reduces the size of Q97 inclusions. (A) HEK293 cells were transfected 
with Q97 and 48 h later treated with 20 µM Gef, 20 µM Erl, 20 µM Flu or 50 µM Dro. 
Representative images of four independent experiments are shown. Scale bars represent 
10 µm. (B) Inclusions were analysed by fluorescence microscopy and quantified using the 
ImageJ software. The mean fold change of the number of cells with inclusions from four 
independent experiments counting more than 100 cells each was calculated. Error bars 
represent SD. (C) The mean fold change of inclusion size from four independent experiments 
counting more than 100 cells each was calculated. Error bars represent SD and p values are 
based on the Student's t-test (unpaired t-test). **p≤0.01.  
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Discussion
The data presented in this thesis demonstrate that the capacity of the ERQC to maintain 
aggregation-prone β-proteins in a more soluble state and to limit their toxicity exceeds that of
the cytosolic PN. In contrast to an α-helical protein, which passes through the secretory 
pathway, β-proteins are not secreted but are retained in the ER (Figure 36). Yet, unlike a 
classic terminally misfolded protein species, such as CPY*, ER-β23 is not efficiently 
degraded but instead accumulates in the ER to high concentrations and interferes with the 
ERAD pathway (Figure 36). ER-β23 appears to be targeted for ERAD as it interacts with 
ERAD factors, which are involved in substrate recognition and in linking substrates to the 
dislocon. However, ER-β23 fails to be efficiently retro-translocated.  This non-productive 
engagement of ERAD factors interferes with the degradation of ERAD substrates. Thus, 
retention of ER-β23 comes at the price of a disturbance of the ER PN by ERAD inhibition
and by adverse effects on the UPR.
Figure 36. Fate of ER-targeted β-sheet proteins. ER-β23 is co-translationally translocated 
into the ER, where it is retained, accumulates to high levels, forming a network of soluble 
polymers and interacts with molecular chaperones. ER-β23 interacts with factors of the early 
ERAD pathway but is not efficiently degraded leading to a block in ERAD.
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It is striking that ER-targeting leads to such a dramatic increase in solubility and 
decrease in cytotoxicity of all three β-protein constructs. The increased solubility of ER-
targeted β-proteins is in line with previous reports that ER-targeting prevents the aggregation 
of proteins with an expanded polyQ repeat (Rousseau et al., 2004). Yet, the high solubility of 
ER-β-proteins is somewhat surprising when taking into account that the ER makes up only a 
fraction of the mammalian cell volume (e.g. around 15% in hepatocytes (Weibel et al., 1969; 
Alberts et al., 2014)). Accordingly, the local concentration of ER-β23 in the ER must be at 
least 20-times higher than the concentration of nt-β23, which mostly localises to the cytosol 
and nucleus (together around 80% volume of hepatocytes (Weibel et al., 1969)). In fact, 
quantitative proteomic measurements suggest that ER-β23 concentrations exceed those of the 
ER chaperone BiP. Since BiP reaches low millimolar concentrations in the ER (up to 5 mM) 
(Weitzmann et al., 2007), ER-β23 must be present in the ER lumen at concentrations at least
in the low millimolar range. Notably, purified β23 (as well as β4 and β17) has previously been 
shown to form insoluble amyloid-like aggregates already at low micromolar concentrations 
(Olzscha et al., 2011). This means that ER-β23 accumulates in the ER at concentrations that 
are around 1,000 times higher than its in vitro solubility. Such an extremely concentrated state 
has been described as supersaturation (Ciryam et al., 2015). The ER thus has a remarkably 
high capacity to maintain aggregation-prone proteins in a soluble state. The insoluble 
aggregates formed by cytosolic β23 have a diameter of 1-2 µm (Olzscha et al., 2011). Since 
the ER lumen is only about 50 nm wide (Shibata et al., 2010; Westrate et al., 2015), space 
constraints may prevent ER-β23 from forming such large insoluble aggregates and thus be 
responsible for this supersaturated state. However, at slightly higher concentrations, the 
mCherry-tagged construct ER-β23-mCh did form insoluble aggregates suggesting that the ER 
can only counterbalance the high intrinsic aggregation propensity up to a certain threshold 
concentration.
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Retention of β-proteins in the ER may protect cells from potentially toxic species that 
could aggregate in other cellular compartments or in the extracellular space such as in the case 
of transthyretin or light chain amyloidoses (Sorgjerd et al., 2006; Blancas-Mejia and Ramirez-
Alvarado, 2013). A possible mechanism for ER-β23 retention in the ER could be the
interactions with ERQC factors that do not release ER-β23 for secretion. However, the 
finding that these chaperones are less abundant than ER-β23 argues against a mechanism of 
retention that involves a 1:1 interaction of ER-β23 with chaperones. Notably, ER-β23 did not 
seem to accumulate at ER exit sites (ERES) and was also not found to interact with factors 
involved in COPII vesicle assembly. ER-β23 may be retained in the ER lumen for stochastic 
reasons because of its low mobility that is due to the formation of soluble but rather immobile 
oligomers and higher order polymers. ER-β23 may form a network of polymers that is 
relatively dynamic and soluble, but not mobile enough to diffuse into secretory vesicles. This 
relatively immobile network may also prevent retro-translocation of ER-β23 via ERAD. Even 
though ER-β23 interacts with ERAD substrate recognition factors and adaptors, it does not 
seem to interact with cytosolic ERAD factors or the proteasome and is not efficiently 
degraded. This suggests that ER-β23 is retained before passing the dislocon. This may be due 
to polymerisation that prevents passage or due to the lack of specific features such as 
glycosylation patterns or other post-translational modifications that may be required. 
However, the mutant NRS protein, NRSG392EΔNN, seemed to interact with SEL1L without 
blocking ERAD, suggesting that the lack of glycosylation sites may not be responsible for 
ERAD inhibition.
It was previously found that Hsc70 and HSP110, cytosolic members of the HSP70 and 
HSP110 chaperone families, respectively, interact with nt-β23 (Olzscha et al., 2011). The 
finding that members of these chaperone families, namely BiP and HYOU1, also interact with 
ER-β23, suggests that these chaperones specifically recognise β-sheet proteins. Interestingly, 
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diseases-causing mutants of A1AT are also specifically recognised by BiP and HYOU1 as 
well as by the ER-specific chaperone CNX that was also found to bind ER-β23 (Schmidt and 
Perlmutter, 2005). In addition, GRP94 and OS-9 have been reported to be involved in ERAD
of ER-retained disease-mutants of A1AT and NRS (Christianson et al., 2008; Schipanski et 
al., 2014). OS-9 has been suggested to be involved in the retention of misfolded proteins in 
the ER lumen in addition to the delivery of ERAD substrates (Bernasconi et al., 2008; 
Olzmann et al., 2013). 
It should be noted that the lectin protein OS-9 has also been shown to recognise non-
glycosylated substrates (Bernasconi et al., 2008; Christianson et al., 2008; Hosokawa et al., 
2009; Olzmann et al., 2013). OS-9 may recognise ER-β23 via a similar substrate binding 
mechanism that involves recognition of β-sheet conformations and is independent of 
glycosylation. Similarly, the chaperone CNX has also been suggested to recognise non-
glycosylated substrates in addition to its glycan-binding activity (Rajagopalan et al., 1994; 
Basu and Srivastava, 1999; Saito et al., 1999; Spee et al., 1999; Danilczyk and Williams, 
2001; Swanton et al., 2003). It is yet unclear, however, whether OS-9 and CNX bind ER-β23 
directly or indirectly as part of larger complexes. OS-9 was shown to be in a complex with 
SEL1L and Hrd1 as well as the ER chaperones BiP and GRP94 (Christianson et al., 2008; 
Olzmann et al., 2013). Similarly to ER-β23, the non-glycosylated A1AT mutant NHKQQQ is 
recognised by both isoforms of OS-9 (OS-9.1 and OS-9.2) but is yet not efficiently targeted 
for degradation (Bernasconi et al., 2008; Hosokawa et al., 2009). However, an ER-retained 
glycosylation mutant of NRS was efficiently degraded and did not affect the stability of CPY* 
suggesting that glycosylation of this substrate is not required for ERAD.
Disease mutants of the A1AT and NRS do not induce the UPR but instead activate the 
ordered protein response (Graham et al., 1990; Hidvegi et al., 2005; Davies et al., 2009). 
ER-β23 did not induce the XBP1 promoter but it appeared to induce the ATF6 promoter at 
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basal levels. However, ER-β23 seemed to have an overall inhibitory effect on UPR induction
upon treatment with the ER stress inducer Tunicamycin (Tm). Interestingly, the cytosolic 
nt-β23 was previously demonstrated to block induction of the cytosolic stress response, the 
HSR (Olzscha et al., 2011). It remains to be determined whether similar to the NRS and 
A1AT mutants, ER-β23 induces NFκB via the ordered protein response. Furthermore, it 
would be interesting to test whether NRS or A1AT mutants also have an inhibitory effect on 
UPR induction.
The inhibition of the ERAD pathway by ER-β23 leads to an impairment of 
proteostasis and may indicate a general problem associated with ER retention of aggregation-
prone proteins in pathological contexts. Primarily, retention is considered a protective 
mechanism and in the case of ER-β23, prevention of secretion and retro-translocation may be 
relatively beneficial as it protects cells from acute toxicity of this protein in the cytosol and 
potentially other intra- and extracellular compartments (Olzscha et al., 2011; Woerner et al., 
2016). For example, retro-translocation of the aggregation-prone prion protein leads to 
cytotoxicity (Ma and Lindquist, 2002) and ER-targeted versions of aggregation-prone polyQ
proteins have been demonstrated to aggregate in the cytosol after retro-translocation 
(Rousseau et al., 2004). At the same time, due to its impairment of ERAD ER-β23 is likely to 
cause toxicity in the ER if cells are challenged by additional ER stress.
The results presented in Part 2 of this thesis demonstrate the potential of improving 
proteostasis capacity with small molecules. The anti-dopaminergic drugs Flu and Dro, as well 
as the EGFR inhibitors Gef and Erl improved UPS activity in the presence of the 
Huntington’s disease model protein Q97. Notably, Flu has also been identified in a high-
throughput screen for compounds that modify A1AT Z mutant accumulation in C. elegans
(Gosai et al., 2010). More recently Flu was also shown to reduce the toxicity of ATZ in 
C. elegans and in mammals (Li et al., 2014) and was also identified in a screen for potential 
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inducers of autophagy (Li et al., 2016). Importantly, the HSR and autophagy are closely 
linked and there is evidence that the HSR can induce autophagy (Dokladny et al., 2015). 
Interestingly, HSR induction and improved proteostasis in the presence of Q97 was also 
observed with a second anti-dopaminergic drug. It remains to be determined whether there is 
any link between the anti-dopaminergic action of these compounds and their effects on the 
proteostasis network. Conversely, dopaminergic signalling was reported to improve 
proteostasis (Joshi et al., 2016).
The finding that the EGFR inhibitors Gef and Erl improve proteostasis is interesting in 
the light of reports showing that EGF signalling plays an important role in longevity of 
nematodes (Rajalingam and Dikic, 2011). Conversely, EGF signalling was on the one hand 
reported to stimulate the UPS but on the other hand suggested to inhibit molecular 
chaperones. However, also in the case of Gef and Erl it is yet unclear whether their 
mechanism of proteostasis modulation is dependent on their inhibition on EGFR.
In summary, the work presented here demonstrates that the remarkable capacity of the 
mammalian ER to retain aggregation-prone β-sheet proteins in a soluble state leads to a 
disturbance of the ERAD pathway and demonstrates the potential of targeting the proteostasis 
network with small molecule modulators. These findings provide novel insights into the 
underlying cellular mechanisms of protein aggregation that broaden our understanding of the 
implications in various diseases.
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Appendices 
Supplementary table 1. Amino acid sequences of model proteins.
Name Amino acid sequence
CPY*-mCh
MGWSCIILFLVATATGAHSQVQLQVDLEMISLQRPLGLDKDVLLQAAEKFGLDLDLDHLLKELDSNVLDAWAQIE
HLYPNQVMSLETSTKPKFPEAIKTKKDWDFVVKNDAIENYQLRVNKIKDPKILGIDPNVTQYTGYLDVEDEDKHF
FFWTFESRNDPAKDPVILWLNGGPGCSSLTGLFFELGPSSIGPDLKPIGNPYSWNSNATVIFLDQPVNVGFSYS
GSSGVSNTVAAGKDVYNFLELFFDQFPEYVNKGQDFHIARESYAGHYIPVFASEILSHKDRNFNLTSVLIGNGLT
DPLTQYNYYEPMACGEGGEPSVLPSEECSAMEDSLERCLGLIESCYDSQSVWSCVPATIYCNNAQLAPYQRT
GRNVYDIRKDCEGGNLCYPTLQDIDDYLNQDYVKEAVGAEVDHYESCNFDINRNFLFAGDWMKPYHTAVTDLL
NQDLPILVYAGDKDFICNWLGNKAWTDVLPWKYDEEFASQKVRNWTASITDEVAGEVKSYKHFTYLRVFNGGH
MVPFDVPENALSMVNEWIHGGFSLEFMVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGT
QTAKLKVTKGGPLPFAWDILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQ
DGEFIYKVKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYKAKKP
VQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYKAAAEQKLISEEDLNGAASEKDEL
ER-α
MAESHLLQWLLLLLPTLCGPGTACEQKLISEEDLGMYGKLNDLLEDLQEVLKNLHKNWHGGKDNLHDVDNHLQ
NVIEDIHDFMQGGGSGGKLQEMMKEFQQVLDELNNHLQGGKHTVHHIEQNIKEIFHHLEELVHR
ER-β4
MAESHLLQWLLLLLPTLCGPGTACEQKLISEEDLGMQISMDYQLEIEGNDNKVELQLNDSGGEVKLQIRGPGGR
VHFNVHSSGSNLEVNFNNDGGEVQFHMH
ER-β17
MAESHLLQWLLLLLPTLCGPGTACEQKLISEEDLGMQISMDYEIKFHGDGDNFDLNLDDSGGDLQLQIRGPGGR
VHVHIHSSSGKVDFHVNNDGGDVEVKMH
ER-β23
MAESHLLQWLLLLLPTLCGPGTACEQKLISEEDLGMQISMDYNIQFHNNGNEIQFEIDDSGGDIEIEIRGPGGRV
HIQLNDGHGHIKVDFHNDGGELQIDMH
ER-α-mCh
MAESHLLQWLLLLLPTLCGPGTACEQKLISEEDLGMYGKLNDLLEDLQEVLKNLHKNWHGGKDNLHDVDNHLQ
NVIEDIHDFMQGGGSGGKLQEMMKEFQQVLDELNNHLQGGKHTVHHIEQNIKEIFHHLEELVHRGPVATMVSK
GEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAWDILSPQFMYGSKAY
VKHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYKVKLRGTNFPSDGPVMQKKTMGWE
ASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYKAKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAE
GRHSTGGMDELYK
ER-β23-mCh
MAESHLLQWLLLLLPTLCGPGTAA*EQKLISEEDLGMQISMDYNIQFHNNGNEIQFEIDDSGGDIEIEIRGPGGRV
HIQLNDGHGHIKVDFHNDGGELQIDMHGPVATMVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGR
PYEGTQTAKLKVTKGGPLPFAWDILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQ
DSSLQDGEFIYKVKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTY
KAKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYK
ER-mCh
MAESHLLQWLLLLLPTLCGPGTAAEQKLISEEDLMVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEG
RPYEGTQTAKLKVTKGGPLPFAWDILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVT
QDSSLQDGEFIYKVKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTT
YKAKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYKKDEL
Q25
MATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQPPPPPPPPPPPQLPQPPPQAQPLLPQP
QPPPPPPPPPPGPAVAEEPLHRPGSLVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQT
AKLKVTKGGPLPFAWDILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDG
EFIYKVKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYKAKKPVQL
PGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYKLRPPSGSRSIDSRGPFEQKLISEEDLNMHTGH
HHHHH
Q97
MATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQ
QQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQPPPPPPPPPPPQLPQPP
PQAQPLLPQPQPPPPPPPPPPGPAVAEEPLHRPGSLVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEG
EGRPYEGTQTAKLKVTKGGPLPFAWDILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGVVT
VTQDSSLQDGEFIYKVKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVK
TTYKAKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYKLRPPSGSRSIDSRGPFEQKLIS
EEDLNMHTGHHHHHH
nt-α
MCEQKLISEEDLGMYGKLNDLLEDLQEVLKNLHKNWHGGKDNLHDVDNHLQNVIEDIHDFMQGGGSGGKLQE
MMKEFQQVLDELNNHLQGGKHTVHHIEQNIKEIFHHLEELVHR
nt-β4
MCEQKLISEEDLGMQISMDYQLEIEGNDNKVELQLNDSGGEVKLQIRGPGGRVHFNVHSSGSNLEVNFNNDGG
EVQFHMH
nt-β17
MCEQKLISEEDLGMQISMDYEIKFHGDGDNFDLNLDDSGGDLQLQIRGPGGRVHVHIHSSSGKVDFHVNNDGG
DVEVKMH
nt-β23
MCEQKLISEEDLGMQISMDYNIQFHNNGNEIQFEIDDSGGDIEIEIRGPGGRVHIQLNDGHGHIKVDFHNDGGEL
QIDMH
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Supplementary table 1. Amino acid sequences of model proteins. Signal sequences are 
presented in green, Myc-tags in purple, the sequence of α-helical proteins in blue, β-proteins 
in red and mCherry is highlighted in red.
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Supplementary table 2. List of ER-β23 interactors
Description
Protein 
IDs
Gene 
names
MW 
(kDa)
Ratio 
H/L 
(IP)
Ratio 
H/L 
(Total)
GO cellular compartments
Protein sel-1 homolog 
1 (SEL1L)
Q9UBV2 SEL1L 88.75 8.72 1.07 ER membrane
Lysosome-associated 
membrane 
glycoprotein 1
P11279 LAMP1 44.88 7.86 0.95 late endosome; lysosome
Protein OS-9 Q13438 OS9 75.56 6.57 *
ER lumen; ER ubiquitin 
ligase complex
PR domain zinc finger 
protein 10
Q9NQV6 PRDM10 137.42 6.51 * nucleus
Zinc finger protein 335 Q9H4Z2 ZNF335 129.61 6.50 0.97 nucleus
Nuclear pore 
membrane 
glycoprotein 210
Q8TEM1 NUP210 205.11 6.10 0.78
ER;nuclear 
envelope;nuclear pore 
complex;ER membrane
HCLS1-associated 
protein X-1
O00165 HAX1 32.42 5.76 0.91
actin 
cytoskeleton;cytoplasmic 
vesicle;ER;mitochondria; 
sarcoplasmic reticulum
Tetratricopeptide 
repeat protein 13
Q8NBP0 TTC13 96.81 5.46 *
Tetratricopeptide 
repeat protein 17
Q96AE7 TTC17 129.56 5.02 *
52 kDa repressor of 
the inhibitor of the 
protein kinase
O43422 PRKRIR 87.70 4.90 0.97 nucleus
Ensconsin Q14244 MAP7 84.05 4.75 0.76
cytoplasm;microtubule; 
perinuclear region of 
cytoplasm
Nodal modulator 1/2/3 Q5JPE7
NOMO1/2/
3
139.44 4.71 0.89 ER membrane
Zinc finger protein 579 Q8NAF0 ZNF579 60.51 4.40 0.70 nucleus
Hypoxia up-regulated 
protein 1 
(HYOU1/GRP170)
Q9Y4L1 HYOU1 111.33 4.32 1.16 ER lumen
MAP7 domain-
containing protein 1
Q3KQU3 MAP7D1 92.82 4.27 0.76
cytoplasm;cytoskeletal 
part;spindle
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Transcription 
intermediary factor 1-
beta
Q13263 TRIM28 88.55 4.26 0.96
euchromatin;heterochrom
atin;nuclear chromatin
Hypermethylated in 
cancer 2 protein
Q96JB3 HIC2 66.16 4.20 *
adherens 
junction;anchoring 
junction;cell 
junction;nucleus;PM
Protein kinase C-
binding protein 1
Q9ULU4 ZMYND8 131.58 4.10 * nucleus
Neuralized-like protein 
4
Q96JN8 NEURL4 166.90 3.94 *
centriole;intracellular non-
microtubule organizing 
center part
Centrosomal protein of 
170 kDa
Q5SW79 CEP170 175.29 3.80 1.04
centriole;centrosome; 
cytoskeletal;microtubule 
organizing center;spindle
Single-stranded DNA-
binding protein, 
mitochondrial
Q04837 SSBP1 17.26 3.79 1.04 mitochondria
Uncharacterized 
protein KIAA0889
O94964-
2
KIAA0889/
SOGA1
183.86 3.73 * extracell. space
Cullin-7 F5H0L1 CUL7 199.75 3.70 *
cytosol;Golgi 
apparatus;nuclear 
ubiquitin ligase complex 
part
Coiled-coil domain-
containing protein 8
Q9H0W5 CCDC8 59.37 3.66 0.95 PM
Protein disulfide-
isomerase A6 (PDIA6)
Q15084 PDIA6 53.90 3.64 1.04
ER lumen;ER-Golgi 
intermediate 
compartment;ER 
membrane
Kinesin light chain 4 Q9NSK0 KLC4 70.55 3.58 0.97
cytoplasm;cytoskeletal 
part;microtubule
Myeloid leukemia 
factor 2
Q15773 MLF2 28.15 3.46 0.78 cytoplasm;nucleus
Cytochrome c oxidase
subunit 2
P00403 MT-CO2 25.57 3.46 1.00
mitochondrial inner 
membrane
E3 ubiquitin-protein 
ligase HERC2
O95714 HERC2 527.22 3.43 1.05
centriole; cytoplasm; 
mitochondrial inner 
membrane
Zinc finger protein 687 Q8N1G0 ZNF687 129.53 3.43 * nucleolus part
Mitochondrial import 
inner membrane 
translocase subunit 
Tim13
Q9Y5L4 TIMM13 10.50 3.38 0.80
macromolecular complex;
mitochondrial inner 
intermembrane
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Erlin-2 O94905 ERLIN2 37.84 3.26 0.98 ER membrane; PM
NADH dehydrogenase 
[ubiquinone] 1 alpha 
subcomplex subunit 
13
E7ENQ6 NDUFA13 30.10 3.26 0.99
mitochondrial membrane;
respiratory chain complex 
I; nuclear
Chromobox protein 
homolog 6
O95503 CBX6 43.90 3.24 *
heterochromatin; 
macromolecular complex; 
nuclear;PcG protein 
complex
Zinc finger and BTB 
domain-containing 
protein 24
O43167 ZBTB24 78.28 3.15 * nucleus
Obscurin-like protein 1 O75147 OBSL1 206.94 3.10 *
cell-cell junction;Golgi 
apparatus;intercalated 
disc; perinuclear region of 
cytoplasm
Kinesin-1 heavy chain P33176 KIF5B 109.68 2.96 0.98
cytosol;microtubule 
associated complex
Zinc finger protein 462 Q96JM2 ZNF462 291.11 2.96 * nucleus
Kinesin light chain 1 E7EVH7 KLC1 83.69 2.92 * cytosol;microtubule
Zinc finger protein 592 Q92610 ZNF592 137.53 2.86 * nucleus
Zinc finger protein 316 A6NFI3 ZNF316 108.44 2.82 * nucleus
Liprin-beta-1 Q86W92 PPFIBP1 114.02 2.77 * PM
Kinesin light chain 2 Q9H0B6 KLC2 68.93 2.73 0.95
cell projection;ciliary 
rootlet;cytoskeletal;kinesi
n I complex
UDP-
glucose:glycoprotein 
glucosyltransferase 2
Q9NYU1 UGGT2 174.73 2.72 *
ER lumen;ER-Golgi 
intermediate 
compartment
Endoplasmin/GRP94 P14625 HSP90B1 92.47 2.70 1.10 ER lumen;ER membrane
Mitochondrial import 
inner membrane 
translocase subunit 
Tim8 B
G3XAN8 TIMM8B 11.16 2.59 0.90
protein transporter 
complex;mitochondrial 
inner membrane
Zinc finger protein 574 Q6ZN55 ZNF574 108.57 2.57 * nucleus
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Calnexin (CNX) P27824 CANX 67.57 2.56 0.95
ER lumen;ER 
membrane;ribonucleoprot
ein complex
Caseinolytic peptidase 
B protein homolog
Q9H078 CLPB 75.45 2.56 0.90 mitochondria
Telomere-associated 
protein RIF1
Q5UIP0 RIF1 274.46 2.50 0.57
chromosome, telomeric 
region;cytoplasm;pronucl
eus;spindle
Low molecular weight 
phosphotyrosine 
protein phosphatase
P24666 ACP1 18.04 2.49 0.91
cytoplasm;nucleus;PM 
part
Polycomb complex 
protein BMI-1
P35226 BMI1 36.95 2.47 0.98
cytoplasm;heterochromati
n; nucleolus
Centrosomal protein of 
97 kDa
Q8IW35 CEP97 96.98 2.47 1.13
centrosome;cytoplasm; 
cytoskeletal part
Coiled-coil-helix-
coiled-coil-helix 
domain-containing 
protein 3
F8WAR4 CHCHD3 27.74 2.46 1.06
mitochondrial inner 
membrane;nucleus
Peroxidasin homolog Q92626 PXDN 165.27 2.44 1.24
ER;extracell. 
space;proteinaceous 
extracellular matrix
Chromatin assembly 
factor 1 subunit B
Q13112 CHAF1B 61.49 2.42 0.90
chromatin assembly 
complex;cytoplasm
Collagen alpha-1(XIV) 
chain
Q05707 COL14A1 193.51 2.42 *
anchoring collagen;ER 
lumen;extracell. matrix
Binding 
immunoglobulin 
protein (BiP/GRP78)
P11021 HSPA5 72.33 2.41 1.30
ER chaperone 
complex;ER lumen;ER-
Golgi intermediate 
compartment;ER 
membrane
ATP-dependent DNA 
helicase Q4
O94761 RECQL4 133.08 2.40 * cytoplasm;nucleus
HLA class I 
histocompatibility 
antigen
P10321;
P01889;
P30460;
P01893
HLA-
C;HLA-
B;HLA-H
44.32 2.33 0.85
endosome;ER to Golgi 
transport;ER 
membrane;extracell.;Golg
i; transport vesicle
Protein SCO2 
homolog, 
mitochondrial
O43819 SCO2 29.81 2.33 0.89
mitochondrial inner 
membrane
E3 SUMO-protein 
ligase CBX4
O00257 CBX4 61.37 2.32 * Golgi;nuclear speck
Voltage-dependent 
anion-selective 
channel protein 1
P21796 VDAC1 30.77 2.30 1.13 mitochondrial membrane
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Zinc finger and BTB 
domain-containing 
protein 7A
O95365 ZBTB7A 61.44 2.29 1.06 nucleus
Formin-like protein 3 Q8IVF7 FMNL3 117.21 2.27 * cytoplasm
Polyhomeotic-like 
protein 2
Q8IXK0 PHC2 90.81 2.24 1.06 nuclear part
Dolichyl-
diphosphooligosaccha
ride-protein 
glycosyltransferase 48 
kDa subunit
P39656 DDOST 50.80 2.19 0.96
ER macromolecular 
complex; ER membrane
E3 SUMO-protein 
ligase 
RanBP2;Putative 
peptidyl-prolyl cis-
trans isomerase
P49792 RANBP2 358.20 2.17 1.09
cytosol; nuclear inclusion 
body
E3 ubiquitin-protein 
ligase RING2
Q99496 RNF2 37.66 2.17 1.02 heterochromatin
Neutral alpha-
glucosidase AB
Q14697 GANAB 106.87 2.16 0.95 ER lumen; Golgi
Zinc finger protein 483 Q8TF39 ZNF483 85.10 2.15 0.78 nucleus
Chromatin assembly 
factor 1 subunit A
Q13111 CHAF1A 106.92 2.13 0.89
chromatin remodeling 
complex; cytosol
Dynamin-like 120 kDa 
protein
E5KLJ5 OPA1 117.74 2.11 0.92
mitochondrial crista;
mitochondrial 
intermembrane space
Histone chaperone 
ASF1A
Q9Y294 ASF1A 22.97 2.10 0.82 nucleus
Ran GTPase-
activating protein 1
P46060 RANGAP1 63.54 2.10 1.02
chromosomal;
cytoskeletal; cytosol;
nuclear pore membrane;
pore complex; spindle 
pole
Zinc finger protein 770 Q6IQ21 ZNF770 80.01 2.07 * nucleus
Zinc finger protein 295 Q9ULJ3 ZNF295 118.87 2.05 * nucleus
Voltage-dependent 
anion-selective 
channel protein 3
F5H740 VDAC3 30.76 2.04 1.14
mitochondrial outer 
membrane
Procollagen 
galactosyltransferase 
1
Q8NBJ5 GLT25D1 71.64 1.96 0.87 ER lumen
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Histone chaperone 
ASF1B
Q9NVP2 ASF1B 22.43 1.89 0.88 chromatin;nucleus
Nuclear envelope pore 
membrane protein 
POM 121
Q96HA1 POM121 127.72 1.75 *
ER envelope;nuclear 
envelope;nuclear pore 
complex;ER membrane
Crossover junction 
endonuclease MUS81
Q96NY9 MUS81 61.17 1.74 * nucleolus
Ubiquitin carboxyl-
terminal hydrolase 
isozyme L5
Q5LJA9 UCHL5 41.69 1.32 0.99
chromosomal part;
cytoplasm; cytosol
Supplementary table 2. List of ER-β23 interactors. Interactors are sorted according to their 
enrichment in ER-β23 IPs (H/L ratio corresponding to ER-β23/pcDNA) from high to low 
values. The H/L ratio represents the combined ratio calculated by MaxQuant (version 1.3.0.5) 
from three independent SILAC MS experiments. Listed are proteins that are enriched ≥2-fold 
in at least two out of three independent experiments. The localisations of interactors were 
annotated using Perseus (1.5.2.12) (annotation of Gene Ontology Cellular Compartments). 
ER-localised chaperones and ERAD factors are highlighted in pale blue. *No ratio could be 
calculated by MaxQuant because measurements were below threshold. 
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Supplementary table 3. Compartmental enrichment of ER-β23 interactors
Category 
value
Total 
size
Selection 
size
Category 
size
Inter-
section 
size
Enrichment 
factor
p value
Benj. 
Hoch. 
FDR
PRC1 
complex
3317 83 9 4 17.76 4.08E-05 5.34E-03
endoplasmic 
reticulum 
lumen
3317 83 27 10 14.80 3.20E-10 2.93E-07
kinesin 
complex
3317 83 12 4 13.32 1.49E-04 1.52E-02
PcG protein 
complex
3317 83 22 5 9.08 1.53E-04 1.40E-02
endoplasmic
reticulum 
part
3317 83 140 17 4.85 2.63E-08 1.20E-05
intracellular 
organelle 
lumen
3317 83 84 10 4.76 2.88E-05 5.29E-03
organelle 
lumen
3317 83 89 10 4.49 4.74E-05 5.43E-03
mitochondrial 
membrane
3317 83 84 9 4.28 1.64E-04 1.37E-02
membrane-
enclosed 
lumen
3317 83 104 11 4.23 3.42E-05 5.23E-03
organelle 
membrane
3317 83 353 22 2.49 2.20E-05 6.73E-03
Supplementary table 3. Compartmental enrichment values of ER-β23 interactors. Gene 
Ontology Cellular Component (GOCC) annotations (category value) of proteins identified by 
MS were assigned using Perseus (1.5.2.12). The enrichment of these category annotations 
among the set of ER-β23 interactors (83 proteins) was calculated over the background of 
GOCC category annotations of all proteins identified (3317 proteins) using the Fisher exact 
test. Enrichment factors of significantly enriched cellular components (cut-off Benjamini-
Hochberg FDR≤0.02) are listed.
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Supplementary table 4. Abundances of ER-β23 interactors in IP eluates
Description
Gene 
names
Abundance in eluate 
(% of all interactors)
GO cellular compartments
Transcription intermediary 
factor 1-beta
TRIM28
29.82 euchromatin;heterochromatin
;nuclear chromatin
Binding immunoglobulin 
protein (BiP/GRP78)
HSPA5
20.60
ER chaperone complex;ER 
lumen;ER-Golgi intermediate 
compartment;ER membrane
MAP7 domain-containing 
protein 1
MAP7D1
6.65 cytoplasm;cytoskeletal 
part;spindle
Single-stranded DNA-binding 
protein, mitochondrial
SSBP1
4.85
Mitochondria
Centrosomal protein of 170 
kDa
CEP170
3.66
centriole;centrosome; 
cytoskeletal;microtubule 
organizing center;spindle
Kinesin-1 heavy chain KIF5B
3.45 cytosol;microtubule 
associated complex
Ensconsin MAP7
3.44
cytoplasm;microtubule; 
perinuclear region of 
cytoplasm
E3 ubiquitin-protein ligase 
RING2
RNF2
2.32
heterochromatin
HCLS1-associated protein 
X-1
HAX1
1.42
actin 
cytoskeleton;cytoplasmic 
vesicle;ER;mitochondria; 
sarcoplasmic reticulum
Mitochondrial import inner 
membrane translocase 
subunit Tim13
TIMM13
1.24
macromolecular 
complex;mitochondrial inner 
intermembrane
Histone chaperone ASF1A ASF1A
1.24
Nucleus
Protein sel-1 homolog 1 
(SEL1L)
SEL1L
1.11
ER membrane
Mitochondrial import inner 
membrane translocase 
subunit Tim8 B
TIMM8B
1.11
protein transporter 
complex;mitochondrial inner 
membrane
Hypermethylated in cancer 2 
protein
HIC2
1.09
adherens junction;anchoring 
junction;cell 
junction;nucleus;PM
Endoplasmin/GRP94 HSP90B1
1.06
ER lumen;ER membrane
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Chromatin assembly factor 1 
subunit A
CHAF1A
0.97 chromatin remodeling 
complex;cytosol
Telomere-associated protein 
RIF1
RIF1
0.95
chromosome, telomeric 
region;cytoplasm;pronucleus;
spindle
Chromatin assembly factor 1 
subunit B
CHAF1B
0.94 chromatin assembly 
complex;cytoplasm
Polycomb complex protein 
BMI-1
BMI1
0.93 cytoplasm;heterochromatin; 
nucleolus
Neuralized-like protein 4 NEURL4
0.77
centriole;intracellular non-
microtubule organizing 
center part
Cytochrome c oxidase 
subunit 2
MT-CO2
0.75 mitochondrial inner 
membrane
Erlin-2 ERLIN2
0.64
ER membrane;PM
Coiled-coil domain-
containing protein 8
CCDC8
0.62
PM
E3 ubiquitin-protein ligase 
HERC2
HERC2
0.61
centriole;cytoplasm; 
mitochondrial inner 
membrane
Protein kinase C-binding 
protein 1
ZMYND8
0.56
Nucleus
Caseinolytic peptidase B 
protein homolog
CLPB
0.53
mitochondria
PR domain zinc finger 
protein 10
PRDM10
0.48
Nucleus
Myeloid leukemia factor 2 MLF2
0.45
cytoplasm;nucleus
52 kDa repressor of the 
inhibitor of the protein kinase
PRKRIR
0.45
Nucleus
Lysosome-associated 
membrane glycoprotein 1
LAMP1
0.40
late endosome; lysosome
Kinesin light chain 2 KLC2
0.37
cell projection;ciliary 
rootlet;cytoskeletal;kinesin I 
complex
Histone chaperone ASF1B ASF1B
0.37
chromatin;nucleus
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Zinc finger protein 579 ZNF579
0.36
Nucleus
Polyhomeotic-like protein 2 PHC2
0.36
nuclear part
ATP-dependent DNA 
helicase Q4
RECQL4
0.35
cytoplasm;nucleus
Nuclear pore membrane 
glycoprotein 210
NUP210
0.31 ER;nuclear envelope;nuclear 
pore complex;ER membrane
Coiled-coil-helix-coiled-coil-
helix domain-containing 
protein 3
CHCHD3
0.30 mitochondrial inner 
membrane;nucleus
Protein disulfide-isomerase 
A6 (PDIA6)
PDIA6
0.26
ER lumen;ER-Golgi 
intermediate 
compartment;ER membrane
Calnexin (CNX) CANX
0.23
ER lumen;ER 
membrane;ribonucleoprotein 
complex
Zinc finger protein 574 ZNF574
0.21
Nucleus
Uncharacterized protein 
KIAA0889
KIAA0889
;SOGA1
0.21
extracell. space
Zinc finger and BTB domain-
containing protein 7A
ZBTB7A
0.19
Nucleus
NADH dehydrogenase 
[ubiquinone] 1 alpha 
subcomplex subunit 13
NDUFA13
0.19
mitochondrial 
membrane;respiratory chain 
complex I;nuclear
Voltage-dependent anion-
selective channel protein 1
VDAC1
0.18
mitochondrial membrane
Cullin-7 CUL7
0.17
cytosol;Golgi 
apparatus;nuclear ubiquitin 
ligase complex part
Zinc finger protein 687 ZNF687
0.17
nucleolus part
Protein OS-9 OS9
0.16 ER lumen; ER ubiquitin 
ligase complex
Ubiquitin carboxyl-terminal 
hydrolase isozyme L5
UCHL5
0.15 chromosomal 
part;cytoplasm;cytosol
Peroxidasin homolog PXDN
0.15
ER;extracell. 
space;proteinaceous 
extracellular matrix
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Tetratricopeptide repeat 
protein 13
TTC13
0.14
HLA class I histocompatibility 
antigen
HLA-
C;HLA-
B;HLA-H
0.14
endosome;ER to Golgi 
transport;ER 
membrane;extracell.;Golgi; 
transport vesicle
Low molecular weight 
phosphotyrosine protein 
phosphatase
ACP1
0.13
cytoplasm;nucleus;PM part
Nuclear envelope pore 
membrane protein POM 121
POM121
0.13
ER envelope;nuclear 
envelope;nuclear pore 
complex;ER membrane
Zinc finger protein 592 ZNF592
0.12
Nucleus
Zinc finger protein 295 ZNF295
0.11
Nucleus
Voltage-dependent anion-
selective channel protein 3
VDAC3
0.11 mitochondrial outer 
membrane
Obscurin-like protein 1 OBSL1
0.10
cell-cell junction;Golgi 
apparatus;intercalated 
disc;perinuclear region of 
cytoplasm
Zinc finger protein 316 ZNF316
0.10
Nucleus
Nodal modulator 1/2/3
NOMO2;
NOMO3;
NOMO1
0.09
ER membrane
Tetratricopeptide repeat 
protein 17
TTC17
0.09
Kinesin light chain 1 KLC1
0.08
cytosol;microtubule
Kinesin light chain 4 KLC4
0.07 cytoplasm;cytoskeletal 
part;microtubule
Formin-like protein 3 FMNL3
0.07
Cytoplasm
Neutral alpha-glucosidase 
AB
GANAB
0.07
ER lumen;Golgi
Protein SCO2 homolog, 
mitochondrial
SCO2
0.07 mitochondrial inner 
membrane
Hypoxia up-regulated protein 
1 (HYOU1/GRP170)
HYOU1
0.07
ER lumen
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Dolichyl-
diphosphooligosaccharide-
protein glycosyltransferase 
48 kDa subunit
DDOST
0.06 ER macromolecular 
complex;ER membrane
Chromobox protein 
homolog 6
CBX6
0.06
heterochromatin; 
macromolecular complex; 
nuclear;PcG protein complex
Centrosomal protein of 97 
kDa
CEP97
0.05 centrosome;cytoplasm; 
cytoskeletal part
Zinc finger protein 483 ZNF483
0.04
Nucleus
UDP-glucose:glycoprotein 
glucosyltransferase 2
UGGT2
0.04 ER lumen;ER-Golgi 
intermediate compartment
Zinc finger protein 462 ZNF462
0.04
Nucleus
Ran GTPase-activating 
protein 1
RANGAP
1
0.04
chromosomal;cytoskeletal; 
cytosol;nuclear pore 
membrane;pore 
complex;spindle pole
Procollagen 
galactosyltransferase 1
GLT25D1
0.04
ER lumen
E3 SUMO-protein ligase 
RanBP2;Putative peptidyl-
prolyl cis-trans isomerase
RANBP2
0.03 cytosol;nuclear inclusion 
body
Liprin-beta-1 PPFIBP1
0.03
PM
Zinc finger and BTB domain-
containing protein 24
ZBTB24
0.02
Nucleus
Dynamin-like 120 kDa 
protein
OPA1
0.02
mitochondrial 
crista;mitochondrial 
intermembrane space
Zinc finger protein 770 ZNF770
0.01
Nucleus
E3 SUMO-protein ligase 
CBX4
CBX4
0.00
Golgi;nuclear speck
Collagen alpha-1(XIV) chain COL14A1
0.00 anchoring collagen;ER 
lumen;extracell. matrix
Crossover junction 
endonuclease MUS81
MUS81
0.00
Nucleolus
Zinc finger protein 335 ZNF335
0.00
Nucleus
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Supplementary table 4. Relative abundance of ER-β23 interactors in the ER-β23 IP 
eluate. ER-β23 interactors are sorted according to their relative abundances in the ER-β23 IP 
eluates. Relative abundance values were calculated from IBAQ values of heavy-labelled 
samples after subtraction of IBAQs from light-labelled samples (pcDNA control eluates) and 
are expressed as % of total (sum of abundance values of all interactors). Localisations were 
annotated using Perseus (1.5.2.12) (GOCC). ER-localised chaperones and ERAD factors are 
highlighted in pale yellow.
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Supplementary table 5. Cellular abundance values of ER chaperones and ERAD factors.
Description Gene names Mol. weight (kDa) Median ppm
ER-β23-mCh 36.01 4540.30
BiP HSPA5 72.33 3635.15
GRP94 HSP90B1 92.47 1118.01
PDIA6 PDIA6 48.12 651.62
Calnex CANX 67.57 235.71
GRP170 HYOU1 111.33 300.18
Erlin-2 ERLIN2 37.84 229.98
SEL1L SEL1L 88.754 4.91
OS-9 OS9 75.561 4.78
Supplementary table 5. Cellular abundance values of ER chaperones and ERAD factors.
Abundance (ppm) of ER-β23-interacting ERQC factors was calculated from IBAQ values of 
proteins identified by label-free MS in ER-β23-mCh-expressing HEK293T cells. Medians of 
three independent experiments are listed.
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Supplementary table 6. SILAC H/L ratios of UPR transcriptional targets in total 
proteome
Protein names
Gene 
names
Mol. 
weight 
(kDa)
Combined ratio 
H/L in total 
proteome
UPR 
transcription 
factor
Alpha-1,3/1,6-mannosyltransferase ALG2 ALG2 47.09 1.12 XBP1
Asparagine synthetase [glutamine-
hydrolyzing];Asparagine synthetase
ASNS 64.37 1.00 ATF4
Calreticulin CALR 48.14 1.01 ATF6
Calnexin CANX 67.57 0.95 XBP1
Coatomer subunit alpha;Xenin;Proxenin COPA 138.34 1.01 XBP1
Coatomer subunit beta COPB1 107.14 0.99 XBP1
Coatomer subunit beta COPB2 102.49 1.01 XBP1
Coatomer subunit epsilon COPE 34.48 1.02 XBP1
Coatomer subunit gamma-1
COPG1;
COPG
97.72 1.02 XBP1
Coproporphyrinogen-III oxidase, 
mitochondrial
CPOX 50.15 0.88 ATF4
NADH-cytochrome b5 reductase 
3;NADH-cytochrome b5 reductase 3 
membrane-bound form;NADH-
cytochrome b5 reductase 3 soluble form
CYB5R3 38.23 0.91 ATF4
Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase 48 kDa 
subunit
DDOST 50.80 0.96 XBP1
Derlin-1 DERL1 28.80 0.90 XBP1
Derlin-2 DERL2 27.57 0.72
ATF6 and 
XBP1 
cooperatively
DnaJ homolog subfamily B member 11 
(ERDJ3)
DNAJB1
1
40.51 1.07
ATF6 and 
XBP1
DnaJ homolog subfamily C member 1 
(ERDJ1)
DNAJC1 63.88 0.82
DnaJ homolog subfamily C member 10 
(ERDJ5)
DNAJC1
0
91.08 1.00 XBP1
ER degradation-enhancing alpha-
mannosidase-like 3
EDEM3 104.66 1.18 XBP1
ERO1-like protein alpha ERO1L 54.39 0.92 ATF6
ERO1-like protein alpha ERO1L 54.39 0.92 ATF4
Growth factor receptor-bound protein 10 GRB10 67.23 0.75 ATF4
Homocysteine-responsive endoplasmic 
reticulum-resident ubiquitin-like domain 
member 1 protein
HERPUD
1
43.72 0.90 ATF6
Heme oxygenase 1 HMOX1 32.82 1.01 ATF4
Endoplasmin
HSP90B
1
92.47 1.10 ATF6
78 kDa glucose-regulated protein HSPA5 72.33 1.30 ATF6
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Hypoxia up-regulated protein 1 HYOU1 111.33 1.16
ATF6 and 
XBP1 
cooperatively
ER lumen protein retaining receptor 1 KDELR1 24.54 0.96
Galectin-3 LGALS3 26.15 0.71 ATF4
Lon protease homolog, mitochondrial;Lon 
protease homolog
LONP1 106.49 0.95 ATF4
Protein OS-9 OS9 75.56 0.71 ATF6
Oligosaccharyltransferase complex 
subunit OSTC
OSTC 16.83 0.83 XBP1
Protein disulfide-isomerase A3 (ERp57) PDIA3 56.78 1.05 XBP1
Protein disulfide-isomerase A4 PDIA4 72.93 1.12 ATF6
Protein disulfide-isomerase A5 PDIA5 59.59 0.98 XBP1
Protein disulfide-isomerase A6 PDIA6 53.90 1.04
ATF6 and 
XBP1
Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase subunit 1
RPN1 68.57 0.95 XBP1
Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase subunit 2
RPN2 69.28 0.92 XBP1
Signal peptidase complex catalytic 
subunit SEC11C
SEC11C 21.54 1.10
ATF6 and 
XBP1 
cooperatively
Protein SEC13 homolog SEC13 35.54 1.10
ATF6 and 
XBP1 
cooperatively
Protein transport protein Sec23A SEC23A 86.16 1.01 XBP1
Protein transport protein Sec23B SEC23B 86.48 1.03 XBP1
Protein transport protein Sec24A SEC24A 119.75 1.01 XBP1
Protein transport protein Sec24B SEC24B 140.42 0.90
Protein transport protein Sec24C SEC24C 118.32 0.95 XBP1
Protein transport protein Sec24D SEC24D 113.08 1.00 XBP1
Protein transport protein Sec31A SEC31A 136.22 1.01 XBP1
Protein transport protein Sec61 subunit 
alpha isoform 1
SEC61A
1
52.95 0.95 XBP1
Protein transport protein Sec61 subunit 
beta
SEC61B 9.97 1.02 XBP1
Protein transport protein Sec61 subunit 
gamma
SEC61G 7.74 0.85 XBP1
Translocation protein SEC62 SEC62 45.86 0.93 XBP1
Translocation protein SEC63 homolog SEC63 88.00 0.94 XBP1
Protein sel-1 homolog 1 SEL1L 88.75 1.07 ATF6
Nucleotide exchange factor SIL1 SIL1 52.75 0.91
Signal peptidase complex subunit 2 SPCS2 25.00 1.00 XBP1
Signal peptidase complex subunit 3 SPCS3 20.31 1.03 XBP1
Signal recognition particle 19 kDa protein SRP19 16.16 1.01 XBP1
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Signal recognition particle 54 kDa protein SRP54 55.70 1.02 XBP1
Signal recognition particle 68 kDa protein SRP68 70.73 1.04 XBP1
Signal recognition particle receptor 
subunit alpha
SRPR 69.81 0.99 XBP1
Signal recognition particle receptor 
subunit beta
SRPRB 29.70 0.95 XBP1
Translocon-associated protein subunit 
alpha
SSR1 33.89 0.99 XBP1
Translocon-associated protein subunit 
gamma
SSR3 22.61 0.96 XBP1
Translocon-associated protein subunit 
delta
SSR4 19.00 0.94 XBP1
Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase subunit 
STT3A
STT3A 80.53 0.99 XBP1
Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase subunit 
STT3B
STT3B 93.67 0.86 XBP1
UDP-glucose:glycoprotein 
glucosyltransferase 1
UGGT1 177.19 1.06
ATF6 and 
XBP1
Transitional endoplasmic reticulum 
ATPase
VCP 89.32 1.01
ATF6 and 
XBP1
Supplementary table 6. SILAC H/L ratios (ER-β23 over control) of UPR targets in the 
total proteome (input lysates). UPR-inducible proteins are sorted alphabetically. The H/L 
ratio represents the combined ratio calculated by MaxQuant (version 1.3.0.5) from three
independent SILAC MS experiments. The UPR transcription factors responsible for induction 
of each gene were annotated based on findings by (Shoulders et al., 2013) (ATF6 and XBP1)
and (Harding et al., 2003) (ATF4).
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Abbreviations
A1AT α1-antitrypsin 
Aβ Amyloid β protein 
ACN Acetonitrile
AD Alzheimer’s disease
APP Amyloid precursor protein
APS Ammonium Persulfate
ATCC American Type Culture Collection
ATF6 Activating transcription factor 6 
BCA Bicinchoninic acid
BFA Brefeldin A
BiP Binding immunoglobulin protein/glucose-regulated protein 78 (GRP78)
BRUB Britton & Robinson Buffer
BSA Bovine serum albumin
CAPS 3-(Cyclohexylamino)-1-propanesulfonic acid
CFTR Cystic fibrosis transmembrane conductance regulator
CHX Cycloheximide
CNX Calnexin
CPY Carboxypeptidase Y
CRT Calreticulin
CTRL Control
DAPI 4',6-diamidino-2-phenylindole
DMEM Dulbecco’s Modified Eagle’s medium
DMF Dimethylformamide
DMSO Dimethylsulphoxide
DNA Deoxyribonucleic acid
dNTP Deoxynucleotide
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DTT 1,4-Dithiothreitol
dsRNA Double-stranded RNA
EDTA Ethylenediaminetetraacetic acid
EGFR Epidermal growth factor receptor
eIF2α Eukaryotic initiation factor 2α
EOR ER overload response
ER Endoplasmic reticulum
ERAD Endoplasmic reticulum-associated degradation
ERES ER exit sites
ERQC Endoplasmic reticulum quality control
FACS Fluorescence-activated cell sorting
FASP Filter-aided sample preparation
FBS Foetal bovine serum
FENIB Familial encephalopathy with neuroserpin inclusion bodies
FDA Food and Drug Administration
FLIP Fluorescence loss in photobleaching
FWHM Full width at half maximum
GCN2 General control nonderepressible 2
GFP Green fluorescent protein
Glc Glucose
GlcNAc N-acetylglucosamine
GRP Glucose-regulated protein 
H Heavy labelled
HBP Hexosamine biosynthetic pathway
HD Huntingtin’s disease
HEK293T Human embryonic kidney cells 293T
HPLC High-performance liquid chromatography
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HRI Heme-regulated inhibitor kinase
HSF1 Heat shock factor 1
HSP Heat shock protein
HSR Heat shock response
IB Inclusion body
IRE1 Inositol requiring enzyme 1 
IRES Internal ribosome entry site
ISR Integrated stress response
JNK c-Jun N-terminal kinase
KEAP1 Kelch-like ECH-associated protein 1
L Light labelled
LB Lysogeny broth
M Medium labelled
mAB Monoclonal antibody
Man Mannose
MAP Mitogen-activated protein
mCh mCherry
MEM Modified Eagle’s medium
MES 2-(N-Morpholino)ethanesulfonic acid
MM Multiple myeloma
MOPS 3-(N-Morpholino)propanesulfonic acid
MRH Mannose-6-phosphate receptor homology
MS Mass spectrometry
MSS Marinesco-Sjögren syndrome
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide
NEF Nucleotide exchange factor
NRF2 Nuclear factor-erythroid 2-related factor 2
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NRS Neuroserpin
NT Non-targeted
OD Optical density
OPR Ordered protein response
OST Oligosaccharyltransferase
PAGE Polyacrylamide gel electrophoresis
pAB Polyclonal antibody
PBS Phosphate-buffered saline
PD Parkinson’s disease
PDI Protein disulphide isomerase
PERK PKR-like ER kinase
PIC Pre-initiation complex
PKR Protein kinase R
PLL Poly-L-Lysine
PNGase F Peptide:N-Glycosidase F
PVDF Polyvinylidene difluoride
RIDD Regulated IRE1-dependent decay of mRNA
RIPA Radioimmunoprecipitation assay
RNA Ribonucleic acid
RNC Ribosome/nascent chain complex
RQC Ribosome quality control complex
RT Room temperature
SAX Strong anion-exchange
SD Standard deviation
SDS Sodium dodecyl sulfate
SILAC Stable isotope labelling by amino acids in cell culture
SR Signal-recognition particle receptor
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SRP Signal-recognition particle
TA Tail-anchored
TCA Trichloric acid
TEMED N,N,N’,N’-Tetramethyl-ethane-1,2-diamine
TFA Trifluoroacetic acid
TfB Transformation buffer
Tm Tunicamycin
UGGT UDP-glucose/glycoprotein glucosyl transferase
uORFs Upstream open reading frames
UPR Unfolded protein response
UPS Ubiquitin proteasome system
WT Wild type
XBP1 X-box binding protein 1
XBP1s Spliced X-box binding protein 1
